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Summary
Systemic toxicity testing forms the cornerstone for the safety evaluation of substances. Pressures to move 
from traditional animal models to novel technologies arise from various concerns, including: the need 
to evaluate large numbers of previously untested chemicals and new products (such as nanoparticles or 
cell therapies), the limited predictivity of traditional tests for human health effects, duration and costs of 
current approaches, and animal welfare considerations. The latter holds especially true in the context of 
the scheduled 2013 marketing ban on cosmetic ingredients tested for systemic toxicity. Based on a major 
analysis of the status of alternative methods (Adler et al., 2011) and its independent review (Hartung et al., 
2011), the present report proposes a roadmap for how to overcome the acknowledged scientific gaps for the 
full replacement of systemic toxicity testing using animals. Five whitepapers were commissioned addressing 
toxicokinetics, skin sensitization, repeated-dose toxicity, carcinogenicity, and reproductive toxicity testing. 
An expert workshop of 35 participants from Europe and the US discussed and refined these whitepapers, 
which were subsequently compiled to form the present report. By prioritizing the many options to move the 
field forward, the expert group hopes to advance regulatory science.
Keywords: skin sensitization, allergic contact dermatitis, toxicokinetics, repeated dose testing, reproductive 
toxicity, carcinogenicity, predictive testing, alternative approaches, risk assessment
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1.1.2  Testing needs for the REACH legislation
As an enormous investment into consumer product safety, the 
ReACH program aims to assess existing (“old”) chemicals 
that have previously undergone very little testing (Hartung, 
2010a). Regulation (eC) 1907/2006, known as ReACH (Reg-
istration, evaluation, Authorisation and Restriction of Chemi-
cals), revises the Dangerous Substances Directive (67/548/
eeC). the registration process has only recently begun, and 
the estimated testing demands are under debate (Hartung and 
Rovida, 2009a,b; Rovida and Hartung, 2009; Rovida et al., 
2011). However, there is little doubt that systemic toxicity 
will account for more than 95% of the testing costs and ani-
mal use of ReACH. It is clear that testing capacities are chal-
lenged and alternative approaches, especially for systemic 
toxicities – as called for in the legislation – might relieve such 
tensions. 
1.2  A framework for replacing systemic toxicity 
testing by new approaches
the advantage and disadvantage of alternative methods lies in 
the reductionist character of their approach. this eases inter-
pretation to the extent that a simpler read-out is likely to re-
sult from such an approach, but raises the issue of what aspects 
of the biology might be missing. Aside from abolishing use-
less tests (1.2.1) (which is not an alternative method but should 
nonetheless be considered as an option), a number of principal 
alternative	approaches	(1.2.2	to	1.2.4	and	1.2.6)	were	identified.	
these include in vitro and in silico (1.2.5), as well as combined 
approaches (1.2.7-1.2.8), by either mining or modeling the re-
spective data and/or relating them back to structure and other 
properties of the test substance.
1.2.1  Abolition of useless tests
A	cost-benefit	analysis	could	help	in	making	decisions	to	aban-
don tests of questionable practical utility. Such considerations 
may be based on reproducibility issues, lack of predictivity, 
lack	 of	 scientific	 basis,	 or	 limited	 contribution	 to	 regulatory	
decision-making. Obviously, “uselessness” is a value judgment. 
For animal tests, a number of limitations (Hartung, 2008b) can 
be evaluated in terms of whether they translate to the given test. 
the socioeconomic impact of wrong or missing assessments 
needs to be taken into consideration (Bottini and Hartung, 2009, 
2010), along with other sources of information to substitute for 
comparison of performance characteristics with other methods. 
tests that have been abolished in the past include the traditional 
lD50 test (OeCD tG 401; OeCD, 1987), the abnormal toxicity 
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1.1  Background
two pieces of european legislation have created the pressure 
to develop novel approaches for systemic toxicity testing, be-
yond the general urge to replace animal testing as prescribed 
in the european Directive 2010/63/eU on the protection of 
animals	used	for	scientific	purposes	(Hartung,	2010d;	Seidle	et	
al., 2011). this report deals with methods for the testing of all 
chemicals, and does not focus only on cosmetics. this activity 
is	aimed	at	providing	a	scientific	roadmap	for	the	replacement	
of animal based safety testing in all domains.2
1.1.1  The 7th Amendment of the Cosmetics Directive
On January 15, 2003, the eU passed a law banning the test-
ing of cosmetics and their ingredients on animals, reinforced 
by marketing bans with different deadlines. Known as the 7th 
Amendment (Directive 2003/15/eC) to the Cosmetics Directive 
(Directive76/768/eeC), this Directive is intended to protect and 
improve the welfare of animals used for experimental purposes 
by	 promoting	 the	 development	 and	 use	 of	 scientifically	 valid	
methods of alternative testing (Hartung, 2008a). the main ob-
jective of this Directive is to prohibit the testing of cosmetic 
products/ingredients on animals through a phased series of eU 
testing and marketing bans. this ban on animal testing and sales 
would start immediately where alternative non-animal tests are 
available, followed by a complete testing ban six years after the 
Directive became effective (i.e., in 2009). therefore, animal ex-
periments for cosmetic products and ingredients are completely 
banned, reinforced with a marketing ban in the eU since 2009, 
irrespective of the availability of animal-free methods, except 
for repeat-dose toxicological endpoints (i.e., toxicokinetics, 
repeated dose toxicity, skin sensitization, carcinogenicity, and 
reproductive toxicity) where the eU marketing ban is delayed 
until 2013 for tests carried out outside the eU. this ban may, 
however, be postponed by a new legislative act if alternative 
tests cannot be found.
1 The introduction text was largely part of the original whitepapers on carcinogenicity and reproductive toxicity and discussed in this context.
2 At the workshop I. Ruhdel pointed out that from an animal protection point of view the workshop should not be seen or communicated  
as an activity in the context of the current discussion on possibly postponing the marketing ban on animal tested cosmetics.
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– standardization and automation
– quality assurance of procedures
– appropriate statistics and prediction models
–	 definition	of	applicability	domains	
– extensions to address solubility issues and nanomaterials
these opportunities will differ from test to test. they can im-
prove	the	predictive	value	of	tests,	making	them	(more)	fit	for	
purpose. Such changes, however, will typically require a (re-)
assessment	of	the	validity	of	the	modified	system.
1.2.5  In silico approaches
A number of approaches (Hartung and Hoffmann, 2009) try to 
link, often via structure and physicochemical descriptors, to re-
sults available for other substances to avoid testing. they are 
somewhat similar to what is referred to as “read-across” but in 
a formalized and quantitative way, using either rules, empirical 
correlations to parameters of interest, or other modeling exer-
cises. For complex endpoints, such models are unlikely to be 
used as stand-alone replacements, but are better suited to pro-
vide valuable supporting information as part of a weight of evi-
dence (Hartung et al., 2010) approach. they can play a key role 
in combination with other tools or to further optimize biologi-
cal measurements. It is foreseeable that some Integrated testing 
Strategies (ItS, see 1.2.7) developed in the near future actually 
will be in silico tools with biological inputs.
the basic problem is that we base our judgments on existing 
knowledge and its availability and quality. Surprising effects 
can hardly be predicted, and all quality limitations of this exist-
ing knowledge (e.g., quality of animal test data or mechanistic 
understanding) will translate to the estimation technique. this 
is not unique to modeling approaches per se, but it is impor-
tant to note that the value of existing information (see 1.2.1) 
is again the critical starting point. While there are established 
measures of similarity of chemicals, these merely address struc-
tural similarity and do not consider the context of the endpoint 
of concern. thus, even if we assume that we may have a fair 
appreciation of structural similarity, understanding whether this 
is key for the distribution of the chemical in the organism and its 
toxic mechanism is an additional consideration.
A limitation of all these techniques is that they can only be 
readily applied to discrete organic substances. that suggests, 
based on rough estimates, that some 50% of the chemicals im-
pacted under ReACH, which comprise mixtures, lack of purity, 
salts, metal compounds, etc., cannot be readily evaluated using 
modeling approaches (Hartung and Hoffmann, 2009). Further-
more, all health effects where small impurities are relevant can-
not be handled with such structure-based estimation techniques: 
Allergic reactions (sensitization), for example, can be caused by 
less than 0.1% of contamination. With the same reasoning as for 
possible contaminants, health effects, where no thresholds can 
be established (carcinogenic, mutagenic, or some reproductive 
toxicants), should not be evaluated on the basis of the structure 
of the main compound only (while these contaminants are typi-
cally present in in vivo or in vitro tests). It is noteworthy that 
these are exactly the tests that consume the most animals and 
resources (>80%) under ReACH.
1.2.2  Reduction to key events
traditional 3Rs or alternative methods have been aimed at a 
one-to-one replacement of animal tests. this appears to be fea-
sible	if	a	key	(rate	determining)	event	can	be	readily	identified.	
examples of such attempts include key events such as muta-
genicity, or possibly cell transformation, for carcinogenicity, 
whereas protein binding is assumed to be a prerequisite for 
skin sensitization. the selection of key events can be informed 
by	 the	 scientific	 understanding	 of	 the	 pathophysiology	 or	
through analysis of what was derived, i.e., what was actually 
observed	 in	guideline	 tests	 that	drove	 the	classification	 (for	
example, which organ toxicities are actually driving regu-
latory decisions) or is seen in intoxicated patients (human- 
relevant manifestations). the obvious central question is: 
Can a key event for the given hazard or test concern be 
readily	 identified?	The	 scientific	 challenge	 lies	 in	 the	 state	
of mechanistic understanding – i.e., for some toxicological 
endpoints	a	single	non-animal	test	can	be	used	to	sufficiently	
characterize the adverse effects of the chemical. For other, 
more complex endpoints, several non-animal approaches are 
required to fully characterize the impact of the chemical on 
the relevant tissue(s).
1.2.3  Negative exclusion by lack of key property
the most prominent example of exclusion criteria (conditio sine 
qua non) are large molecular size or barrier models – no bio-
availability/penetration, no harm. the obvious problem is the 
reliance on negative data (no transfer). this concept is further 
refined	 by	 the	 threshold	 of	 toxicological	 concern	 (TTC)	 ap-
proach (Kroes et al., 2005), where exposure (and thus resulting 
availability	in	sufficient	quantity)	–	not	absolute	bioavailability	
– is evaluated: For non-cancer endpoints, NOAels or, alterna-
tively, tD50 (toxic dose 50%) values are collected for a large 
number of chemicals and their distribution is used in combina-
tion with a safety factor to set a threshold where no adverse 
effect is expected. ttC values have been derived for different 
structural classes, e.g., Cramer classes, while other ttC have 
been	derived	and	subsequently	refined	on	the	basis	of	specific	
structural alerts for genotoxicity.
Similarly, many toxic endpoints rely on reactive chemistry al-
lowing interaction with target structures. the absence of struc-
tural features allowing direct reactivity or activation via metab-
olism represents another example of exclusion of a hazard.
1.2.4  Optimization of existing tests
In vitro tests have no fewer limitations than their in vivo coun-
terparts (Hartung, 2007a). A number of strategies may be able to 
improve the predictive value of existing test systems:
– extension of metabolic capacity
– organotypic 3-dimensional (co)-cultures
– more physiologic culture conditions such as homeostasis, 
oxygen supply, cell density
– transition from cell lines to primary cells or stem cell-derived 
systems
– use of human cells
–	 refinement	and	expansion	of	endpoints	measured
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alone alternatives and are now combined because they did not 
achieve this. the downside to this might be that they are not 
sufficiently	complementary	to	make	a	major	change	in	an	ITS.	
the systematic construction of components for an ItS repre-
sents a key opportunity to advance the overall ItS approach. A 
very promising way of constructing a testing strategy is break-
ing the (patho-)physiology down to crucial elements, e.g., the 
different elements of the reproductive cycle (as was done for 
the ReProtect project) (Hareng et al., 2005) or the key proc-
esses of neurodevelopment in the series of DNt workshops. 
However, this still leaves open the question of how to integrate 
all these tests.
the concept of ItS was advanced substantially during the 
development of the ReACH technical guidance (Schaafsma et 
al., 2009). Regulatory toxicology to date has been developed 
as a toolbox of tests, which allows the health effects of new 
substances (especially pre-market drugs and pesticides) to be 
classified	before	carrying	out	a	risk	assessment.	Given	that	lit-
tle was known about the inherent properties of a given chemi-
cal and minimal information about possible future uses was 
available, each test within the toolbox was optimized to have 
as few as possible false-negative results, which might repre-
sent a later safety risk. Indeed, in the absence of information 
it is preferable to “over-label” a possible hazard, often called 
the “precautionary principle.” As a consequence, an unknown 
proportion of substances are abandoned based on false-pos-
itive test results in their development as drugs or consumer 
products, but this is usually accepted since similar substanc-
es	with	 favorable	profiles	are	available	as	alternatives	 in	 the	
test battery. Note that this situation is completely different for 
ReACH purposes, where the same test methods need to be ap-
plied	to	test	valuable	commodity	substances	with	a	significant	
history of safe use.
Many tests in the toxicological toolbox are dichotomous, 
i.e., they can have only two outcomes (positive or negative). 
this suggests that when optimizing the test for few false-neg-
atives, the number of false-positives is increased. However, 
even the simplest biological aspects are not dichotomous: Sex 
is male or female, but what about transvestites, transsexuals, 
hermaphrodites, castrates, turner (only one x chromosome) 
or	Klinefelter	(XXY)	syndrome?	There	is	a	grey	area.	When	
we set our thresholds, we determine the extent of grey and 
whether we favor false-positives or false-negatives. Due to 
the precautionary approach in toxicology, thresholds are set 
to minimize false-negatives, thus favoring false-positives. Al-
though some non-animal test methods have prediction models 
with	only	binary	outcomes	(often	to	reflect	the	reference	test	
result), this is rarely the way they are applied, and most non-
animal test methods are now being designed to predict dose 
response information. 
the “one suits all” philosophy of the animal test toolbox 
leads to the problem that usually only one test is available to 
give	 the	 final	 result.	This	means	 that	 the	 proportion	 of	 false-
positives cannot be corrected. even worse, if several tests al-
lowing false-positives are combined, e.g., the mutagenicity test 
battery or testing in several species for repeated dose toxicity, 
the role of in silico techniques will principally be within ItS, 
not as stand-alone replacements. they will support other types 
of information, help to prioritize and – following evaluation – 
increasingly substitute for testing. It might be that they can serve 
as 2nd generation alternative methods, i.e., modeling validated 
in vitro methods, because these more simple but standardized 
tests allow for the generation of large datasets, which would 
facilitate modeling of new key events.
1.2.6  Information-rich single tests
the sensitivity of the test system, i.e., here the spectrum of 
interactions with xenobiotics covered by the test system, can 
be increased by measuring more endpoints, e.g., by omics or 
high-content imaging. this can be done by supervised analy-
sis (measuring known biomarkers or hazard pathways) or in an 
unsupervised manner by testing for any response, which only 
then is interpreted as a signature of effect. Prominent exam-
ples are cell systems combined with transcriptomics, proteom-
ics, or metabolomics. this typically will lead to signatures of 
toxicity (Sot), such as a reduction of information to patterns 
of signals associated with the hazard. Notably, identifying bi-
omarkers from the variety of signals should shift the approach 
away from the more traditional (1.2.2) and (1.2.3) approaches. 
High-content measurements, such as image analysis, represent 
other technologies increasingly applied here. We should bear in 
mind that even the most sophisticated measurements and bioin-
formatics can hardly overcome the limitations of the cell sys-
tems. therefore, the experience gained with the development 
and validation of alternative methods with simple endpoints is 
of critical importance when moving towards wholly novel tech-
nologies. Good Cell Culture Practices form only one example 
here (Coecke et al., 2005; Hartung, 2010b; leist et al., 2010; 
Wilcox and Goldberg, 2011).
1.2.7  Integrated testing strategies (ITS)
In every case where no single property or single test system can 
be	identified	to	cover	a	hazard,	tests	will	need	to	be	combined	
and results integrated. One key example is the combination of 
toxicity data on the one hand (e.g., derived in vitro and/or in sil-
ico with kinetic data (e.g., modeling) in ItS, see, e.g., DeJongh 
et al., 1999; Forsby and Blaauboer, 2007; Blaauboer, 2010). the 
purposes of combining tests can be:
– covering different mechanisms or applicability domains
– increasing the predictive value compared to a single test
–	 avoiding	costly	tests	or	animal	tests	by	filtering	out	certain	
substances
– adding kinetic information to hazard evaluations
– integrating existing data
In the simplest case an ItS is a battery of tests, and any positive 
result is taken as an indication of toxicity, as is the case for the 
combined mutagenicity tests. More sophisticated combinations 
with interim decision points are emerging (Jaworska et al., 
2011; Jaworska and Hoffmann, 2010), but accepted concepts 
regarding how to construct and validate them are not available. 
A major problem seems to be that most methods now being 
combined into ItS were originally developed to work as stand-




but with the possibility of a similar effect is possible. Normal-
ly there is no time to rule out false-positives. False-negatives, 
however, represent possible disaster (not only the worst case, 
when successful drugs have to be withdrawn from the market, 
but also when expensive clinical evaluations have to be stopped 
because of side-effects or the need for additional toxicological 
studies). 
For chemicals and consumer products, the situation is, in 
principle, very similar. For work safety, over-labeling is not 
very critical, and for consumer products there is often a choice 
among less critical chemicals. It is telling that more than 90% 
of	the	new	chemicals	notified	are	not	acutely	toxic	(more	than	
50% of the animals survive a dose of 2 g/kg); this means that 
such non-toxic substances mostly have been further developed 
to	applications	that	reach	the	market	and	notification.
Several business impact studies have been carried out for 
ReACH. the fundamental problem of applying tests optimized 
for new chemicals to existing chemicals, however, has so far es-
caped attention: How much effort will be spent to demonstrate 
that	a	result	is	indeed	a	false-positive?
typical measures include:
– repetition of the test





All these measures are as costly as, or sometimes even enor-
mously more costly than, the original test. Worse, they always 
leave some doubt with regard to the substance. thus, it is criti-
cally important that the number of false-positives be limited up 
front.	 In	 the	field	of	carcinogenicity,	 in	particular,	 the	precau-
tionary principle produces many false-positive results. It is well 
known that the in vivo test for carcinogenicity has produced 
enormous numbers of false-positive results already (see below). 
In addition to the in vivo test for carcinogenicity, the current in 
vitro test battery for mutagenicity, i.e., the combination of two 
tests, results in a false-positive rate of 65-90% for non-carci-
nogenic substances. this means that the already high propor-
tion of false-positive results from the cancer bioassay will be 
further increased by an enormous number of non-carcinogenic 
substances showing a genotoxic effect in one of the two in vitro 
tests. Furthermore, aspects of variability related to a test, e.g., 
inter-animal variation, or within- or between-laboratory vari-
ability, can cause false-positive results. 
ITS	do	more	than	define	how	to	test	strategically;	they	also	
determine whether to test at all, as existing and non-testing in-
formation can also be integrated. there are three reasons why 
testing of a substance might not be necessary:
–	 Available	information	on	a	given	substance	is	sufficient.	
–	 Information	on	 related	compounds	 is	 sufficient	 to	 extrapo-
late.
– exposure or uptake by the organism is so low that testing can 
be waived. 
these three aspects have to be separated from creating new 
reproductive toxicity, or carcinogenicity, a further increase in 
the proportion of false-positives will arise. this will be the case 
particularly	when	non-specific	tests	are	used	for	relatively	rare	
hazards (Hoffmann and Hartung, 2005). In such a case, the 
false-positives likely outnumber the real-positives, e.g., by ten-
fold in case of the cancer bioassay (see below). 
the extent of false-positives also is determined by the number 
of replicate animals. In its most typical application (discriminat-
ing between non-responding and responding animals), the use 
of replicates again reduces false-negatives and increases false-
positives. Similarly, multiple testing increases the number of 
false-positives.	Setting	a	significance	level	of	95%	implies	that	
one out of 20 results is false-positive. to date, the cancer bio-
assay includes more than 60 endpoints, the reproductive two-
generation study 80 and a 28-day repeated dose study 40 – argu-
ably,	it	is	difficult	for	any	substance	to	test	negative.	The	same	
reasoning holds true for other tests. the more tests done on a 
single chemical, the more likely that there is a positive result in 
one. A cynic might conclude that a non-toxic substance must be 
one that has not been tested often enough.
ReACH foresees the application of the toxicological toolbox 
to existing chemicals of often enormous economic value. the 
costs of ReACH have been calculated until now on the basis 
of the actual costs of the tests that would be required to prepare 
the	dossiers.	The	consequence	of	false-positive	classifications	
is largely overlooked, at least by regulatory agencies, though 
the potential impact is not lost on companies. the consequenc-
es include unnecessary restrictions of use and safety measures, 
unjustified	 abandoning	 of	 chemicals,	 or	 laborious	 follow-up	
studies to rule out a particular unwarranted safety concern. the 
only rational exit from this dilemma is through a combination 
of tests – a test strategy, where at least one sensitive (few false-
negatives)	 test	 and	 one	 specific	 (few	 false-positive)	 test	 are	
combined. Integrated testing Strategies (ItS) are needed. 
there is a fundamental difference between the testing needs 
of new versus existing chemicals: Any new chemical represents 
a possible health hazard, while the longer a chemical is in use, 
the lower the uncertainty. After the creation of a new chemical, 
its utility is uncertain; while the longer it is in use, the more its 
economic value becomes evident. the consequence is simple: 
false-positive toxicological results are less and less tolerable. 
While we tend to accept the result of a toxicological evaluation 
early after generation of a chemical and uncertainty is not wel-
come, for advanced chemicals in broad use it is unavoidable that 
problematic test results be questioned.
Drug development represents a good example of the attitude 
toward	new	substances,	especially	since	this	field	has	pioneered	
and shaped our toxicological approach. Classically, i.e., when 
the toxicological toolbox was developed, around 10,000 sub-
stances were synthesized and evaluated to bring one product to 
the market. Since the bulk of the cost is generated in the clini-
cal phase of development, and toxicological studies represent 
an	“entry	permit”	for	first-time	testing	in	humans,	an	early	and	
clear statement on the health hazards of a substance is most im-
portant. typically, a broad variety of similar substances related 
to the lead compound under development are synthesized and 
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exposure/bioavailability-based waiving represents another 
key decision point in many ItS. For most health effects (most 
likely even for cancer and reproductive toxicology), a mini-
mum concentration must be reached in the target tissue. If this 
can be excluded due to exposure scenarios and/or limited up-
take by the organism, it might not be necessary to conduct 
further testing. However, this means that the judgment is not 
definite	but	depends	on	chemical	use	(exposure	scenarios	and	
route of application). this approach is most promising for cos-
metics, where clear exposure scenarios are given. It also can 
apply to strictly controlled intermediates when containment 
can be assured by appropriate risk management measures, and 
hence ttC type approaches can be useful to set “health bench-
marks” for exposures because likely exposure scenarios can be 
formulated. It is worth noting that the best-established alterna-
tive approach to assess uptake is the one for skin absorption 
(OeCD test guideline 428; OeCD, 2004), again favoring ap-
plications for cosmetic ingredients. At the same time, we need 
ways to incorporate dermal absorption into risk assessments 
under ReACH, rather than being forced to live with conserva-
tive 100% defaults.
When composing and validating a test strategy, it is crucial 
to assess the performance characteristics of all building blocks. 
emerging methodologies (e.g., from Bayesian decision theory) 
may provide valuable tools for strategic development (Jaworska 
and Hoffmann, 2010).
Some principles for ItS are evident:
–	 Combine	 sensitive	 and	 specific	 tests;	 combine	 screening	
and	confirmatory	tests.	Pertinent	examples	are	mutagenicity	
tests, where the positive results of a battery of usually two 
in vitro tests (accepting a huge proportion of false-positives, 
i.e., 95%) are subsequently ruled out by the animal experi-
ment. 
– For rare health effects, identify the negatives; use prioritiza-
tion to increase frequency of positive results.
– Assigning a test result means reducing information; combi-
nation of raw data from two tests might be more powerful 
than	combining	two	final	test	results.
– For the mutagenicity test battery it has been shown that tests 
of low predictivity on their own can be combined to result in 
highly predictive tests (Jaworska et al., 2005).
– Allow interim decisions to obviate further testing (tiered test-
ing strategies).
–	 Conduct	inexpensive	and/or	non-animal	tests	first.
– Interlink tests for various health effects, e.g., using the same 
control groups or addressing several endpoints in one animal 
study (beware of multiple testing).
1.2.8  Pathways of Toxicity (PoT) and systems toxicology
Our	scientific	understanding	of	how	genes,	proteins,	and	small	
molecules interact to form molecular pathways that maintain 
cell function is evolving rapidly. Pathways that lead to adverse 
health effects when perturbed are referred to as Pathways of 
Toxicity	(PoT).	The	exploding	scientific	knowledge	of	mode	of	
action in target cells, tissues, and organs, driven by advances in 
molecular and computational tools and coupled with the con-
knowledge. Again, the strategic combination of individual tests 
is often needed. Combinations of tests are required when the 
performance of one test cannot suit all needs. the following 
aspects have to be taken into account to optimize the approach 
for a given purpose:
– work load and costs
– animal consumption
– certainty of result and resulting safety level
– applicability, e.g., for chemical classes
Components of ItS other than testing in vitro or in vivo are:
– Use of existing information: Possible sources of information 
will	differ	for	given	substances	and	fields.	The	most	impor-
tant questions are how to retrieve them and how to judge 
their quality (and, thus, their utility). Quality of science does 
not depend on quality measures like ISO or Good labora-
tory Practice, but such quality-assurance programs safeguard 
proper documentation and the reliability of results. Similarly, 
adherence to international test guidelines is not a prerequisite 
for good toxicology, but it facilitates comparability and ac-
ceptance. It will be necessary to agree on criteria for each 
given	 purpose,	which	might	 benefit	 from	 the	 development	
of scoring systems for the quality of studies and possibly 
thresholds for acceptability. 
– extrapolation from existing information: Several ways of 
using information on other chemicals have to be distin-
guished:
- read-across (interpolation from existing data of related 
chemicals),	 i.e.,	 the	 data	 gap	 filling	 conducted	 within	 a	
category of substances
- chemical grouping (testing of prototypic compounds out 
of a group of similar ones only)
- structural alerts and rule-bases (structural characteristics 
that raise concerns or rule out possible hazards (SAR – 
structure activity relationships))
- (quantitative) structure activity relationships, i.e., (Q)SAR 
(correlation of chemical characteristics – physicochemical 
descriptors, with activities) 
the basic question is intriguing: can we use information on 
similar chemicals to draw conclusions for those for which we 
have	no	test	results?	Certainly	not	always.	Who	could	possibly	
predict that a shift of an OH-group in a dioxin molecule changes 
the	potency	a	thousand	fold?	The	question	is	whether	the	uncer-
tainty of such estimation techniques is larger than the uncertain-
ty of tests and interspecies predictivity. Few formal validations 
have been initiated for some methods ((Q)SAR and rule-based 
systems). there are parallel efforts underway elsewhere to de-
fine	which	scientific	principles	and	approaches	are	merited	 to	
confirm	and	justify	the	appropriateness	of	a	read-across.	In	gen-
eral, formal validations are avoided and instead concrete exam-
ples to help benchmark potential acceptance under regulatory 
frameworks by establishing consistent approaches dependent on 
context for each chemical and endpoint under consideration are 
needed. Some similar assessments of read-across approaches 
and chemical grouping will be necessary. However, concepts 
for validation – especially of ItS – are only emerging (Kinsner-
Ovaskainen et al., 2009).
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ing strategy in 2009. Depending on the proponent, more or 
less emphasis is given to technological updates, throughput 
of testing, costs, replacement of animal testing, or quality of 
toxicological assessments. there is no doubt that all aspects 
synergize to bring about a potentially revolutionary change 
(Hartung, 2008c).
Although a broad discussion has ensued on the design and fea-
sibility of the new toxicity testing paradigm, we are only at the 
beginning of such a shift. Recognizing that success will require 
a long-term, concerted effort by many investigators working in 
a coordinated manner, two NIH institutes (NHGRI, NIeHS), 
along with ePA and FDA, entered into a formal collaboration in 
2009, now known as tox21. these partners have demonstrated 
high-throughput screening assays to identify toxicity pathways 
and are developing computational models and analysis, and in-
formatics tools – all of which can be leveraged for this project. 
Although	there	is	not	yet	a	consensus	definition	for	PoT	(con-
cepts range from perturbed physiological pathways to adverse 
outcome pathways, modes of action, or signaling cascades), the 
general	 idea	 is	 to	develop	a	field	of	systems	 toxicology	using	
systems biology as a “role model.” Parallel developments in all 
fields	of	the	life	sciences	will	support	this,	but	toxicology	has	
some features that will help drive its development:
– an urgent need for change
– immediate commercial applications
– reference substances to induce toxicities
– the foundation of (pre-)validated alternative methods from $ 
500+ million of research funding
– a culture of Good laboratory Practice (GlP), Good Cell 
Culture Practice (GCCP), and validation (and increasingly 
eBt) for quality control
comitant development of high-throughput and high-content 
screening assays, enables interrogation of these Pot and pro-
vides a means to study and evaluate the effects of thousands of 
chemicals.	A	number	of	PoT	have	been	identified	already;	how-
ever, most Pot are only partially known, and no common anno-
tation exists. Mapping the entirety of these pathways – a project 
we have termed the Human toxome – will be a large-scale ef-
fort, perhaps on the order of the Human Genome Project.
the 2007 NRC vision document, Toxicity Testing for the 
21st Century – a Vision and a Strategy (Krewski et al., 2010), 
has strongly endorsed the concept of Pot. this vision em-
braces new high-content, high-throughput, and bioinformatics 
tools for identifying Pot. europe and the US have pursued 
the development of new toxicological tools in very different 
ways (Hartung, 2010b). the NAS/NRC tox-21c report calls 
for a paradigm shift in toxicology. In February 2008, several 
American agencies, recently joined by the FDA, announced a 
coalition to facilitate its implementation (Collins et al., 2008): 
“We propose a shift from primarily in vivo animal studies to 
in vitro assays, in vivo assays with lower organisms, and com-
putational modeling for toxicity assessments.” In USA Today 
of the same day, Francis Collins, now Director of the National 
Institutes of Health, stated: “(toxicity testing) was expensive, 
time-consuming, used animals in large numbers, and didn’t 
always work.” In the same article, elias Zerhouni, then Direc-
tor of NIH, said: “Animal testing won’t disappear overnight, 
but the agencies’ work signals the beginning of the end.” Only 
four years after publication of the NAS/NRC report, we have 
seen numerous conferences and symposia addressing the re-
port and its implementation, the formation of an alliance of 
US agencies, and the development of a new ePA toxicity test-
Fig. 1.1: The evolution of toxicology and its quality assurance
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velopmental neurotoxicity, funded by FDA, currently form the 
basis for the creation of a Pathway of toxicity Mapping Center 
(PotoMaC) at Johns Hopkins University.
The	 identification	and	use	of	PoT	is	 the	basis	 for	undertak-
ing a revolutionary approach to toxicity testing. Although mod-
ern	toxicology	has	identified	many	modes	of	action,	they	have	
largely remained isolated mechanisms that cannot be broadly 
applied	to	sufficient	numbers	of	toxicants	to	warrant	the	estab-
lishment of dedicated toxicity tests, and they do not yet satisfy 
regulatory	 needs.	 This	 means	 that	 our	 proposed	 PoT	 defini-
tion and development of novel test strategies not only initiates 
a	novel	test	paradigm	in	general,	but	will	also	benefit	specific	
screening programs. It aims to change the general toxicity test-
ing paradigm. the key challenges to this are:
–	 a	harmonized	definition,	annotation,	visualization,	and	shar-
ing of Pot.
–	 strategies	 from	 systems	 biology	 for	 PoT	 identification	 and	
their validation.
– composition of integrated testing strategies based on these 
PoT	with	a	definition	of	adversity	and	subsequent	translation	
to a risk assessment paradigm. 
Mapping	 the	Human	Toxome	will	 be	 a	 first	 step	 towards	 the	
development of a Human toxicology Project. In contrast to the 
currently used phenomenological “black box” that is animal 
testing,	pathways	of	toxicity	(PoT)	will	be	identified	primarily	
in human in vitro systems to provide more relevant, accurate, 
and mechanistic information for the assessment of human toxi-
cological risk. the ultimate future goal is to bring together a 
broad	scientific	community	 to	map	 the	entirety	of	 the	Human	
toxome. 
the concentration at which a substance triggers a Pot will be 
extrapolated to a relevant human blood or tissue concentration 
and,	finally,	 a	 corresponding	dose	by	 (retro-)	PBPK	 (physiol-
ogy-based pharmacokinetic) modeling, informing human risk 
assessment (Adler et al., 2011). Perhaps more importantly, if a 
substance	does	not	trigger	any	of	these	PoT,	it	may	for	the	first	
time be possible to establish the lack of toxicity (i.e., safety) of 
a substance at a given concentration. this project will need to 
combine several of the latest emerging technologies in life sci-
ences. transcriptomics and metabolomics currently are the most 
advanced	technologies	for	pathway	identification,	but	these	are	
rarely combined to map pathways. 
the main difference from ItS is that this approach will op-
erate at the subcellular level and break modes of action and 
mechanisms down to the underlying pathways or the pertur-
bation of physiological pathways (notably, two very different 
definitions).	 The	 term	 pathway	 might	 be	 misleading,	 as	 we	
are more likely referring to perturbations of networks. the ap-
proach only becomes meaningful if a common annotation of 
Pot is developed. Hence, a central repository of Pot constitut-
ing the (Human) toxome can be created (Hartung and McBride, 
2011). this might serve in the future to identify Pot associated/
crucial/amplifying or pathways of defense (PoD) protecting/re-
versing/dampening a given hazardous effect. the link to classes 
of substances, cell populations, species, or resulting phenotypic 
changes	will	foster	the	understanding	of	the	specific	effect.
toxicology is increasingly embracing the technologies of the 
21st century (Bhogal et al., 2005). the discussion surround-
ing tox-21c has accelerated this process, as many have started 
to develop and commercialize these technologies, which lend 
themselves to the vision’s implementation (van Vliet, 2011). 
this parallels developments in all life sciences implement-
ing and exploiting the new technologies. Unlike most medical 
questions, toxicology has the advantage of having a relatively 
clear	start	and	end	to	the	pathways,	i.e.,	defined	substances	and	
hazards, as compared to usually multi-factorial contributors to 
disease and complex manifestations impacted by individual 
constellations of the patient.
the basic idea of tox-21c is to change in the level of reso-
lution. In a nutshell, biochemistry/molecular biology are used 
to describe phenomena versus physiology/cellular pathology, 
which, so far, have been used predominantly when discussing 
modes of action. Figure 1.1 illustrates the larger perspective on 
the evolution of approaches: technologies have developed over 
the last century from animal to in vitro/in silico and, more re-
cently, mode of action resolution. the concept of tox-21c is to 
further	 refine	 resolution	 of	 analysis	 to	 the	molecular	 basis	 of	
Pot. these technologies correspond to different quality assur-
ance measures, however, where the validation of ItS (typically 
built from combining mode of action tests) and evidence-based 
toxicology (eBt) (Hartung, 2009b; Hoffmann and Hartung, 
2006;	 Griesinger	 et	 al.,	 2007)	 are	 only	 emerging.	 The	 figure	
captures how current regulatory toxicology is formed by the 
earlier technologies, leading to a deterministic (point estimate), 
typically precautionary risk assessment. the vision is that the 
new tools of mode of action models, their combination in ItS, 
and the Pot-based emerging technologies allow the formula-
tion of a Systems toxicology approach. As discussed elsewhere 
(Hartung, 2010c), these integrated and information-rich assess-
ments require a shift to a more probabilistic evaluation, where 
each and every test changes to some extent the probability of a 
hazard and/or its uncertainty. 
the Pot approach represents the continuation of omics by 
reducing phenotypic characterization (“signatures”) to the un-
derlying Pot. this introduces a new quality – that of convert-
ing correlations into a hypothesis that can be tested or, in other 
words, validated. Pot can be manipulated (blocked, triggered) 
or	PoT-specific	assays	can	be	designed.	
We	hypothesize	 that	 the	 number	 of	PoT	 is	 finite.	This	 cor-
responds with the idea that the number of vulnerable targets of 
a	cell	(its	critical	infrastructure)	is	finite.	If	this	is	the	case,	or	
at least if a limited number of Pot can cover a large number of 
agents and hazards, then a comprehensive list of Pot (the Hu-
man toxome) (Hartung and McBride, 2011) will allow us to de-
scribe toxic effects at a new level of resolution. We will be able 
to annotate Pot to cell types, hazards, toxin classes, species, 
etc., in a manner similar to how we currently annotate (tran-
scribed) genes. It is important to note that the Human toxome 
will not be populated by a single test and a single measurement 
independent of its information-richness, but will require the 
confirmatory	combination	of	various	models	and	technologies.	
Pilot projects for endocrine disruptors, funded by NIH, and de-




often rendering the systems overtly responsive. the problem of 
defining	adversity	 (Boekelheide	and	Andersen,	2010;	Boekel-
heide and Campion, 2010) can therefore be correlated with the 
thresholds of the prediction model of the alternative method 
they	were	identified	in.	Alternatively,	methods	trying	to	define	
the point of departure of biological responses are emerging 
(Judson	et	al.,	2011).	However,	this	is	only	a	first	step	to	finding	
acceptable methods to distill results from the rich datasets suit-
able to inform a risk assessment process. A prime example was 
given in 2010: the quick evaluation of dispersants used for the 
gulf oil spill disaster (Judson et al., 2010) shows that the new 
technologies can indeed deliver such information in a timely 
and cost-saving manner.
 
Need for probabilistic risk assessment
In order to make use of the novel high-content, high-throughput, 
and Pot information, we also need to develop ways of distilling 
relevant information out of the large datasets that will be pro-
duced. this requires a radical change from the past: traditional 
hazard	identification	methods	have	been	descriptively	based	or	
based on empirical studies, which are resource-intensive and 
inefficient	(see	above).	Furthermore,	empirical	studies	lack	the	
capacity to detect low probability events, such as those expe-
rienced in low dose carcinogenicity. the current deterministic 
methods are based on point estimates, which are almost always 
worst-case estimates. In order to improve the transparency, con-
sistency, and objectivity of the assessments, a need for more for-
mal approaches to data integration has been recognized (OeCD, 
2009).
three main conceptual requirements for a multi-test decision 
framework, based on integration of multiple pieces of evidence 
and a decision-theoretic setting, have recently been formulated 
(Jaworska et al., 2010). According to the analysis, the frame-
work must:
– be probabilistic, in order to quantify uncertainties and de-
pendencies;
– be consistent by allowing reasoning in both causal and pre-
dictive directions;
– support a cyclic hypothesis and data-driven approach, where 
the hypotheses can be updated when new data arrive.
the formal framework that potentially meets these require-
ments, allowing for evidence maximization and reduction of 
uncertainty, can be found in Probabilistic Risk Assessment Net-
works	(PRA).	These	PRA	methods	are	designed	specifically	for	
prospective analysis of the likelihood of low probability events 
(Greenland, 1998). PRA tools are not new to the risk assessment 
process (Jager et al., 2001; Verdonck et al., 2005) and they have 
been used mainly in the derivation of exposure assessment sce-
narios. the intent is to shift the emphasis of these tools to hazard 
identification	and	use	PRA	to	analytically	assess	the	probability	
that a substance could potentially cause harm. the advantage of 
PRA is that uncertainties are transparently taken into account, 
and the cautionary aspect is left to the risk management process. 
ePA toxCast has started to develop a risk assessment frame-
work based on high-throughput test systems (HtS) data (Judson 
the critical question is whether there is a limited number of 
PoT?	It	is	likely	that	the	number	of	critical	cellular	infrastruc-
tures is limited, which means that the points of vulnerability, to 
which the Pot would converge, should also be limited.
Definition of PoT
There	 is	 no	 generally	 accepted	 definition	 of	 PoT.	 First,	 PoT	
are	 causal	 in	 contrast	 to	 adaptive	 pathways.	We	might	 define	
as overarching xenobiotic Response Pathways, which include 
Pot, pathways of defense (PoD) and epiphenomena (epiP), 
which do not affect the manifestation of the altered phenotype. 
Note that epiP can still serves as biomarkers if triggered con-
sistently with the Pot, but blocking them would not alter the 
manifestation	of	toxicity.	Three	proposed	definitions	are:
PoT are molecularly defined chains of not necessarily 
linear cellular events stretching from point of chemical 
interaction to perturbation of metabolic networks and 
phenotypic change. PoT are causal – either necessary 
or aggravating – and will typically have a threshold of 
adversity.
Or
PoT are the formal description of toxic modes of action 
on the resolution of underlying biochemistry and mo-
lecular biology. 
Or
PoT are causal links between a given toxicant and its 
effect in a systems toxicology approach.
These	definitions	distinguish	PoT	by	molecular	resolution	from	
MoA and by causality from signatures/biomarkers. It leaves 
open the interactions between different Pot (synergies, leading 
“pacemaker” Pot, etc.) and of Pot with PoD.
three very different approaches were taken to explore the 
concept: toxCast of the US ePA (Judson et al., 2011; Kavlock 
and Dix, 2010) uses a broad variety of from the shelf avail-
able	pathway	assays	to	characterize	biological	profiles	of	sub-
stances in an HtS manner to associate these with their (mainly 
animal)	toxic	profile.	The	“Hamner	approach”	(Andersen	et	al.,	
2011) selected some known relevant pathways to explore the 
Pot concept. the approach spearheaded by CAAt (Hartung 
and	McBride,	2011)	aims	for	an	unsupervised	identification	of	
Pot by omics technologies. the latter was just awarded an NIH 
transformative Research grant, “Mapping the Human toxome 
by	Systems	Toxicology,”	which	aims	to	further	define,	annotate,	
and validate Pot as well as create a public database to share Pot 
from	various	groups	and	fields.	The	consortium	includes	both	
the Hamner Institutes for Health Sciences and toxCast, thus 
raising the possibility of merging and synergizing the different 
approaches.
Formally developed alternative methods have one major ad-
vantage compared to the research models typically found in 
the literature: beside their higher degree of standardization and 
documentation, they need to include a prediction model, i.e., a 
formal algorithm for deriving predictive results. this means that 
the	level	of	response	indicating	adversity	is	defined.	This	is	rare-
ly the case for tests, which have not been formally evaluated, 
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Transition in regulatory toxicology
Developing	 the	 technologies,	 however,	 is	 only	 a	 first	 step.	A	
possible transition to a new regulatory toxicology based on Pot 
represents an enormous and multi-faceted challenge (Hartung, 
2009d), including:
– testing strategies instead of individual tests: 
 the new Pot approaches will be usable only in combination; 
however, we have no concept for composing or validating 
ItS.
– Statistics and multiple testing: 
 Multiple testing challenges number of replicates and statis-
tics.
– threshold setting: 
	 We	need	to	define	adversity.
–	 What	to	validate	against?	
 Since no human data are typically available, and no animal 
test is replaced one-to-one, only sound science can guide us.
–	 How	to	open	up	regulators	for	change?	
 the comfort zone of the regulators is a major obstacle to 
change.
– the global dimension: 
 No method accepted in one economic area will make a 
change.
– Quality assurance for the new approach: 
 the new technologies require QA from Good Cell Culture 
Practices, Good Modeling Practices, adaptation of Good 
laboratory Practices to evidence-based toxicology.
– Validation of the new approach: 
 traditional validation is too slow, costly, and rigid to serve 
the new technologies.
– How to change with step-by-step developments becoming 
available?
 the simple incorporation of some new approaches might ob-
scure the need for a fundamental change, but who wants to 
wait	until	a	completely	novel	scheme	is	available?
–	 How	to	organize	transition?
 there is a need for objective assessment, e.g., by evidence-
based toxicology, to assess traditional and novel approach-
es.
– Making it a win/win/win situation:
 every stakeholder will not be happy with new approaches 
that are more complex and more circumspect with regard to 
certainty of its result. We have to demonstrate the compensa-
tory advantages of better predictivity.
et al., 2011) that has kinetic, mechanistic, and uncertainty com-
ponents. Building on this approach, extending it to high-content 
(omics) data, and analytically combining the information within 
a PRA-based Bayesian network, is the logical next step.
Regulatory science is, for practical purposes, bound by the 
concept	 of	 classification	 and	 labeling	 to	 definitively	 assign	 a	
substance to hazard classes. Science, however, can only deliver 
probabilities (Hartung, 2010c). this is due to the nature of the 
underlying data: Biological objects we test are highly variable, 
and there are other uncertainties associated with diagnostic er-
rors (Hoffmann and Hartung, 2005). this comforts neither the 
regulator	 nor	 the	 regulated	 players,	 as	 it	 impedes	 definitive	
hazard judgments and the resulting decisions. tests change the 
pre-test to a post-test probability of hazard (Aldenberg and Ja-
worska, 2010; Jaworska et al., 2010; Pepe, 2004), reducing un-
certainty.	This	new	understanding	analytically	refines	the	initial	
hazard information. the paradigm change like this will also al-
low new methods to enter the regulatory arena more easily, as 
these	refined	methods	are	not	perceived	as	a	“game-changing,”	
full replacement, but as changers of probabilities. With the suc-
cessful PRA use in estimates and hazard judgments, its impact 
will grow and – we hope – eventually become central to hazard 
testing strategies, simultaneously reducing the costs and time 
associated with traditional approaches. 
It will be necessary to combine the elements of high-informa-
tion content methods (HIC), HtS, and ItS via PRA. the intent 
is	to	identify	human	hazards	prospectively	via	efficient	and	ef-
fective analytical methods. the basic hypothesis of a PRA-HIC/
HtS framework is that the approach provides useful informa-
tion for current knowledge gaps and also better informs haz-
ard decisions. PRA approaches, historically, have been based 
on traditional toxicological data (Chen et al., 2007). Here, we 
suggest using the data coming from HtS and HIC approaches. 
It is essential to develop a conceptual framework for integration 
of such test data coming from different sources to allow for in-
tegrated and reliable endpoint assessment, which we generally 
refer to as ItS. Such a decision-analytic framework will yield 
a more comprehensive basis upon which to guide decisions. 
A natural outgrowth of this approach is an increased capabil-
ity to combine and reuse existing data. the integration of such 
probabilistic hazard information with probabilistic exposure in-
formation (van der Voet and Slob, 2007) and probabilistic dose 
response assessments by PBPK (Kodell et al., 2006) represent 
logical extensions of this approach. As a result, the goal must be 
to adapt HtS, HIC, and PRA to better inform hazard decisions 
of manufacturers and regulators.
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rather than with a dose given to the animal, making it difficult to 
extrapolate the findings to an intact organism. One of the most 
obvious differences between the situation in vitro and in vivo 
is the absence of processes of absorption, distribution, metabo-
lism, and excretion (i.e., biokinetics) that govern the exposure 
of the target tissue in the intact organism. In addition, metabolic 
activation and/or saturation of specific metabolic pathways or 
absorption and elimination mechanisms may also become rel-
evant for the toxicity of a compound in vivo. These differences 
may lead to misinterpretation of in vitro data if such information 
is not taken into account. Therefore, predictive studies on bio-
logical activity of a compound require the integration of data on 
the mode of action with data on biokinetic behavior.
QIVIVE is the process of estimating the environmental expo-
sures to a chemical that could produce target tissue exposures in 
humans equivalent to those associated with effects in an in vitro 
toxicity test (e.g., an EC50, a benchmark concentration, or an 
interaction threshold identified by a biologically based dose-re-
sponse model for the toxicity pathway of concern). Using a com-
bination of quantitative structure-property relationship (QSPR) 
modeling, physiologically based biokinetic (PBBK) modeling, 
and collection of in vitro data on metabolism, transport, binding, 
etc., QIVIVE can provide an estimate of the likelihood of harm-
ful effects from expected environmental exposures.
Biokinetic modeling describes the dose and time-dependent 
absorption, distribution, metabolism, and elimination of a chem-
ical within an organism. Biokinetic models can be divided into 
two general groups: data-based (classical) models and physi-
ologically-based models (Andersen, 1991; Filser et al., 1995). 
Physiologically-based biokinetic (PBBK) models are especially 
useful for in vitro-to-in vivo, route-to-route, and animal-to-hu-
man extrapolations because they incorporate relevant anatomi-
cal structures that can be parameterized using independently 
derived parameters. In contrast to data-based models, PBBK 
modeling allows the description of the time-course of a com-
pound’s amount/concentration at the site of its action. PBBK 
modeling can contribute to reduction and refinement of animal 
studies by optimization of study design through identification of 
critical parameters and timeframes in kinetic behavior (Bouvier 
d’Yvoire et al., 2007; Clewell, 1993). In addition, PBBK models 
incorporating QSAR- and in vitro-derived parameters, coupled 
with in vitro assays of tissue/organ toxicity, have the potential 
to replace in vivo animal studies for quantitative assessment of 
the biological activity of xenobiotics (Blaauboer, 2001, 2002, 
2003).
The overall goal of this paper is to identify the key research 
needs to support a viable QIVIVE capability. The research 
proposed in this paper is considered to be fundamental to the 
successful use of in vitro kinetic data and PBBK modeling for 
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2.1  Introduction: toxicokinetics
A recent expert panel review of the available science relevant to 
the 7th Amendment of the EU Cosmetics Directive’s 2013 mar-
keting ban (Adler et al., 2011) analyzed toxicokinetics, among 
other issues, and concluded that it would take more than five 
years for the development of methods for estimating in vivo ki-
netics necessary to support risk assessments based on in vitro 
assays for systemic toxicity. The proposed roadmap identifies 
the key research needed to support quantitative in vitro-to-in 
vivo extrapolation (QIVIVE) for systemic toxicity for all chemi-
cals. The common aim of this research is to foster the develop-
ment of a methodology that incorporates state-of-the-art bioki-
netic modeling techniques to extrapolate critical concentrations 
at which in vitro toxicity is observed to be equivalent to in vivo 
doses based on the prediction of in vivo target tissue dosimetry. 
Kinetics should not be seen as a separate endpoint; rather, it is a 
tool to understand in vitro toxicity results and properly extrapo-
late them to human exposure. This methodology will provide a 
general framework for replacement of in vivo animal systemic 
toxicity assays with alternative in vitro toxicity testing. 
The aim of classical toxicological risk assessment is to es-
tablish safety factors for human exposure based on the evalu-
ation of the outcome of animal tests. The principal concern is 
finding the dose that causes no toxicologically relevant effect in 
the animal studies and extrapolating to the no-effect dose in the 
human under the application of appropriate safety factors. Most 
of the efforts to replace animal testing with alternative meth-
ods have focused on the use of in vitro tests for topical toxicity, 
such as skin and eye irritation (Hartung, 2010a). In contrast to 
their relatively straightforward application for topical toxicity, 
the use of in vitro toxicology methods as replacements for sys-
temic toxicity testing faces significant challenges. In particular, 
these studies associate an effect with a concentration in medium 
2  A Roadmap for the Development  
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chemical may suffice for many chemicals. Even with such a 
simple model, it would be possible to estimate the systemic 
concentrations expected to result from an in vivo exposure to a 
given dose. Thus, the model could be used to relate the concen-
trations at which toxicity is observed in an in vitro toxicity assay 
to the equivalent dose expected to be associated with toxicity 
for in vivo exposure. Similarly, biokinetic modeling of the in 
vitro toxicity assay can provide important information on the 
temporal profile of cellular exposure to a free chemical, which 
can be used in the design of the most appropriate in vitro experi-
mental protocol (Teeguarden and Barton, 2004).
The greatest challenge in parameterizing even the simplest 
biokinetic models is the estimation of metabolic clearance. 
QSAR algorithms for predicting metabolism parameters have 
only been developed for a limited number of chemicals, prima-
rily volatile organic compounds that are substrates for CYP2E1 
(Peyret and Krishnan, 2011). Thus, it would be necessary to per-
form in vitro assays of the dose-response (capacity and affinity) 
for metabolic clearance (Houston and Carlile, 1997; Kedderis, 
1997; Kedderis et al., 1993; Kedderis and Held, 1996). Eventu-
ally, as data accumulates for a large number of chemicals, it may 
become possible to predict clearance using QSAR approaches. 
Qualitative prediction of whether a drug is likely to be cleared 
by metabolism (including the CYP isoenzyme involved) or by 
urinary excretion on the basis of its physicochemical proper-
ties, has recently been demonstrated (Kusama et al., 2010). Of 
course, there is much more extensive data on drugs than on en-
vironmental chemicals.
There are chemicals, of course, for which a one-compartment 
description would not be expected to be adequate: highly li-
pophilic compounds, for example, or compounds for which the 
extrapolation of in vitro toxicity data to in vivo. This research 
roadmap will specifically address uncertainties in the effect of 
biokinetics on the estimation of systemic toxicity (both acute 
and subchronic) of xenobiotics from in vitro assays.
2.2  Overview of QIVIVE
Figure 2.1 illustrates a conceptual structure for the use of bi-
okinetic information in the estimation of in vivo toxicity from 
in vitro assays. In this scheme, available in vitro data on the 
absorption, tissue distribution, metabolism, and excretion of a 
chemical are used to parameterize a chemical-specific biokinet-
ic model. In many cases, current quantitative structure-property 
relationship (QSPR) techniques can be used to estimate chemi-
cal properties and kinetics when the specific data for that chemi-
cal is lacking. For example, simple empirical correlations have 
been developed for estimating the tissue partitioning of a chemi-
cal from its water solubility, vapor pressure, and octanol/water 
partitioning (DeJongh et al., 1997; Paterson and Mackay, 1989; 
Poulin and Krishnan, 1995). In addition, emerging quantitative 
structure-activity relationship (QSAR) techniques (e.g., know-
ledge-based systems) and other in silico models will become in-
creasingly useful for identifying likely metabolites and predic-
ting potential target tissues for toxicity (Barratt, 2000), so that 
the appropriate assays of in vitro effects can be selected. These 
target tissue assays then can provide information on the nature 
and concentration-response of the toxic effects of the chemical.
The complexity of the biokinetic model would depend on the 
physicochemical and biochemical characteristics of the chemi-
cal. A simple one-compartment description of the administered 
Fig. 2.1: A recommended scheme for incorporation of QSAR (QSPR) information, in vitro metabolism data, and biokinetic 
modeling in the estimation of human toxicity from in vitro assays 
(adapted from Blaauboer et al., 2001)
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quantitative assessment of the biological activity of xenobio-
tics (Blaauboer, 2001, 2002, 2003). Target tissues evaluated by 
in vitro assays can be included explicitly in the physiological 
structure of these models. The models can provide a mechanis-
tic description of barrier functions (gut, bile, kidney, blood-brain 
barrier, skin, and placenta (if reproductive or developmental 
toxicity are under investigation)), so that the data obtained from 
transporter assays could be readily incorporated. Important re-
search areas for in vitro methods include the development of 
validated, stable human hepatocyte systems, as well as in vitro 
systems for key transporters (renal, biliary, etc.). At the same 
time, QSAR applications need to be developed specifically to 
provide the kind of information needed by the PBBK models 
(metabolism constants, binding, etc.). Unfortunately, except in 
the case of drug-like compounds, the principal limitation in the 
development of useful QSAR applications appears to be the 
dearth of suitable data available for training knowledge-based 
systems. Nevertheless, in silico methods are of great interest, 
and some of them are under development or in the testing phase. 
They will gain more importance depending on the data, which 
will be fed in and, therefore, reliable and relevant in silico meth-
ods are to be expected.
The utility of an approach that integrates cell-based assays 
with QIVIVE has been demonstrated in the case of acute neu-
rotoxicity for eight chemicals: benzene, toluene, lindane, acry-
toxicity results from a metabolite. The physiological mammalian 
structure (tissue volumes, blood flows, ventilation rate, glomer-
ular filtration rate, etc.), however, is well characterized (EPA, 
1988; Brown et al., 1997), and there is no difficulty describing 
tissues separately when necessary. As mentioned above, tech-
niques exist for estimating tissue-specific partitioning for many 
types of compounds. Other data required would also depend on 
the class of chemical. For volatile chemicals, ventilatory clear-
ance can be estimated from the blood-air partition. For water-
soluble chemicals, urinary clearance can be estimated from the 
glomerular filtration rate or the renal blood flow (for secreted 
compounds). For some classes of chemicals, it would also be 
necessary to determine the fractional binding of the chemical 
to plasma proteins or the partitioning of the chemical into red 
blood cells.
An important underpinning of this process is that the kind of 
information necessary for a chemical depends on its structure 
and physicochemical properties. It seems reasonable to expect 
that chemicals could be categorized into classes based on their 
properties, and that this categorization would simplify the proc-
ess of determining the data needed for a particular compound. 
This concept is illustrated in Figure 2.2.
PBBK models incorporating QSAR- and in vitro-derived 
parameters, coupled with in vitro assays of tissue/organ tox-
icity, have the potential to replace in vivo animal studies for 
Fig. 2.2: Classification of compounds based on their physico-chemical properties 
(adapted from Blaauboer et al., 2001)
In this figure, the key physicochemical properties of a compound include its volatility, water solubility, and lipophilicity. These properties 
can be thought of as dimensions in which compounds can be categorized. In this way, compounds with similar properties can be 
grouped, and data for similar compounds can be used to fill gaps in the knowledge of a particular compound. For example, a recent  
study evaluated the possibility of predicting the in vivo kinetics of volatile organic compounds (VOCs) using PBBK models derived  
solely on the basis of physiological data and QSPR modeling (Liao et al., 2007). The authors concluded that acceptable predictions could 
be made for inhalation of lipophilic VOCs, such as trichloroethylene, but that the necessary QSPR algorithms were not available for  
water-soluble VOCs such as acetone.
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of potential in vivo exposures without consideration of bioavail-
ability and clearance of the chemicals (Blaauboer, 2010). Two 
recent studies evaluated the possibility of applying a simple 
QIVIVE approach to interpret the results of high-throughput 
assays conducted under the EPA ToxCast program (Rotroff et 
al., 2010; Wetmore et al., 2011). In these studies, hepatic meta-
bolic clearance and plasma protein binding were experimental-
ly measured for ToxCast Phase I chemicals. The experimental 
data were used to parameterize a simple in vitro-to-in vivo ex-
trapolation model to estimate the human oral equivalent doses 
necessary to produce steady-state in vivo blood concentrations 
equivalent to in vitro AC50 (concentration at 50% of maximum 
activity) or LEC (lowest effective concentration) values in the 
in vitro ToxCast assays. 
A simple clearance description (Wilkinson and Schenker, 
1975) was used to estimate expected steady-state blood concen-
trations. The equation assumes zero-order uptake of a daily dose 
from the gut (assuming 100% oral bioavailability) with both re-
nal and hepatic clearance. The steady-state concentration in the 
blood is then (see discussion in next section):
Css = ko/[(GFRxFub) + (QlxFubxClint/(Ql + FubxClint))]
In this equation, the term GFRxFub represents the renal ex-
cretion of unbound parent compound in blood by glomerular 
filtration, where GFR is the glomerular filtration rate, which 
is about 6.7 l/h in human adults (Rule et al., 2004), Fub is the 
fraction of the drug in the blood that is unbound (free), and ko 
is the input rate in mg/kg/h. The second term in the denomi-
nator is hepatic clearance, where Ql is liver blood flow (typi-
lamide, parathion/oxon, diazepam, caffeine, and phenytoin 
(Blaauboer, 2001). The aim of the study was the prediction of 
acute and subchronic neurotoxicity by integrating PBBK mod-
eling with quantitative toxicity data obtained from non-animal 
studies. Specifically, the study evaluated the ability of in vitro 
neurotoxicity tests to predict the in vivo toxicity of the above 
chemicals, using PBBK models describing their biokinetic be-
havior to conduct QIVIVE. Model simulation of the target tis-
sue dosimetry (i.e., the parent brain concentration) formed the 
basis for the prediction of the compound’s systemic toxicity 
(Cronin et al., 2011) for different exposure scenarios (acute and 
subchronic). Subsequently, the neurotoxic concentrations esti-
mated in in vitro tests (Kuegler et al., 2010; Crofton et al., 2011) 
could be compared with the brain concentrations simulated by 
the model. This approach allowed the authors a comparison of 
the toxic in vivo dose known from the literature with the model-
predicted dose suspected to cause neurotoxicity. Overall, the 
results of this study showed that a reasonable prediction of the 
systemic toxicity could be made for six out of the eight inves-
tigated compounds. The discrepancy between the observed and 
estimated LOELs ranged from a factor of less than two for com-
pounds with low toxicity, to a factor of ten for chemicals of high 
toxicity (Forsby and Blaauboer, 2007).
2.2.1  Example of a simple QIVIVE approach for  
parent chemical toxicity
High-throughput in vitro toxicity screening can provide efficient 
identification of the potential biological activity of chemicals. 
However, the concentrations at which effects are observed in 
the in vitro assays cannot be used to directly evaluate the safety 
Tab. 2.1: Comparison of in vitro-to-in vivo extrapolation modeling results with in vivo based results  
(modified from Wetmore et al., 2011)
  IVIVE IVIVE IVIVE IVIVE
 In Vivo Derived   fu=0.99 fu=0.99,







2,4-dichlorophenoxyacetic acid 9.05-90.05 39.25 40.34 39.25 40.34
Bisphenol-A < 0.13 0.35 0.40 0.06 0.07
Cacodylic acid 1.80 3.06 – 3.06 –
Carbaryl 0.03 0.07 0.07 0.03 0.03 
Fenitrothion 0.03 17.91 – 0.10 –
Lindane 0.46 13.21 – 0.07 –
Oxytetracycline dihydrate 0.36 2.00 0.44 2.00 0.44
Parathion 0.17 24.63 – 0.14 –
Perfluorooctane sulfonic acid 19,990 160.78 179.96 160.78 179.96 
Perfluorooctanoic acid 20,120 55.34 58.19 0.40 0.40
Picloram 0.27 57.63 32.01 0.37 0.19 
Thiabendazole 0.45 13.76 15.20 13.76 15.20
Triclosan 2-10 1.56 1.59 0.01 0.01
a Css, concentration at steady state for 1 mg/kg/day dose
b Predicted using the 1 µM metabolic clearance rate
c IVIVE performed incorporating Caco-2 data into the simulation, if available
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sumptions (Wilkinson and Schenker, 1975) were employed: (1) 
restrictive hepatic clearance (assuming only unbound chemical 
is available for clearance), using Fub determined experimentally; 
and (2) non-restrictive hepatic clearance (assuming all of the 
chemical is available for clearance), where the Fub was set to one. 
Riclosan is an example of a chemical that appears to have restric-
tive clearance, while picloram appears to have non-restrictive 
clearance, and the behavior of lindane appears to be intermediate 
between the two extremes. In general, the assumption of restric-
tive clearance produces a more conservative (higher) estimate of 
Css. In fact, these two clearance assumptions represent extremes 
bracketing the possible relationship between chemical disposi-
tion/transport and hepatocellular metabolism that can result in 
Css estimates that differ by several orders of magnitude. Hepatic 
clearance is complexly determined by a number of factors, in-
cluding liver blood flow, the association and dissociation rates for 
binding of the chemical to plasma proteins such as albumin, the 
kinetics of hepatocellular uptake of the chemical, and the kinet-
ics of hepatocellular metabolism. Indeed, no approaches have yet 
been demonstrated to predict the fraction of compound available 
for metabolism, even in the case of drugs.
The assumption of 100% oral bioavailability is conservative 
from a human health standpoint because lower absorption re-
sults in a higher oral dose required for achieving a specific Css; 
however, incorporation of Caco-2 assay data on bioavailability 
into the QIVIVE model can increase the predictivity of the Css 
cally on the order of 90 l/h in adults) and Clint is the intrinsic 
metabolic clearance for first-order conditions of metabolism 
in the liver at low concentrations. Hepatocellular clearance 
in this study was experimentally determined at 1 μM and the 
slope of the disappearance of the chemical over time was 
determined. Clearance was normalized to cell number, with 
the units μl/min/106 cells. In vivo intrinsic clearance was es-
timated by simply multiplying the in vitro clearance by the 
number of cells per gram of liver (roughly 137 x 106) and the 
weight of the liver (about 1820 g in an adult). Css calculations 
were performed using an arbitrary dose of 1 mg/kg/day. The 
Simcyp simulation platform (Rostami-Hodjegan and Tucker, 
2007) was used to perform Monte Carlo analysis to simulate 
variability across a population of 100 healthy individuals of 
both sexes from 20-50 years of age. A coefficient of variation 
of 30% was used for intrinsic and renal clearance. Reverse 
dosimetry was then used to generate oral equivalent doses ac-
cording to the following formula:
Oral Equivalent Dose (mg/kg/day) = AC50 or LEC/Css
For a small number of these chemicals, it was possible to find in 
vivo biokinetic data to estimate a steady state concentration at an 
exposure of 1 mg/kg/day for comparison with the in vitro predic-
tions. The results of the comparison are shown in Table 2.1.
For comparison purposes, two alternative hepatic clearance as-
Fig. 2.3: Key research needed to support QIVIVE
BASKETTER ET AL.
ALTEX 29, 1/12 21
one of the advantages of using in vitro metabolism data over 
in vivo experiments.
2.3  Research gaps
The subsequent sections of this paper will attempt to elucidate 
the key research areas needed to support QIVIVE for assessing 
risks on the basis of in vitro toxicity data, including:
– Improving the accuracy of in vitro toxicity assays by deter-
mining the free concentration of chemical instead of simply 
using the nominal concentration
– Extrapolating in vitro kinetic results to estimate in vivo clear-
ance
– Obtaining parameters for PBBK models to perform 
QIVIVE 
The proposed key research areas are summarized in Figure 2.3 
and Table 2.2.
2.3.1  Characterization of free concentration
The free concentration of a chemical drives both its kinetics and 
dynamics (Mendel, 1992). The concentration of free chemical 
in an in vitro assay that elicits a certain response may differ 
determination, as in the case of oxytetracycline dihydrate and 
picloram in Table 2.1. On the other hand, the assumption that 
renal clearance is solely a function of Fub and the GFR is not 
necessarily conservative, since active renal resorption would 
result in a higher Css at a given dose, as in the case of the two 
perfluorinated chemicals in Table 2.1.
Other limitations of this simple approach include:
– The analysis is predicated on the assumption that blood con-
centrations equivalent to the nominal in vitro AC50 or LEC 
values would produce equivalent responses in vivo. Howev-
er, the concentration of free chemical in an in vitro assay that 
elicits a certain response may differ from the nominal AC50 
value due to factors such as protein-lipid composition of the 
media and binding of the chemical to surfaces (Blaauboer, 
2010).
– The biokinetics and bioactivity were only evaluated for the 
parent compound. No attempt was made to evaluate biologi-
cal activities and dosimetry of metabolites.
2.2.2  Example of a QIVIVE approach for toxicity  
of a metabolite
A couple of publications by Punt and colleagues (Punt et al., 
2008, 2009) present an example of a more sophisticated QI-
VIVE approach using metabolism data collected in a number 
of subcellular fractions. Although the intent of the study was 
to evaluate the relevance of carcinogenicity of estragole re-
ported in high-dose animal studies to human exposure situa-
tions, a similar QIVIVE approach also could be applied for the 
interpretation of in vitro toxicity assays. The key metabolism 
parameters to be estimated were rates of multiple biotrans-
formation reactions that determine the level of carcinogenic 
species (1-sulfooxyestragole) in the liver. Due to the complex-
ity of metabolism steps involved in formation of the ultimate 
carcinogenic metabolite of estragole as well as detoxication of 
parent compound and other intermediate metabolites, the ap-
proach using a combination of subcellular fractions along with 
different cofactors was more valuable for the purpose of their 
modeling than using a more integrated system such as hepa-
tocytes (Punt et al., 2008, 2009). By manipulating cofactors 
such as NADPH, UDPGA, NAD+, and PAPS in the selected in 
vitro system of microsomes or S9, multiple steps of estragole 
metabolism mediated by CYPs, UGTs, dehydrogenases, and 
SULTs, respectively, could be characterized. The rates of those 
reactions were used to describe the critical metabolism path-
ways in estragole bioactivation and detoxication. Those reac-
tions were described well with Michaelis-Menten kinetics and 
the resulting Vmax and Km parameters were scaled to in vivo 
based on the microsomal or S9 protein content. The interplay 
of these multiple reactions was integrated in the PBBK model 
and the simulated concentrations of two estragole metabolites 
in the rat and human urine were reasonably consistent with the 
observed in vivo data considering the purpose of the modeling 
was to evaluate the dose-dependent changes in bioactivation, 
not to predict the absolute dose metrics (Anthony et al., 1987; 
Punt et al., 2008, 2009). The estragole QIVIVE case also dem-
onstrated that the capability to evaluate the relative importance 
of extrahepatic metabolism in different exposure conditions is 
Tab. 2.2: Kinetics research needs to support in vitro based  
risk assessment
Research Area









• pathway/metabolite ID/kinetics (organotypic)
• renal clearance
• respiratory clearance
• placenta in repro and developmental models
• zebrafish
Data collection development of in silico approaches
• metabolite identification
• protein binding in cell-based assays
• tissue partitions (some classes of compounds)
• restricted vs unrestricted hepatic clearance
• metabolism rates
• gut absorption/metabolism (non-druglike compounds)
• transporter substrates/renal clearance
QIVIVE case studies
• classes of physicochemical properties
• different metabolism pathways
• parent vs stable metabolite vs reactive metabolite
• portal of entry vs liver vs remote toxicity
Development of generic PBPK modeling platforms
• user friendly, open access
• database for physiological parameters
• inhalation, dermal, and oral exposure
• multiple parallel metabolic pathways
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2.3.2  In vitro estimation of intestinal absorption  
and metabolism
To accurately predict the systemically available dose of the 
chemical, it is important to consider potential metabolism at the 
portals of entry in addition to the hepatic metabolism. Despite 
its importance as a modifier of oral bioavailability, intestinal 
metabolism has received less attention than other extrahepatic 
metabolism. The mucosal epithelium of the gastrointestinal (GI) 
tract contains substantial amounts and types of xenobiotic-me-
tabolizing enzymes, among which CYP3A enzymes have been 
the focus of a great deal of research in pharmaceuticals due to 
their role in causing reduced oral bioavailability and as a ma-
jor source of inter-individual variability resulting from variable 
constitutive expression of gut CYPs and potential drug-drug in-
teractions (Paine et al., 1997). From the risk assessment point of 
view, other phase I and II enzymes in the GI tract should also be 
carefully considered in IVIVE. In addition to the liver, the GI 
tract is a key site for hydrolysis of a number of ester compounds 
of environmental concern that are used in pesticides and con-
sumer products, including pyrethroids, phthalates, and parabens 
(Kluwe, 1982; Crow et al., 2007; Imai, 2006). The significance 
of intestinal phase II metabolism to total chemical clearance is 
another factor to be considered in IVIVE of metabolism. Intes-
tinal glucuronidation of BPA demonstrates the importance of 
consideration of intestinal metabolism to provide key informa-
tion for describing BPA biokinetics for human health risk as-
sessment based on in vitro metabolism information (Mazur et 
al., 2010).
Compared to IVIVE of hepatic metabolism data, there are 
several challenges in extrapolating in vitro intestinal metabo-
lism parameters to in vivo. First, the intestine is not a homog-
enous organ and therefore spatial differences are evident in dis-
tribution of metabolizing enzymes within the mucosa as well as 
along the length of the intestine (van de Kerkhof et al., 2007). 
This factor makes it difficult to interpret and extrapolate in vitro 
metabolism parameters obtained from intestinal tissue-driven 
in vitro systems such as microsomes and S9 fractions (van de 
Kerkhof et al., 2007). Intestinal cell lines such as Caco-2 (Kar-
leta et al., 2010) have been used to determine absorption param-
eters in vitro (Sambuy et al., 2005), but use of these cell lines as 
a surrogate for metabolism in the GI tract is problematic due to 
differences in enzyme expression compared to human intestinal 
tissue (Imai et al., 2005; van de Kerkhof et al., 2007). Another 
complication comes from the fact that intestinal metabolism of-
ten is greatly influenced by chemical flux into the enterocytes, 
i.e., intestinal metabolism is closely related to the uptake/ab-
sorption process, making it difficult in terms of both measure-
ment and interpretation of the results (Paine et al., 1997; Yang et 
al., 2007). More studies are warranted to develop better in vitro 
tools to predict intestinal metabolism, and then better extrapola-
tion strategies can be developed based upon the relevant in vitro 
metabolism data for coherent extrapolation considering the in-
terplay with chemical absorption processes in the intestine.
2.3.3  In vitro determination of dermal exposure
For environmental and cosmetic chemicals, the dermal route of 
exposure is highly likely. Therefore, in vitro assays should be fur-
from the nominal concentration (added amount of chemical di-
vided by volume of the medium) due to factors such as protein/
lipid binding in the medium (Gulden et al., 2002; Seibert et al., 
2002), evaporation, precipitation, and adherence of the chemical 
to surfaces (Blaauboer, 2010). To determine the in vivo plasma 
concentration expected to elicit a target-tissue response similar 
to the cellular response in the in vitro assay, the free fraction 
must be determined in both the in vitro and in vivo exposures 
(Gulden et al., 2006; Gulden and Seibert, 2003; Teeguarden and 
Barton, 2004). To the extent that the cells in the in vitro assay 
are representative of the cells in the in vivo target tissue, equal 
free concentration in the medium and plasma will be associated 
with the same intracellular exposures (Gulden et al., 2001).
Protein binding can be a key determinant of disposition (Gul-
den and Seibert, 1997), affecting compound availability for 
uptake into cells in vitro as well as target tissues in vivo. For 
example, the use of whole serum or serum albumin in cell-based 
assays can greatly alter the apparent dose-response for cellular 
toxicity compared to serum-free media (Hestermann et al., 2000; 
Brunner et al., 2010). A high fraction bound also gives rise to 
concerns regarding potential competitive binding by other com-
pounds that could modulate the free concentration (Teeguarden 
and Barton, 2004). Methodologies to estimate protein binding 
and approaches for the description of the kinetics of binding 
in biokinetic models have been areas of intense interest over 
the past four to five decades. Consideration of protein binding 
faces two parallel challenges: first, when compounds are bound 
in media or capillary blood, what fraction should be regarded as 
available for transport into cells or tissue, and, second, how does 
the binding influence medium/cell or blood/tissue partitioning.
In general, medium, cells, blood, and tissues all will contain 
free and bound forms of the compound. For equilibration, only 
the free compound diffuses across the medium/cell or plasma/
tissue interface, and at equilibrium the free concentration on 
both sides of the interface is expected to be equal (except in the 
case of active transport). However, the equilibrium relationship 
of the concentration in cells or tissues compared to the medium 
or plasma is typically described with empirical partition coef-
ficients based on measurements of total concentrations of the 
compound. Differential binding, therefore, will influence appar-
ent partitioning. However, there are quite a number of different 
determinants of apparent partitioning, complicating the inter-
pretation of such data:





– Blood:plasma ratio 
The blood:plasma ratio is needed for converting tissue:plasma 
partitions to tissue:blood, or fraction unbound in the plasma to 
fraction unbound in the blood (Yang et al., 2010). 
Furthermore, the application of analytical techniques is con-
sidered a prerequisite for proper QIVIVE. The workshop par-
ticipants agreed that their use (as opposed to nominal concentra-
tion) is critical and their importance not enough appreciated.
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ing pesticides and endocrine active compounds, they have not 
been well studied compared to CYPs and other phase I and II 
enzymes. To describe the role of esterases on detoxication of 
the chemical, it is necessary to include extrahepatic metabo-
lism, most representatively the metabolism in blood due to the 
presence of carboxylesterases and other types of esterases. Me-
tabolism in the GI tract and skin should also be characterized 
to estimate esterase-mediated detoxication capacity in the body 
(Prusakiewicz et al., 2006).
2.3.5  Identification of the key metabolism pathways  
and toxic moieties
To be performed correctly, QIVIVE requires information on 
what the active entity would be in the target tissue based on the 
potential mechanisms of toxicity. Predicting primary metabolic 
pathways, along with the potential for producing active metabo-
lites, could be supported by in silico approaches such as QSAR 
(Kusama et al., 2010). Knowledge built on drug data showing 
the role of chemical properties in metabolism, binding, and par-
tition would help this categorization. To determine the extent 
and design of in vitro metabolism assays aided by such tools, 
the criteria for this classification should be based on major path-
ways of metabolism, since that is the key information needed in 
designing in vitro metabolism studies for IVIVE. 
2.3.6  Organotypic models of in vivo hepatic function
Ensuring realistic metabolism, both qualitatively (the types of 
metabolites formed) and quantitatively (the relative amounts of 
these various metabolites) is one of the most difficult challenges 
in QIVIVE. One possible direction for meeting this challenge is 
the development of organotypic hepatic systems (bioreactors) 
that appropriately reflect the complexity of in vivo hepatic func-
tion. In principle, these systems could be used to provide data 
for in silico modeling of both kinetics and dynamics (Sung et al., 
2010). However, a number of difficulties will need to be over-
come: (1) developing screening analytical chemistry methods 
that would allow rapid evaluation of metabolites produced and 
excreted from the cells or cell aggregates in culture, (2) devel-
opment of stable organotypic liver cultures that recapitulate in 
vivo metabolism for sequential or parallel metabolic networks, 
and (3) ensuring metabolic competencies, both metabolite pro-
duction and parent and metabolite loss, from the tissue culture 
system by metabolism or routes of non-specific loss, such as 
renal excretion.
These organotypic hepatic cell cultures could be used to rap-
idly assess metabolism and confirm QSAR predictions of likely 
metabolites. Metabolites that were identified in some significant 
yield might themselves be studied in the in vitro test systems. 
In the past, analytical methods development was tedious and 
time-consuming. It is possible, however, that this process could 
be accelerated with modern methods of higher throughput ana-
lytical chemistry. The ultimate goal would be the development 
of tissue cultures or hepatic bioreactors (Seagle et al., 2008) that 
include recirculation and medium replenishment over time to 
mimic an in vivo situation.
The ability to assess metabolism by examining effluent com-
pounds from the culture systems could be coupled with other 
ther developed to predict the rate of dermal penetration and me-
tabolism in the skin. The challenge in predicting accurate dermal 
uptake and metabolism is similar to that for intestinal absorption, 
in that absorption and metabolism are competing processes. Hu-
man skin contains both CYP enzymes (Storm et al., 1990) and 
esterases (Prusakiewicz et al., 2006), which can be of importance 
for presystemic clearance of a compound as well as for genera-
tion of toxic metabolites if the skin is a target tissue.
2.3.4  In vitro estimation of metabolism
The success of IVIVE is largely dependent on the quality and 
relevance of in vitro metabolism data (Coecke et al., 2006). 
There have been significant improvements in the quality of 
human tissue preparation in recent years, as well as paral-
lel advances in application strategies of those in vitro data to 
predict in vivo kinetics (Chiba et al., 2009; Gomez-Lechon et 
al., 2007; Houston and Galetin, 2008). These advances have 
made it possible to implement QIVIVE for PBBK models dur-
ing drug development (De Buck and Mackie, 2007; Pelkonen 
and Turpeinen, 2007; Rostami-Hodjegan and Tucker, 2007). 
For pharmaceutical compounds, however, the screening of new 
chemical entities involves evaluation of whether the candidate 
possesses drug-like properties, including relatively moderate 
metabolism and inactive metabolites. Thus, IVIVE for drug me-
tabolism has focused largely on metabolic stability screening 
to inform the drug’s half-life and oral bioavailability using the 
clearance model (Pelkonen and Turpeinen, 2007; Houston and 
Galetin, 2008). For this type of IVIVE, linking the total intrinsic 
clearance in vitro in conjunction with the unbound fraction in 
blood and the liver blood flow to predict in vivo clearance has 
been the most common practice (Fagerholm, 2007; Houston and 
Galetin, 2008)
Although the experience built upon drug data can be applied 
to the IVIVE approach for chemicals, the challenges in QIVIVE 
for chemicals are different from those for pharmaceuticals, pri-
marily due to the wider range of chemical properties compared 
to drugs. There is also a greater need to consider the role of 
metabolism in determining chemical toxicity. For chemicals, 
IVIVE should preferably be conducted at the level of an in-
dividual enzyme/metabolic pathway primarily responsible for 
formation of the active species or depletion of the active par-
ent compound instead of measuring total intrinsic clearance 
of the parent chemical. The apparent limitation of applying 
total clearance-based IVIVE to chemicals has its difficulty in 
describing the formation and clearance of toxic metabolite(s). 
Another limitation arises from dealing with the broader range of 
exposure concentrations and routes for chemicals compared to 
a narrower/targeted concentration range and oral route for drug 
candidates. IVIVE issues will also vary depending on the kinds 
of enzymes involved in chemical metabolism. Both chemical 
properties and knowledge of mechanism of action inform which 
metabolic pathways would be primarily responsible for chemi-
cal metabolism. This information can serve as criteria for cate-
gorizing chemicals into subgroups for different strategies based 
on primary metabolic enzymes. 
Despite the fact that esterases are known to play an important 
role in metabolizing many environmental chemicals, includ-
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2.3.7  Possible strategy to determine metabolites
Techniques to estimate the concentration of a substance at the 
site of action include both direct and indirect ones: biomarkers, 
microdialysis, imaging, mass spectrometry, and simulations by 
modeling (Pelkonen et al., 2008). Special emphasis should be 
placed on the use of advanced bioreactors (Darnell et al., 2011), 
including relevant cell systems, e.g., HepaRG cells, to mimic 
the appropriate metabolism combined with analytical methods. 
Mass spectrometry, in particular, has proven to be an optimal 
tool to determine metabolites. As Pelkonen and co-workers state 
(Pelkonen et al., 2009) “…in silico or in vitro, in conjunction 
with animal data, provide useful and necessary information, on 
which to base the first PK studies in humans. The prerequisite 
is to use appropriate and up-to-date techniques and biological 
preparations.” The final goal would be to build a virtual hu-
man to model the whole process a compound undergoes in the 
human body to enhance drug development and improve risk 
assessment. A starting concept, taking into account available 
techniques, can be found in Figure 2.4.
2.3.8  In vitro estimation of renal clearance
The state of the art for in vitro models of renal clearance is not 
as advanced as in the case of liver clearance, although some 
progress has been made in the case of drugs (Kusuhara and Sug-
iyama, 2009). The relative spatial complexity of renal tubular 
transport systems compared to the more homogenous hepatic 
metabolic analyses to evaluate fidelity between the in vivo and 
in vitro pathways. A well-designed liver bioreactor could func-
tion in a fashion similar to isolated-perfused liver preparations 
(Bessems et al., 2006). Analysis of metabolites produced in a 
bioreactor might also serve to benchmark expected metabolic 
pathways. Evaluation of the fidelity of the bioreactor and new 
organotypic systems could be verified by assessing metabolite 
profiles with specific test compounds, i.e., using compounds 
whose metabolism has already been well-studied in vivo.
It may be necessary to develop co-culture systems or micro-
fluidic systems that maintain metabolism, recirculation, contin-
uous addition of test compound, and ongoing loss from the cul-
ture system. The microfluidic, body-on-a-chip design (Maguire 
et al., 2009) has potential for creating custom in vitro toxicity 
evaluations for multiple cells plated onto different parts of the 
microfluidic plate. This system requires more development, es-
pecially to move from a laboratory research device to low to 
medium throughput. The system was designed based on PBPK 
model structures developed by Shuler and colleagues (Esch et 
al., 2011). Another possibility might be to have a relatively large 
hepatic bioreactor and to divert flow to multiple chambers with 
various cell types for in vitro testing. The cells would have con-
tinuous flow of the bioreactor fluid, and the effluent from the 
culture plates could be collected and re-circulated to the biore-
actor. While these designs are not yet available, they are techni-
cally within reach.
Fig. 2.4: Proposed strategy to assess metabolite effects in in vitro studies
(adapted from Pelkonen et al., 2009)
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the researcher and analysts, so they will be able to augment 
each other. As recently explained by Jaworska and Hoffmann 
(2010) via the concept of Bayesian networks, the structure of 
the testing strategy matters and will influence the risk assess-
ment process. Complex networks will not lose rare but impor-
tant events or small but multiple perturbations in key nodes 
(Jaworska and Hoffmann, 2010). 
2.4  Conclusions and recommendations: 
toxicokinetics
The main objective of this chapter was to determine the re-
search needs for developing a methodology to incorporate 
in vitro kinetic data into in vivo biokinetic models to support 
risk assessments based on cellular toxicity assays. The pro-
posed methodology starts with the identification of the criti-
cal aspects of the metabolism of a compound for the intended 
purpose of the risk assessment. This preliminary information 
includes a combination of qualitative metabolism studies and 
selected in vitro toxicity assays to identify the active species 
and primary metabolic pathways responsible for producing 
and detoxifying the toxic entity. Current examples of IVIVE 
often rely, in part, on existing in vivo data. As experience with 
IVIVE accumulates, however, it will become increasingly 
possible for such information to be gained from in silico-based 
prediction tools and targeted in vitro kinetic studies, particu-
larly using organotypic in vitro systems that better mimic in 
vivo conditions. 
The current state of the art presents an excellent opportunity 
for development of improved in vitro ADME methodologies. 
The technologies necessary to support these initiatives are now 
coming to maturity, and the need for rapid toxicity testing of 
both drugs and commercial chemicals is becoming more acute. 
Recent advances in stem cell biology may allow the develop-
ment of custom bioreactors with more relevant cellular com-
ponents and allow the bioreactor to serve as both a metabolite 




1. For the extrapolation of an in vitro assay to in vivo the 
measurement of the free chemical concentration is ab-
solutely necessary.
2. In vitro biokinetics should be taken into consideration 
to improve the quality of in vitro toxicity data.
3. The use of kinetic parameters to correlate in vitro effec-
tive concentrations to a dose is absolutely essential.
4. Quality training data for the wide range of chemical 
property classes should be made available, particularly 
for “non-druglike” compounds.
5. Analytical methods and computational modeling should 
be taken into account and employed wherever possible.
architecture greatly increases the difficulty of developing rep-
resentative in vitro model systems. However, it should at least 
be possible to develop assays to identify whether a compound 
is a substrate for a particular transporter (Yang et al., 2009). 
This would provide an indication of the likelihood that a com-
pound’s renal clearance might deviate from expectations based 
on glomerular filtration. A similar capability could be developed 
for assessing biliary clearance.
2.3.9  PBBK model development
The parameters in a PBPK model can be categorized into four 
types: exposure, physiological, partitioning, and metabolism. 
The exposure parameters are determined solely by the char-
acteristics of the exposures and the physiological parameters 
are available from the literature (Brown et al., 1997). These 
types of parameters are not chemical-specific, and the val-
ues used in the evaluation of an untested compound would 
be the same as those used for well-characterized compounds. 
Partitioning and kinetic parameters, however, are chemical-
specific and need to be estimated for untested compounds. 
A number of software platforms are available to support ge-
neric PBPK modeling for pharmaceuticals using in vitro me-
tabolism data, as exemplified by the Simcyp platform (Jamei 
et al., 2009; Rostami-Hodjegan and Tucker, 2007). Because 
these generic platforms are designed to support modeling of 
drug compounds, their focus is on oral and intravenous expo-
sures, and on metabolism by oxidative (CYP) and conjugative 
(UGT) enzymes. Effective use of these software platforms 
for PBPK modeling of environmental and personal care com-
pounds would require enhancements in two areas: (1) addi-
tion of descriptions of dermal and inhalation exposure, and 
(2) addition of data on esterase metabolism enzymes. In the 
field of environmental risk assessment, PBBK models typi-
cally have been developed for individual chemicals. Although 
generic modeling platforms are available for some classes of 
compounds, e.g., MEGen (Loizou and Hogg, 2011), the de-
velopment of generic models has not been as extensive as in 
the pharmaceutical area. A useful generic modeling platform 
would include the following features:
– user-friendly, open access
– database for physiological parameters
– inhalation, dermal, and oral exposure routes
– capability for multiple parallel metabolic pathways
2.3.10  Integrated testing strategies (ITS)
Toxicokinetics and the methods mentioned already should not 
be understood as stand-alone methods or endpoints. Kinetics is 
a tool to understand and modify any in vitro result and should 
be incorporated into testing strategies as a requirement for any 
extrapolation to in vivo. In general, an integrated testing strat-
egy should consist of information about the physicochemical 
properties of a substance, the structure activity relationships 
(QSARs), in vitro data, and kinetic and dynamic modeling. 
All these factors combined should then lead to an evalua-
tion against in vivo data (Dejongh et al., 1999). Experimen-
tal research, computational methods, and integrated testing 
strategies should be developed in an interactive way between 
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stricted versus unrestricted hepatic clearance should be 
investigated. Data should be collected for hepatic and 
renal clearance, metabolism rates, gut absorption, and 
metabolism, especially for non-drug-like compounds. 
Also, identification of transporter substrates is a poten-
tial area of in silico modeling.
10. QIVIVE case studies, with special emphasis on those 
that did not work, should be performed for different 
classes of physicochemical properties, different me-
tabolism pathways, toxicity from parent versus stable 
metabolite versus reactive metabolite, and portal of en-
try versus liver versus remote toxicity.
Special research areas:
11. The very promising areas of in vitro bioreactors and the 
microfluidic human-on-a-chip should be further devel-
oped and standardized.
12. High-Throughput Toxicity Screens combined with ki-
netics data should be further investigated. 
13. An equivalent to the Lipinsky rules for drugs should be 
developed for chemicals.
Further research areas:
6. Improved in vitro models are needed, particularly in 
the areas of intestinal and dermal absorption and the 
associated presystemic metabolism. Hepatic, renal, and 
respiratory clearance also are of special interest. Orga-
notypic culture kinetics and metabolite identification 
should be investigated. Barriers should be taken into 
account by appropriate in vitro assays. 
7. The development of generic PBPK modeling platforms 
should be furthered. They should be user-friendly and 
have open access, with a database for physiological pa-
rameters. They should be able to simulate inhalation, 
dermal, and oral exposure, allowing description of mul-
tiple parallel metabolic pathways.
8. Standard methods for the characterization of the free 
concentration in cell-based assays should be developed, 
including the features of binding, metabolism, and ac-
tive transport into the cell. 
9. In the area of data collection and in silico approaches, 
metabolite identification and protein binding in cell-
based assays should be addressed. Furthermore, re-
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record of past and present activity in this area (Adler et al., 2011; 
Aeby et al., 2010; Basketter and Maxwell, 2007; Basketter, 2008; 
Basketter et al., 2007; Basketter and Kimber, 2011; Bauch et al., 
2011; De Silva et al., 1995; dos Santos et al., 2009; Hartung et 
al., 2011; Kimber et al., 1999b, 2001, 2010, 2011; Martin et al., 
2010; Maxwell and Mackay, 2008; Patlewicz et al., 2007; Reu-
ter et al., 2011; Ryan et al., 2005; Vandebriel and van Loveren, 
2010). However, our intention here is not to provide yet another 
scholarly review article. It is rather to provide a personal perspec-
tive with regard to the development of alternative methods for 
skin sensitization testing, how the current landscape appears to 
us, and what we believe are the requirements for (and distractions 
from) achieving real success in addressing this challenge. This is 
not, therefore, a consensus document. One important aim is to be 
provocative, to excite argument and discussion. If what follows 
is at odds with the views of others, we apologize in advance for 
any perceived criticism and ask only that the article be viewed as 
a stimulus for informed debate.
We have chosen to address this issue by tackling a number of 
relevant questions for an assessment of the current state of the 
art of alternative methods for skin sensitization testing and what 
future needs might be. These are as follows:
1. What is it that we are really trying to achieve – what will 
success look like?
2. Is the international scientific community marshaled in the 
right way to make real progress in this area?
3. What should be the future research imperatives?
4. Skin sensitization testing in vitro – can we do it already?
5. Is hazard identification alone good enough?
6. What needs to change?
3.2  What is it that we are really trying to  
achieve – what will success look like?
There is a genuine need to identify chemicals that have the po-
tential to cause skin sensitization and allergic contact dermatitis 
(ACD) and to accurately assess the likely risks to human health. 
Many hundreds of chemicals cause skin sensitization, and ACD 
is a common occupational and environmental disease (Febriana 
et al., 2011). Historically, the identification of contact allergens 
relied on the use of guinea pig tests (Buehler, 1965; Magnusson 
and Kligman, 1969). More recently, the murine local lymph node 
assay (LLNA) has found favor as a method that, compared with 
guinea pig tests, offers important animal welfare benefits (Kim-
ber et al., 2002, 2011). The LLNA provides a generally robust and 
reliable means of identifying chemicals that have the potential to 
cause skin sensitization but also permits a characterization of rel-
ative sensitizing potency, which is required for the development 
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3.1  Introduction: skin sensitization
Allergic contact dermatitis resulting from skin sensitization is 
an important occupational and environmental health problem. 
Many hundreds of chemicals are known to cause skin sensi-
tization, and allergic contact dermatitis is the most common 
manifestation of immunotoxicity in humans. It is important, 
therefore, that skin sensitization hazards/risks of new chemicals 
and products be evaluated accurately. In fact, toxicologists have 
methods and models that provide a reliable basis for the iden-
tification of skin sensitizing chemicals, assessment of relative 
sensitizing potency, and the development of effective risk as-
sessments. However, current practices rely heavily on animal 
models of skin sensitization, particularly the local lymph node 
assay (LLNA), the preferred method for safety assessment. 
There are now compelling reasons to develop novel ap-
proaches to skin sensitization testing that do not require the use 
of experimental animals. There has been – and continues to be 
– a very substantial investment in achieving this goal. Several 
promising methods are now undergoing validation. However, 
no non-animal test has yet been formally validated. Against that 
background, the purpose of this chapter is to provide a partisan 
(some might say biased!) view of the current development of 
alternative methods for assessment of skin sensitizing activity, 
to reflect on some of the challenges that we face in delivering 
novel testing strategies, and to provide a view of what is needed 
to improve and accelerate progress towards this objective.
A quick glance at the title of this chapter will trigger a feeling 
of déjà vu in many readers. Indeed, our own reaction would have 
been “Does the scientific literature really need another review 
of skin sensitization and the development of alternative methods 
for hazard and risk assessment?” The answer must be no – surely 
there is nothing new to say. There are already sufficient – or more 
than sufficient – reviews and overviews available. Some of those 
are cited here, and collectively they provide a comprehensive 
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course, failure to negotiate any one of the hurdles will lead to 
the absence of sensitizing activity.
It will be clear that the move from an animal model to a 
non-animal method is fraught with difficulties and challenges. 
Put simply, mice used within the LLNA represent integrated 
biological models that incorporate, in a fully coordinated and 
physiologically relevant way, all the events and processes that 
are needed for the acquisition of sensitization. So, if a chemical 
is positive in the assay, then the assumption is that it has suc-
cessfully achieved all that a chemical must accomplish to drive 
sensitization. 
In a similar vein, it is estimated currently that approximately 
25% of contact allergens must be activated by air oxidation, or 
within the skin, to acquire the chemical reactivity necessary to 
associate with proteins. It has proven difficult to achieve effec-
tive incorporation within in vitro models of appropriate and ad-
equate oxidative/metabolic capacity.
The move from a fully integrated biological (animal) model 
is, therefore, necessarily going to be challenging. Nevertheless, 
that is the aim: to develop a method that will allow characteriza-
tion of skin sensitizing activity without the use of animals and 
possibly with a higher level of confidence.
It is worth reflecting briefly on what is meant by the above phrase: 
“characterization of skin sensitizing activity.” The first step in any 
toxicological investigation is the identification of hazard, and in the 
context of this article, to discriminate between chemicals that do, 
and chemicals that do not, have the potential to cause skin sensiti-
zation. Although that is an important step (and the aspect for which 
formal validation is required), it is not sufficient for addressing the 
likelihood that exposure to the chemical under any given set of 
circumstances will result in an adverse effect. For an effective risk 
assessment, an appreciation of relative potency is necessary. In the 
context of skin sensitization, this equates to the amount of chemi-
cal encountered on a skin surface that is required for the induction 
of sensitization. This, of course, is true for all forms of toxicologi-
cal evaluation, but it is particularly important with regard to skin, 
because it is known that contact allergens vary by up to five orders 
of magnitude in relative skin sensitizing potency. 
A measure of relative potency is provided by the LLNA be-
cause it is known that the readout used (the proliferation of drain-
ing lymph node cells) not only has a causal relationship with the 
acquisition of sensitization but also correlates quantitatively with 
sensitizing activity (Kimber and Basketter, 1997). Achieving an 
understanding of relative potency with a full in vitro approach is 
going to be very challenging. This is a theme that we will return to 
in Chapter 2.6. Drawing together the elements discussed above, 
the answer to the first general question we posed is as follows: 
The aim is to develop a non-animal method(s) that will provide a 
means of identifying contact allergens with an accuracy at least 
equivalent to, or approaching that of, the preferred animal mod-
els. While that is the minimum requirement, ideally, any novel 
method should improve upon the performance and reliability of 
the LLNA (considered the best animal model) and simultaneous-
ly provide an accurate assessment of relative potency. 
Success, therefore, will be the development of a non-animal 
approach that provides a basis for reliable hazard and risk assess-
ments of at least comparable accuracy to those afforded by the 
of accurate risk assessments (Api et al., 2008; Basketter et al., 
2007; Rovida, 2011). However, it has to be acknowledged that, as 
with all test methods, the LLNA is not without limitations.
There are strong scientific, ethical, and legislative reasons 
why it is important to ensure that opportunities to Reduce, Re-
fine, and Replace the use of experimental animals in research 
and investigative studies are exploited quickly and effectively. 
Probably the most appropriate code of practice when consider-
ing the use of animals in research is to pose a number of ques-
tions: (a) is the issue being addressed legitimate and important? 
(b) is it possible to address the question effectively without the 
use of experimental animals? If the answer to the latter question 
is no, then the third question is; (c) what is the best and most 
appropriate experimental design to ensure that the principles of 
the 3Rs are adhered to and a robust answer achieved?
Translating this to the theme of this article, the assumption is 
that it is not currently possible to conduct an evaluation of the skin 
sensitizing activity of chemicals without the use of animals (either 
guinea pig tests or the LLNA) that is fully accepted by regulators. 
Although this assumption will be tested further under question 4, 
it is certainly the case that no validated, non-animal methods for 
the identification of skin sensitizing chemicals are currently avail-
able. As a consequence, and in line with the scientific, ethical, and 
legislative imperatives (such as the 7th Amendment to the Cos-
metics Directive in the EU) that are driving interest in developing 
non-animal methods, there has been a very substantial investment 
in alternative strategies for skin sensitization testing.
A detailed survey of the many approaches is unnecessary here, 
and more information is available from the review articles cited 
above. The important point, however, is that alternative methods, 
in most cases, are based upon an attempt to identify biological 
properties or structural motifs of chemicals that are believed to 
be required for the acquisition of skin sensitization. The palette of 
strategies that has been considered is based on the understanding 
that for a chemical to cause skin sensitization a number of things 
have to be achieved, or biological/biochemical hurdles must be 
cleared. These include, but are not limited to: (a) the chemical 
gaining access to the viable epidermis, (b) the stable association 
of chemical with protein to form a complete antigen, (c) the ac-
tivation, mobilization, and migration of cutaneous dendritic cells 
(DC) for transport of antigen to regional lymph nodes, and (d) 
the activation within lymph nodes of responsive T lymphocytes. 
Another approach has been to apply a systems approach to model 
in silico the key chemical and biological pathways that drive the 
induction of sensitization (Maxwell and Mackay, 2008).
For the most part, the alternative methods being explored (in 
vitro and in silico) are based upon evaluation of the ability of 
a chemical to provoke one (or more) of these required events 
or processes. That strategy appears appropriate, but it is crucial 
to bear in mind that the ability of a chemical to clear any one 
of those biological or (bio)chemical hurdles does not necessar-
ily mean that it should be classified as a skin sensitizer. Does 
the ability of a chemical to cause covalent bonds with protein 
necessarily signify that it will cause sensitization? Similarly, is 
there any reason to believe that if a chemical is capable in vitro 
to cause the activation of DC that this property alone will be 
sufficient to translate into skin sensitizing activity in vivo? Of 
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between fundamental mechanistic research and research driving 
the application of the test by industry and regulatory authorities 
on the one hand, and research applying established knowledge 
focused on the design of new test methods. If so many investiga-
tors are applying their skills to the development of alternative 
predictive tests, where will the transformational research that will 
provide the basis for really innovative developments in the future 
come from?
As an illustration, one area of investigation that has attracted 
considerable interest in the context of new approaches to skin 
sensitization testing is dendritic cell (DC) biology. There are a 
variety of proposed test methods based on the use of cultured 
DC, or DC-like cell lines, the theory being that exposure of such 
cells to skin sensitizing chemicals, but not to non-sensitizers, will 
provoke functional or phenotypic changes that will serve as bio-
markers of sensitizing activity and as readouts for cell-based as-
say systems (An et al., 2009; Arkusz et al., 2010; Ashikaga et al., 
2010; Ouwehand et al., 2010; Python et al., 2007; Johansson et 
al., 2011). There is no doubt that some of these assays perform 
rather well and show real promise. Nevertheless, the approach is 
predicated on a (largely unproven) assumption that the impact of 
chemical allergens on DC or DC-like cells in culture (usually at 
cytotoxic concentrations) is reflective of the changes induced in 
epidermal Langerhans cells (LC) and dermal DC during the ini-
tiation of sensitization in intact skin. However, despite much en-
thusiasm for this approach, and despite considerable investment 
that has supported a wide range of proposed assay methods, very 
little is known about how chemicals cause changes in cultured 
DC, or what relevance, if any, this has to the acquisition of sensi-
tization. In the rush to develop a test or a new method intriguing 
and important questions about fundamental mechanistic biology 
are ignored – or at least put aside.
3.4 What should be the future research 
imperatives?
There needs to be a realignment of “pure” and “applied” research 
in skin sensitization, with increased emphasis on exploring some 
of the important uncertainties and intriguing unknowns. Among 
the many issues that remain to be clarified are the following:
– The balance achieved in the skin and regional lymph nodes 
between the immunostimulatory, promotional, and regulatory 
signals delivered by discrete populations of DC, and how that 
balance impacts the acquisition of sensitization.
– The role of regulatory T cells (Treg cells) in controlling and 
constraining the induction of skin sensitization, the elicitation 
of ACD, and the relationship of Treg cells with effector T lym-
phocytes in determining the net vigor and quality of immune 
responses to contact allergens.
– The influence of the ways in which haptens interact with target 
proteins on the development of skin sensitization. 
This list is merely indicative, certainly not exhaustive. Other in-
vestigators doubtless will be drawn to other research questions. 
However, the common thread in the examples highlighted above 
is that they each have the potential to inform our understanding of 
the factors that govern sensitizing potency. The balance achieved 
LLNA. If that is what success looks like, then a frequently asked 
question is whether it is reasonable to expect that a single in vitro 
approach or test method will provide the required level of certain-
ty. Some speculate that it will be necessary to develop a suite of 
methods that collectively provide a basis for making judgments 
about sensitizing potential. This sounds sensible, but relying on 
a battery of assays may prove to be technically demanding and 
experimentally unwieldy. 
3.3  Is the international scientific community 
marshaled in the right way to make real progress 
in this area?
The most important opportunities in applied toxicology, includ-
ing the development of alternative test methods applicable in 
an industrial context and for regulatory purpose, derive from an 
investment in “pure” research and an improved understanding 
of relevant cellular and molecular mechanisms. We mentioned 
above that there has been a huge investment, particularly in Eu-
rope, directed at promoting the development of alternative meth-
ods for skin sensitization testing. There is no suggestion that the 
motives driving this investment are anything other than laudable, 
but it is relevant to question whether the focus of that invest-
ment is the most likely to deliver the necessary breakthroughs. 
There has been too much emphasis placed on supporting applied 
research, often focused narrowly on the design and development 
of new methods. In recent years, too many new approaches have 
been proposed. In most cases, however, few of them have proven 
useful for a workable, full-replacement strategy.
Why have we seen a change of emphasis in skin sensitization 
research from characterization of the mechanisms through which 
cutaneous immune and inflammatory responses are induced and 
orchestrated, to new test development? A number of factors have 
influenced this:
– Everyone wants to develop a test. Even a superficial survey of 
platform and poster presentations at toxicology conferences re-
veals an ever-increasing number of papers describing attempts 
to develop “alternative” test methods for the identification of 
skin sensitizing chemicals. Naturally, many of these communi-
cations have merit, but not all. It is evident that some investi-
gators do not have a clear understanding of what “alternative” 
is really required nor what is required by those charged with 
making decisions about the safety of new chemicals or prod-
ucts.
– Research follows the money, and it is clear that many investiga-
tors have found it necessary to develop more research themes 
focusing on applying current knowledge for test development 
to attract funding.
– In certain commercial sectors, and particularly the cosmetics 
industry (because of the deadlines imposed by European regu-
lation), there is a very clear and pressing need to develop non-
animal methods so that new innovation can be supported when 
it is no longer possible to use animal tests. 
A case is not being made that all currently supported research 
in skin sensitization is without value. Indeed, there have been 
important achievements. However, there is now an imbalance 
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zation, (f) the balance achieved between activated epidermal LC 
and activated dermal DC, and (g) the amount of antigen delivered 
to draining lymph nodes. 
Again, the options listed above are not exhaustive, and there 
may be a number of other events that influence overall potency. 
Nevertheless, it is the case that we really have little understanding 
of how events induced in the skin and regional lymph nodes in 
the minutes and hours following topical encounter with a contact 
allergen shape the T lymphocyte response that will be induced. 
Tackling this question will not be easy, but a research investment 
in this area might elucidate the pivotal events and processes that 
determine the effectiveness of immune responses to contact aller-
gens – and may also provide an appreciation of how the vigor of 
immune responses in general is controlled. Certainly, an under-
standing of the key events that impact on skin sensitizing potency 
would be of enormous value in considering novel approaches to 
testing that would deliver not only hazard identification but also 
an assessment of relative potency. In conclusion, therefore, the 
proposal is that there should be a greater investment in tackling 
some of the important questions remaining about the way in 
which the acquisition of skin sensitization is induced and orches-
trated. In addition, a high priority should be given to investiga-
tion of the chemical, biochemical, and immunological events that 
determine the relative potency of skin sensitizing chemicals.
3.5  Skin sensitization testing in vitro – can we do 
it already?
There are currently no formally validated methods for the (haz-
ard) identification of contact allergens using non-animal methods. 
But an important and interesting question is this: Leaving aside 
considerations of validation and regulatory acceptance, are we 
already in a position to make sound judgments regarding the skin 
sensitizing potential of chemicals? If we were to effectively mar-
shal our collective know-how about skin sensitization, together 
with access to data generated by selected in vitro approaches, 
would it be possible to achieve something approaching a 90% 
overall accuracy of prediction of skin sensitizing activity – a per-
formance in line with the LLNA or better? Such a hypothetical 
scenario would have two parts.
The first of these would be to bring together a small group of 
seasoned investigators with experience of skin sensitization and 
making judgments about the sensitizing potential of chemicals. 
This expert panel would include those with expertise in QSAR 
and aligning sensitizing potential with structural motifs and phys-
icochemical properties. That expertise could be supplemented by 
access to one or more expert systems that seek to predict skin-
sensitizing activity as a function of chemical structure.
The second element would be the availability of data generated 
by selected in vitro tests, albeit test methods that have not yet been 
validated (although those mentioned are in the latter stages of 
formal evaluation). There are several assay systems from which 
to choose, including the following: peptide binding assays (Ger-
berick et al., 2004, 2009; Troutman et al., 2011) and based upon 
the Nrf2/Keap 1 electrophile-sensing pathway the KeratinoSens 
assay (Emter et al., 2010); and the CeeTox Assay (McKim et al., 
between stimulatory and regulatory signals from DC, the balance 
achieved between effector T lymphocytes and Treg cells, and the 
impact of the kinetics and selectivity of the interaction of chemi-
cal allergens with skin proteins are all strong candidates with re-
gard to influencing sensitizing potency.
Other exciting research themes could also be identified. There 
is no shortage of relevant challenging and exciting areas of re-
search in skin sensitization. Addressing issues such as those list-
ed above will not necessarily lead directly and immediately to 
the identification of alternative test methods, but there can be no 
doubt that the increased understanding of relevant immunobio-
logical mechanisms that would result from such research would 
drive innovation and open up the development of new strategies.
Sensitizing potency, however, is currently the key challenge. 
It is now understood that contact allergens vary by up to five or-
ders of magnitude with respect to their relative skin sensitizing 
potency. In practical terms, this means that with potent chemical 
allergens only very low levels of exposure are required for the de-
velopment of sensitization, whereas with weak allergens repeated 
high-level exposure may be required for sensitization to develop. 
The phenomenon is clear, but we really do not understand why 
this is – and what specific factors govern potency. The question is 
of great academic interest but is also of considerable importance 
in the development of new test methods. If an in vitro assay is 
going to provide useful information about relative potency, then 
there will need to be readouts that correlate quantitatively with 
sensitization and are reflective of dose-response relationships. 
At a relatively simplistic level it is clear that the extent to 
which sensitization is acquired is associated with the vigor of 
T lymphocyte responses in regional lymph nodes draining the 
site of exposure to the inducing chemical allergen (Kimber and 
Dearman, 1991; Kimber et al., 1999a). This is not unexpected, 
because skin sensitization is mediated by T lymphocytes, and 
the greater the level of proliferation in draining lymph nodes the 
larger will be the pool of antigen-responsive T cells. However, as 
alluded to above, it has to be acknowledged that, in addition to 
the extent of clonal expansion, the effectiveness of skin sensitiza-
tion will likely be impacted by the quality of the T lymphocyte 
response. One qualitative aspect of that response is the balance 
between effector T lymphocytes that will drive the elicitation of 
ACD, and Treg cells that will down-regulate and constrain sen-
sitization. In addition, the overall effectiveness of sensitization 
may be influenced by the “breadth,” or clonal diversity, of the T 
lymphocyte response. 
One can conclude, therefore, that the main influence on the ef-
fectiveness of skin sensitization will be the quantity and quality 
of the T lymphocyte response generated. However, this does not 
provide any indication of the events induced following encounter 
with a contact allergen that shapes the response. There are sev-
eral factors that individually, or in concert, may impact the vigor 
and quality of the T lymphocyte response. These include: (a) the 
speed with which the chemical reaches the viable epidermis, (b) 
the nature of “danger signals” elaborated, (c) the kinetics of as-
sociation with target proteins, (d) the promiscuity of chemical 
interaction with proteins, either in terms of number of proteins 
with which adducts are made, and/or at the level of amino acid 
selectivity, (e) the kinetics of LC and DC activation and mobili-
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The above is a pragmatic approach and has not been tested 
adequately in practice; there has been only a single partial at-
tempt – by Natsch et al. (2009). Nor does it claim to distinguish 
between threshold events and those that bear a direct quantita-
tive relationship with sensitizing potency. Nevertheless, it does 
at least provide a framework for how some assessment of po-
tency might be informed by the use of readouts from in vitro 
tests combined with appropriate SAR analyses. 
It is relevant here also to highlight that a number of other 
strategies have been proposed for informing skin sensitizing 
potency without recourse to animals. These include the devel-
opment and deployment of appropriate mathematical models 
(Maxwell et al., 2011; Maxwell and Mackay, 2008), the devel-
opment of an Integrated Testing Strategy (ITS) for skin sensiti-
zation in the form of a Bayesian Network (Jaworska et al., 2011; 
Maxwell et al., 2011; Maxwell and Mackay, 2008) and a tiered 
approach combining a keratinocyte-based test for identifying 
skin sensitizers and an epidermal equivalent-based potency test 
(dos Santos et al., 2011; Galbiati et al., 2011).
Notwithstanding the crafting of theoretical frameworks for 
considerations of potency that may or may not work in practice, 
the answer to the question posed in this section is that a non-
animal solution to hazard identification alone (although being a 
significant achievement) is insufficient for a full safety evaluation 
and risk assessment. This view is clearly reflected by the recent 
expert review of a European Expert Group (Adler et al., 2011).
3.7  What needs to change?
Against the background of the issues described above, we have 
listed what we believe to be the most important changes that are 
required to promote the development of effective non-animal 
methods for the assessment of skin sensitizing activity. In no 
particular order the key issues are:
– The need for a realignment of skin sensitization research so 
that there is greater emphasis on exploring basic mechanistic 
aspects in the expectation that this will yield information and 
understanding that, in time, will provide a platform for real 
innovation and, hence, new ground-breaking solutions.
– Such a research investment would provide a much clearer 
understanding of the factor(s) that serve to determine the po-
tency of skin sensitizing chemicals.
– The need to bring a greater realism to some within the scien-
tific community who are seeking to develop novel test meth-
ods. It needs to be understood and appreciated that for a new 
method to be valuable it has to be technically robust, perform 
reliably, and offer the required level of predictive perform-
ance.
– In tandem with the above, there needs to be a greater willing-
ness among some test developers to take a more dispassionate 
approach to the evaluation of putative tests. There is a need 
for a critical evaluation of the strengths and limitations of 
novel methods compared with existing in vivo models, even 
with their limitations.
– For the evaluation and validation of new methods (of what-
ever type) there is a need to evaluate specificity, sensitivity, 
2010), as well as a variety of cellular assays based on the use of 
cultured DC or DC-like cells (Aeby et al., 2010; Ashikaga et al., 
2010; Reuter et al., 2011; Sakaguchi et al., 2006; Johansson et al., 
2011). It would be interesting to evaluate, prospectively and with 
an unbiased set of chemicals, how such an expert panel (with 
access to QSAR models and data derived from selected in vitro 
tests) would fare compared with the LLNA or with human ACD.
The foregoing is not a cri de coeur for the use of unvalidated 
tests in the safety assessment process (which would be inap-
propriate). Rather, it should be viewed as a reflection of how 
near we perhaps are to being able to identify skin sensitizing 
chemicals without recourse to animal experiments – if there is 
a willingness to align the experience and expertise which is al-
ready available with the outputs of selected test methods.
3.6  Is hazard identification alone good enough?
If resources are marshaled carefully, the identification of skin 
sensitizing hazards, without the need for animal tests, should be a 
realistic goal. Hazard identification might be sufficient to satisfy 
regulatory requirements (and, of course, where there is no skin 
sensitization hazard, further work will be unnecessary). How-
ever, just as safety evaluation cannot be completed solely on the 
basis of exposure data, the absence of information about relative 
potency for identified skin sensitization hazards will not support 
the development of accurate risk assessments or enable mean-
ingful risk management. This is important because over several 
decades of the implementation of regulatory identification of skin 
sensitization hazard, there is no evidence of any impact on the 
clinical burden of allergic contact dermatitis. One could go so 
far as to argue that efforts to develop effective risk assessments 
based largely or solely on exposure data are doomed to failure, as 
it is rarely possible to link specific exposures with the develop-
ment of allergic contact dermatitis.
One answer, therefore, is to make a greater research invest-
ment in the expectation that a more complete understanding 
of the immunology and biochemistry of skin sensitization will 
disclose the pivotal events in determining potency. Another ap-
proach is to consider how information deriving from currently 
available non-animal models for sensitization testing might be 
used to rank chemical allergens according to potency. Previous 
exercises have explored how, in theory at least, it might be pos-
sible to derive an estimate of overall potency by integrating in-
formation from two or more of several in vitro approaches. One 
strategy explored was to assign chemicals scores on the basis of 
whether there was a structural alert, and on relative activity in in 
vitro tests configured to measure the ability of chemicals to: (a) 
gain access to the viable epidermis, (b) form stable associations 
with peptides or proteins, (c) stimulate the activation/maturation 
of DC or DC-like cells, or (d) provoke proliferative responses 
by cultured T lymphocytes. In some cases the scores were bi-
nary (that is 1 or 2; for epidermal bioavailability and structural 
alerts). For other readouts a scale of 0 to 5 was used. Based on 
this paradigm, the relative sensitizing potential of a chemical 
would be calculated as the product of individual scores (Basket-
ter and Kimber, 2009; Jowsey et al., 2006). 
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A second area where there has been considerable progress 
has been in defining the phenotype, function, and impact on the 
induction of skin sensitization of discrete functional subpopula-
tions of cutaneous DC. Of particular interest is the interplay be-
tween epidermal LC and dermal DC (Bobr et al., 2010; Clausen 
and Kel, 2010; Kaplan, 2010; Kaplan et al., 2008; Kimber et al., 
2009; Noordegraaf et al., 2010). Our increased understanding 
of the roles played by skin DC not only in initiating but also in 
orchestrating cutaneous immune responses to contact allergens 
may pave the way to more sophisticated and more informative 
DC-based assay systems.
An investment in high quality research addressing important 
questions will always pay important dividends – and that holds 
true for skin sensitization and our need to drive new innovation 
in safety assessment.
Recommendations: skin sensitization
1. Recent investments in the development of alternative in 
vitro methods for skin sensitization hazard identifica-
tion have resulted in the design of a substantial number 
of potential assays. Those that show promise should be 
evaluated as soon as possible.
2. Progress in the development and refinement of in silico 
approaches to skin sensitization testing (mathematical 
modeling and computational chemistry) should be ac-
celerated.
3. The main priority now is to develop non-animal meth-
ods for assessment of skin sensitizing potency of contact 
allergens. In this context it is important to identify bio-
markers or chemical signatures that are quantitatively 
associated with the acquisition of skin sensitization. 
4. The ability of existing in vitro tests, QSAR methods, and 
other testing strategies to inform skin sensitizing poten-
cy, in addition to identifying skin sensitizing hazards, 
should be investigated.
5. New strategies for potency assessment based on ap-
proaches such as: (a) an appreciation of the balance be-
tween promotional and regulatory signals by skin DC, 
(b) an understanding of the impact of the vigor, quality, 
and breadth of T cell responses on the development of 
sensitization, (c) the design of appropriate mathemati-
cal models, and (d) integrated testing systems should be 
explored.
6. An investment in developing a more detailed under-
standing of the cellular and molecular events that initi-
ate, orchestrate, and control immune responses to skin 
sensitizing chemicals should be encouraged.
7. An investment in activities facilitating the application of 
the emerging tests by industry and regulatory authorities 
and assessing the limitations and strengths of the tests 
before full validation should be considered.
and overall accuracy with a gold standard dataset. In this case, 
that translates into a dataset that is populated by chemicals 
where there is sound evidence for the presence or absence of 
significant skin sensitizing potential in humans.
– Finally, there is a critical need for a general acknowledge-
ment that the complete replacement of animal methods (such 
that safety assessments remain at least as effective as they are 
currently) requires that alternative approaches inform both 
hazard identification and assessment of potency. At present, 
formal validation activity addresses only the first of these.
3.8  Conclusions and recommendations:  
skin sensitization
The purpose of this chapter was to provide a critical and partisan 
appraisal of the current landscape with regard to skin sensitiza-
tion testing. There is no doubt that there have been considerable 
achievements. Peptide binding assays continue to evolve and ap-
pear very promising. Cellular assays based on induced responses 
by DC, DC-like cells, and other cell types have considerable mo-
mentum currently, and there are three such assays currently under-
going formal validation in Europe. Efforts continue with the de-
velopment and evaluation of SAR paradigms. New opportunities 
based upon an appreciation of the activation of the Keap 1/Nrf2 
pathway are being explored (McKim et al., 2010). The Keratino-
Sens assay recently has completed an inter-laboratory evaluation 
and has been submitted for formal validation (Andreas Natsch, 
personal communication). In addition, an inter-laboratory evalua-
tion of a tiered-approach combining the IL-18 assay (Galbiatti et 
al., 2011) and the epidermal equivalent potency test (dos Santos et 
al., 2011) is currently ongoing. So progress continues, and in all 
likelihood it soon will be possible to configure testing strategies 
based on accumulated expertise and experience combined with 
data from those in vitro and in silico approaches that are found 
to perform well, to identify skin sensitizing hazards without the 
use of animals. The aim will be to ensure that such predictive ap-
proaches are at least as accurate or probably better than the LLNA 
– and that also should be achievable.
However, as highlighted elsewhere, there is more to achieve 
and more that needs to be achieved. An increased investment 
will be needed in research focused on providing a more de-
tailed understanding of the cellular and molecular mechanisms 
through which skin sensitization is induced and orchestrated. 
The dividends of that research investment will provide the mo-
mentum for truly innovative solutions to the unaddressed chal-
lenges and that will inform our understanding of the biological/
biochemical bases that determine relative potency.
Two examples serve to illustrate the point. Work by Stefan Mar-
tin (University of Freiburg) and others has provided new insights 
into the role of the innate immune system in skin sensitization, and 
interactions between inflammatory reactions and adaptive and in-
nate immune responses. This research will help define the danger 
signals and cofactors that are required for the effective acquisition 
of sensitization (Lass et al., 2010; Martin et al., 2008, 2011; Martin 
and Jakob, 2008; Schmidt et al., 2010; Weber et al., 2010). 
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mammalian species (non-human primate or dog). The mecha-
nistic and conceptual basis for RDT may be broad, and it is not 
well understood for many compounds. In some cases, it may be 
due to a build-up of toxic substance(s) in one or more sensitive 
areas of the body. In other cases, the changed compound concen-
tration is not a driving factor. In such cases, defense mechanisms 
may be exhausted, the tissue may be altered by regulations and 
counter-regulations, or immunological reactions involving the 
specific or non-specific immune system may be triggered. Be-
sides assessing obvious signs of toxicity and organ specific tox-
icity, a number of other endpoints are evaluated, including body 
weight, hematological parameters, urinary constituents, and 
histopathology of each organ system. RDT testing is thought to 
be extremely important in toxicity testing, as it is considered to 
model repeated exposures to lower doses of a compound, which 
is more likely to occur in a real-world situation than short term 
exposure to high doses. Moreover, this approach also offers the 
opportunity to assess recovery in between dosing. Toxicities not 
seen in acute testing or in reproductive toxicity testing may be 
revealed by RDT tests.
Regulatory risk assessments for chemicals, pharmaceuticals, 
and cosmetics, including REACH, TSCA and the FDA and EMA 
guidances, respectively, require RDT testing as an integral part 
of assessing the potential risks of a substance. The EU Cosmet-
ics Directive (Cosmetic Directive 76/768/EEC), by adopting its 
7th Amendment (2003/15/EC), has already instituted an animal 
testing ban, and as of January 1, 2013, a marketing ban will go 
into effect for any new substance tested on animals. Thus, the 
need for alternative methods is clear. Besides these regulatory 
reasons, animal testing is considered ethically questionable by 
many, and it is expensive. Most importantly, the present animal-
based regulatory tests do not provide specific information on 
human hazard, and they fail to provide a mechanistic rationale 
that would explain toxicity and allow science-based predictions. 
This problem is currently circumvented by the introduction of 
safety factors, and the need to move to more specific and useful 
results for toxicity testing is clear. 
The classical 1:1 replacement approaches have found their 
limit when faced with the problems of assessing RDT. The ad-
verse effects can be based on a complex web of disturbances in 
multiple target tissues, and the interplay between various path-
ways and systems requires new modeling approaches, integrat-
ing multiple models, pharmacokinetic parameters, and a large 
battery of mechanistic tests designed to elucidate PoT.
In 2010, with the 2013 deadline looming, experts in the vari-
ous areas of toxicology were invited by the European Com-
mission and stakeholders (such as industry, non-governmental 
organizations, EU States, and the Commission’s Scientific 
Committee on Consumer Safety (SCCS)) to analyze the status 
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4.1  Introduction: repeated dose toxicity
This chapter provides an overview of possibilities for replacing 
animals in repeated dose toxicity (RDT) testing and recommen-
dations to improve and speed up the process of that replace-
ment. The importance of RDT testing in the safety evaluation of 
chemicals, agrochemicals, pharmaceuticals, and cosmetics can-
not be overestimated. RDT evaluation examines the potential 
for chronic toxicity and for organ-specific toxicities not seen in 
acute testing. The present testing schemes are based on rodent 
or non-rodent studies performed for 4 weeks (subacute toxic-
ity), 13 weeks (subchronic toxicity), or 26-102 weeks (chronic 
toxicity). The tests, as they currently exist, are often followed 
up with further testing to more clearly define the nature of ini-
tial findings. Nevertheless, the false positive and false negative 
rate with respect to human adverse effects may be as high as 
50% (Olson et al., 2000). The focus of toxicity testing in general 
should be to capture all potential toxicants and to assess their 
hazard. Species differences imply that the use of animals to as-
sess toxicity is probably not the most efficient or detailed way 
to the end of safe and effective chemicals, pharmaceuticals, and 
cosmetics. Moreover, statistical issues, extrapolation from high 
to low doses, and other difficulties reviewed many times con-
tribute to the weaknesses of animal-based safety testing. This 
chapter provides information on current and potential future in 
vitro and in silico approaches for assessing the major endpoints 
used in repeated dose toxicity. It also contains suggestions for 
improving and implementing those tests, and it outlines a road-
map forward in the field of alternatives to RDT testing.
The objective of RDT testing is to assess the potential hazard 
of a chemical after long-term exposure. The goal of such stud-
ies is to define a No Observed Adverse Effect Level (NOAEL) 
for the compound in question. Currently, the testing is usually 
performed in a rodent (usually rat) and potentially a non-rodent 
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is something that could begin today and quickly show measur-
able results. The suggestion to create a consortium with a vision 
of generating such a database may sound naïve in the present 
competitive environment. However, this type of exercise could 
lead to a clear and definitive advance in the prediction of toxici-
ties without further use of animals. Setting up such a consortium 
would require strong regulatory pressures and incentives, par-
ticularly with regard to breaking down of barriers to data shar-
ing. It would be well worth the effort, however, to come closer 
to the larger goal of animal-free toxicity testing.
There are several examples of this type of initiative already: 
The U.S. Environmental Protection Agency (U.S. EPA) has rec-
ognized the relevance of collecting high quality regulatory in 
vivo data and making it accessible for cross-chemical computa-
tional toxicology analysis to create an in silico assessment for 
chemical compounds. They have created a U.S. EPA ToxRef 
Database that profiles chemicals based on chronic toxicity. This 
database has already proven to be very valuable (Liebsch et al., 
2011; Martin and Jakob, 2008). Another example of relevant 
collaboration is the Innovative Medicine Initiative (IMI) project 
eTox1. This consortium aims to create a drug safety database 
from industry legacy toxicology reports and public data that will 
allow in silico prediction of toxicities.
Linking these types of efforts across different business and 
product areas could confirm common pathways of toxicity or 
help identify new ones. The OpenTox2 initiative could be a 
starting point; however, OpenTox currently only works on open 
collaborations, communications, and advisory boards. To func-
tion optimally, and have more impact in creating predictive as-
says and tools, it would need to add more rigorous experimental 
data sharing. 
4.3  Integrated testing strategies
It is clear that, at present, we cannot screen for repeated dose 
toxicity using only alternative methods. However, the imple-
mentation of decision trees and tiered approaches, i.e., inte-
grated testing strategies (ITS), will contribute greatly to the re-
ducing the use of animals (Grindon et al., 2008; McKim, 2010; 
Vanhaecke et al., 2011). This is something that can begin now 
and be modified as more and more alternative tests become 
available. Approaches such as the decision tree proposed by 
Vanhaecke et al. (2011) for predicting liver toxicity represent a 
very good start. The authors propose integrating computational 
and cell-based toxicity information, along with pre-existing 
data, to arrive at a theoretical NOAEL and assess an accept-
able margin of safety. Similar strategies could be developed 
for all relevant organ systems, and be implemented in a variety 
of sectors, to achieve meaningful validation. However, such 
ITS will need to be broadly discussed among different experts 
in the toxicities assessed and in the technologies used. Before 
implementing the ITS, a very careful evaluation of the assays 
is needed. For example, Vanhaecke et al. (2011) suggests us-
of alternative methods and to estimate the time necessary to 
achieve a full replacement of animals in the cosmetic industry. 
An extensive and detailed document (Adler et al., 2011) sum-
marized their conclusions. In that document, virtually all of the 
available in vitro and in silico methods were considered, and 
the unanimous conclusion was that seven to nine years will be 
required before there will be replacement of animal testing for 
skin sensitization and five to seven years to finalize methods to 
predict toxicokinetics. A timeline for full animal replacement 
could not be set for repeated dose toxicity, carcinogenicity, and 
reproductive toxicity. An additional group of experts in the field 
of alternative methods has reviewed the outcome of this report, 
and they came to the same conclusion (Hartung et al., 2011). For 
this reason, this chapter will not list the existing tests and meth-
ods again but rather will discuss current gaps of knowledge and 
ways forward to arrive at an alternative testing strategy within a 
reasonable time period. 
Although the above documents focused specifically on test-
ing for cosmetics, many of the underlying themes apply to all 
areas of toxicity testing, including pharmaceuticals, agrochem-
icals, and industrial chemicals. The tests requested by the vari-
ous regulatory bodies for RDT evaluation are in most aspects 
equivalent. Also, independent of the commercial product area, 
the mechanisms that are the basis of toxic effects are expected 
to be the same.
This chapter aims to place the available methods (extensively 
covered in previous papers) in a chronology, providing a road-
map for replacement of RDT testing based on what can and 
should be done now and what will require more time and effort. 
Thus, the methodologies reviewed below are in order of cur-
rent feasibility, with particular note of steps that must be taken 
to move each methodology closer to fruition. The final section 
summarizes the findings of this group of authors and provides 
recommendations for moving forward.
4.2  Create new alliances
It is in the interest of every party, including chemical, phar-
maceutical, food, and cosmetics companies, to decrease the 
number of animals used, not only for ethical reasons but also 
from a budgetary point of view. This is particularly the case 
when regulators request a more expensive second species study 
in repeated dose toxicity testing. To combine efforts in the chal-
lenging task of reducing the use of animals to predict for repeat-
ed dose toxicity (and, in general, any type of toxicity) would 
dramatically increase the possibility of success. Each company 
(regardless of the area of business), and each of the different 
regulatory agencies, has a database of information on toxicity, 
as well as investigative data that could advance the develop-
ment and validation of in vitro/in silico systems immensely; 
inform pathways of toxicity based on in vivo data, and speed 
the process of reducing and replacing animals in repeated dose 
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ner, will improve our understanding of the cellular pathways 
involved in toxic processes and thereby improve our ability to 
predict toxicity. Understanding alterations in signaling path-
ways, and the role of these alterations in the activation of toxic 
effects, is crucial not only to elucidate how and why a toxic 
effect is occurring but also to extrapolate the effect to and from 
an in vitro system. The task of identifying relevant pathways, 
understanding them, and demonstrating correlation with toxic-
ity is a challenging one, particularly if we consider that often 
it is the interaction between pathways and their localization 
that results in toxicity or protection of a cell (Latta et al., 2000; 
Volbracht et al., 1999).
Cells receive, process, and respond to information and sig-
nals through many distinct molecular pathways, which permit 
them to function properly. Often, components of several differ-
ent pathways interact, resulting in signaling networks to create 
these cellular responses. A toxicological response often is in-
duced by a disruption of these signals. For example, protracting 
a signal for a long period of time could lead to a toxicological 
response rather than a physiological one. Similarly, the strength 
of the signal could be enhanced by a toxicant and, therefore, un-
balance the normal cellular responses or disrupt feedback loops. 
In considering the analysis of signaling pathways, it should be 
taken into account that often it is not a new pathway that is acti-
vated but rather a normal signal that is disrupted by the toxicant 
(see Fig. 4.1). Therefore, it is necessary to have an idea of the 
threshold that must be crossed to exert a toxic effect. Together 
with the identification of the pathways themselves, a quantifica-
tion of the major players in the pathways should be performed. 
The identification of common pathways of toxicity, and the 
quantification of the signals therein, should continue to be the 
major focus of toxicological research, as not only will it move 
the field forward in understanding, it will assist in the develop-
ment and validation of the in vitro and in silico systems we need 
to replace animals in repeated dose toxicity testing (Stokes and 
Wind, 2010).
ing stem-cell-derived hepatocytes, which currently are not the 
best model to screen for liver toxicity (Guguen-Guillouzo et 
al., 2010). The use of reference compounds appropriate to each 
organ system to test the ITS would be particularly useful in 
such a validation. 
In some cases, such as in reducing animal use for REACH 
in the chemical industries, decision trees and tiered approaches 
may be well characterized and ready to be implemented. How-
ever, in other areas, such as in the pharmaceutical industry, 
these approaches are still in a validation phase and have yet to 
prove their ability to predict and manage risk at an early stage. 
Technologies and assays used in any ITS would be regularly 
reviewed and revised, of course, to ensure their continuous de-
velopment and improvement.
Of note, and rarely mentioned, is the fact that ITS can and 
should incorporate human data, including epidemiological, ge-
netic, and medical/clinical data, whenever applicable. As for 
data from in vitro and in silico systems, standards must be set to 
ensure the use of quality and comparable data in each system, 
bearing in mind that the overarching goal is to predict human 
toxicity. The use of this data cannot and should not be ignored 
in developing testing approaches.
4.4  Signaling pathway identification and analysis
In 2007, the United States National Academy of Sciences 
(NAS) published a report Toxicity Testing in the 21st Century – 
a Vision and a Strategy, which envisioned a new approach to 
toxicology (NRC, 2007). The report called for the application 
of new and advanced technologies and biological knowledge 
to move toxicology forward. One focus of the report was the 
identification of common pathways of toxicity. New frontiers 
of science, such as systems biology, bioinformatics, high-
throughput screening, high-content screening, transcriptomics, 
proteomics, and metabolomics, applied in a synergistic man-
Fig. 4.1: Pathway of Toxicity (PoT) alterations – alterations in the magnitude or timing of signaling
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pathway, and a more detailed analysis of pathways inhibition 
should be performed. Knocking out genes is another approach. 
Different strategies have been followed to do this systematically 
in murine and human cells. One modern approach is the gen-
eration of haploid stem cells, and the knockout of every gene 
of the genome in such cells, which then can be differentiated 
to any given cell type. More traditional approaches use cells 
from humans with different mutations, and a sophisticated vari-
ant uses such cells together with a derived cell type in which the 
mutation has been repaired. A completely different and comple-
mentary strategy useful for PoT mapping is the visualization of 
pathway activities by cellular reporter constructs.
Case studies
To bring together new technologies and existing toxicological 
knowledge, extensive case studies will take a central role, and 
their importance cannot be overestimated. One important ba-
sis will be an assembly of compounds causing RDT. Among 
these, the ones not identified in acute studies need to be identi-
fied. Many such examples are known from the pesticides field 
(Spielmann and Gerbracht, 2001; van Ravenzwaay, 2010). A 
first selection would involve those that result in human toxicity, 
or for which the animal toxicity is seen in the range of human 
exposure. The case study, then, would examine whether toxi- 
city would have been predicted correctly by alternative methods. 
The cases where this approach failed are especially interesting. 
This should give an incentive for the establishment of methods 
that fill the gap. It would be worthwhile to promote such stud-
ies in EU-funded research consortia. The road to the future in 
this area leads through learning from the past. Such efforts need 
support as goal-oriented applied research. They are not funded 
by classical scientific funding bodies, which appear to consider 
them too applied and not sufficiently innovative. Unfortunately, 
it is not broadly accepted that such work forms the basis for 
large innovations in the field of risk assessment. 
4.5 In vitro methods
4.5.1  A brief overview of in vitro models
The need for in vitro systems, which can address all areas cov-
ered in RDT testing, is obvious. This section provides a brief 
overview of the available technologies and highlights some bar-
riers and considerations. The cellular tools currently available 
are primary cultures or established cell lines from animals or 
humans (Skelin et al., 2010). 
Primary cultures obtained from animals have three major limi-
tations, the most obvious one from the point of view of reduc-
ing animal use being that animals are used. The number of 
animals used to perform experiments with primary cultures is 
fewer than for in vivo testing, but often a significant number of 
animals must be sacrificed to obtain a primary culture, particu-
larly for difficult-to-culture cell-types. A second limitation of 
primary cultures is the short life span of the cultures. With the 
exception of some neuronal systems (Viviani, 2006) that have 
There are a number of mechanisms by which these pathways 
can be investigated – many of them pioneered in medical re-
search in order to identify pathway alterations that result in hu-
man pathologies. These include technologies from knockout 
yeast and mice, to antibodies and perhaps RNA interference 
(RNAi) (Moffat and Sabatini, 2006). The concept of each of 
these technologies is that a specific member of the pathway in 
question can be perturbed, which can lead to identification of 
important pathway members, how they interact, and to what 
degree.
RNA Interference (RNAi) and other interventions to define 
pathways of toxicity (PoT)
RNAi technology is based on the concept that by introducing a 
sequence-specific iRNA that will lead to a post-transcriptional 
gene-silencing process, one can identify important pathway 
interactions and mechanisms. This tool is important because 
knocking down (KD) the gene(s) inhibits the entire pathway, 
allowing identification of the proteins that play a role in signal-
ing through post-translational modifications and monitoring of 
their role in signaling (Virshup and Shenolikar, 2009). Different 
specific RNAi sequences can result in different percentages of 
KD in the cells, giving hints as to the threshold of inhibition or 
activation needed to create a toxic effect in the signaling path-
way. In other words, this technology is based on a “quantitative” 
indication of the signaling pathway.
RNAi in combination with bioinformatics tools can provide 
even more knowledge on the signaling pathways involved in 
toxicity. There are several examples of software and algorithms 
created to correlate the KD pathway from an RNAi experiment 
with other pathways (Kaderali et al., 2009). Expanding the ge-
netic analysis of the KD genes can achieve a similar result: A 
transcriptomic evaluation of gene changes within a pathway can 
provide an overview not only of the specificity of the inhibition, 
but also of possible correlations among pathways that could 
highlight new toxicological interactions, particularly if included 
in a bioinformatics analysis.
RNAi has proven useful in areas such as in identifying path-
ways involved in cancer and apoptosis induction (MacKeigan et 
al., 2005). However, applying this technology directly to the in 
vitro systems mentioned above might not be immediately fea-
sible, since thus far RNAi methods are well established in cell 
lines and in dividing cells but are difficult to use in non-dividing 
primary cultures and ESC-derived cells. Luckily, the signaling 
pathways involved can be investigated in non-primary, non-
ESC cell lines, and the discoveries made there can be applied to 
the in vitro technologies to improve predictability.
RNA interference has been described here in more detail as 
an example for a pathway-mapping tool. Other approaches are 
available and are being developed. One involves the selective 
inhibition of pathways by chemicals. These act especially fast, 
and new pathways have been identified in this way (Falsig et al., 
2004b; Lotharius et al., 2005; Lund et al., 2005). A big advan-
tage is that they can also be combined for more sophisticated 
pathway mapping (Falsig et al., 2004b). The major disadvan-
tage is that often they do not selectively inhibit only a specific 
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and Guilak, 2003). This could be an interesting area to explore 
further, particularly considering the accessibility of adipose tis-
sue from surgical operations. 
Embryonic stem cells (ESC) are isolated from the inner cell 
mass of 5-6-day-old blastocysts (Davila et al., 2008) and are ful-
ly pluripotent, meaning they are capable of giving rise to most 
tissues of the organism, including germ line cells. Under proper 
differentiation they should be capable of generating all the cell 
types present in an organism. 
In 2006, Takahashi and Yamanaka published a breakthrough 
in stem cell biology: mouse somatic cells that could be repro-
grammed back to pluripotent stem cells. The era of induced 
pluripotent stem cells (iPSC) had begun (Takahashi and Ya-
manaka, 2006). One year later, the same group showed that 
human somatic cells can also be reprogrammed into pluripo-
tent stem cells by transduction of four defined transcription 
factors: Oct3/4, Sox2, Klf4, and c-Myc. The derived cells had 
the same morphologic, genetic, and epigenetic characteristics 
as stem cells (Takahashi et al., 2007). However, before con-
sidering the use iPSC for clinical or toxicological purposes, 
the issue of the mechanism of reprograming must be solved, 
since this process implies the use of viral transduction (which 
leads to a safety concern for clinical applications) and the 
activation of transcription factors and oncogenes present also 
in cancer stem cells (a concern for both clinical and toxico-
logical use) (Jaenisch, 2009). That said, various papers al-
ready have been published reporting that reprogramming of 
somatic cells can be achieved without using viral delivery 
of reprogramming factors and evaluating the relevance of c-
Myc and Klf4 in this process. A reliable methodology for do-
ing so across many labs would increase the potential for these 
cells in both clinical and toxicological applications (Cox and 
Rizzino, 2010; Jaenisch, 2009). Thus, iPSCs may have great 
potential for predicting toxicity. They can be a source of po-
tentially all tissues derived from various human populations 
with different pharmacogenomics profiles and a variety of 
genetic variabilities. 
Stem cells represent a cellular system that has several advan-
tages compared to stabilized cell lines and primary cultures, in-
cluding normal genetic profile, normal growth, uniform cellular 
physiology, and pharmacology (McNeish, 2007). They have a 
number of unique features that make them attractive and poten-
tially valuable for toxicological screening (Ameen et al., 2008; 
Davila et al., 2008; Jensen et al., 2009; McNeish, 2004):
a) Stem cells divide and renew themselves for a long period 
of time, and therefore they can provide an almost unlimited 
supply of cells. Since, like all in vitro dividing cells, stem 
cells can accumulate mutations, karyotyping the cells is nec-
essary after long periods in culture to confirm genetic nor-
mality prior to use in testing. 
b) Stem cells are pluripotent and therefore potentially able to 
differentiate into any human tissue. This opens the possibil-
ity of creating different cell types from the same organ in one 
culture. For example, an ideal in vitro liver toxicity system 
would have a “liver-like” organ that includes not only hepa-
tocytes but also all other relevant cells, such as Kupffer cells, 
a relatively long life in vitro, many cultures have a lifespan of 
2 to maximum 14 days (Volz et al., 1991). Additionally, even 
if the survival of the culture can be increased using improved 
culturing methods, some of the relevant function and signaling 
pathways of the cells can be lost (Hartung, 2007a). For exam-
ple, hepatocyte cultures are relevant, not only to predict one 
of the most common types of toxicity observed when testing 
chemicals and drugs, but also to properly predict metabolism 
and pharmacokinetics – key parameters necessary to properly 
forecast repeated dose toxicity. Several efforts have been made 
in improving this relevant cellular system and, at present, the 
cultures can survive for several weeks. However, during this 
time the cultures lose their metabolizing capacity (Miranda et 
al., 2009) and therefore lose value in predicting for repeated 
dose toxicity. A third limitation, which may also be seen as an 
opportunity, is that these systems will be predictive (potential-
ly) of animal toxicity, rather than human toxicity, and assess-
ment factors for interspecies variation would still be necessary 
in the final risk assessment (Falsig et al., 2004a; Lund et al., 
2006). Since the goal is to predict human toxicity, continuing 
to use animal systems may not be ideal. However, these animal 
systems may be seen as an interim step in the process of full 
animal replacement, in that it will be easier to validate/assess 
the value of these tests by comparing the in vitro results to al-
ready available in vivo data from the current animal tests, and 
these tests may be easier/quicker to develop than the respective 
human systems.
Human primary cultures are perhaps the most relevant system 
for in vitro screening from the standpoint of species specificity 
and maintenance of the optimal genetic profiles and signaling 
pathways. However, a major disadvantage of human primary 
cultures is the poor availability of human samples (often derived 
from cadavers or cancer patients), resulting in little control over 
the phenotypes selected for screening. 
An alternative to primary cultures is immortalized human cell 
lines. While these cells have the advantage of being easy to cul-
ture and the ability to increase screening throughput, they may 
have altered signaling pathways, and in some cases their meta-
bolism is changed (more glycolytic energy generation). In most 
cases they lose xenobiotic-metabolizing capacity (Hartung, 
2007a). Conditionally-immortalized cells, or cells in which the 
immortalizing transgene can be deactivated, may offer a com-
promise solution (Lotharius et al., 2005; Scholz et al., 2011).
Stem cells can be classified into three major categories, ac-
cording to derivation: embryonic stem cells (ESC), adult stem 
cells (ASC) and induced pluripotent stem cells (iPSC). Adult 
stem cells (ASCs) comprise, e.g., Mesenchymal Stem Cells 
(MSCs), are present in somatic tissues and have characteristics 
of multipotent adult progenitor cells. They are not able to dif-
ferentiate into all cell types of the organism. However, it should 
be taken into consideration that both bone marrow mesenchy-
mal stem cells (BMSC) and adipose-derived mesenchymal stem 
cells (ADMSC), when properly differentiated, have potential for 
hepatic and neuronal differentiation (Banas et al., 2007; Gimble 
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cell-systems that constitute them will be important in predicting 
complex toxicities. 
Endpoints
The main toxicological endpoints for in vitro technologies 
have been the classical markers for cell death, such as mem-
brane permeability, intercellular energy levels, glutathione lev-
els, and other general endpoints that represent a high level of 
toxicity. However, it is important to remember that toxicity is 
first induced by the malfunctioning of cells, from which sig-
nificant cell dysfunction and death follow, i.e., if we consider 
compounds that act on the cytoskeleton or on exocytosis, we 
must consider cytoskeletal component alteration or enzyme re-
lease as a significant endpoint, rather than just cell death. In this 
way, the substitution of classical “toxicological” endpoints with 
functional ones is a way in which classical toxicity prediction 
could be improved, especially when predicting organ-specific 
toxicities. For example, compounds that are cardiotoxicants of-
ten are found to be cytotoxic in hepatocytes or other types of 
cell cultures. This information may be useful for acute toxicity 
but less relevant for the assessment of organ-specific toxicity in 
the heart. In this case, it is more relevant to consider the contrac-
tive capacity of cells, rather than the induction of apoptosis.
Another good example of the concept of more specific toxi-
cological endpoints improving the overall quality of in vitro 
testing in general is that better in vitro ADME (absorption, dis-
tribution, metabolism, and excretion) prediction significantly 
reduced the attrition percentage for compounds in development 
in the pharmaceutical industry (Kola and Landis, 2004). Specif-
ic studies of ADME-related mechanisms led to the development 
of good predictive systems with the most indicative endpoints. 
Recently, more investment has been made in developing new 
approaches to investigate more sophisticated and meaningful 
endpoints. High-content screenings, platforms for biomarker 
detection, TaqMan Low-Density Arrays, and new technologies 
for the assessment of phosphorylated proteins are examples of 
technologies that allow the investigation of a wider variety of 
toxicological pathway endpoints.
In vitro exposure
Kinetics and biodistribution are two key factors that must be 
included in the evaluation of repeated dose toxicity. However, in 
vitro screenings often do not consider the actual (as opposed to 
nominal) in vitro concentration, bioavailability, and degradation 
of compounds. Frequently, synthesized compounds are not sta-
ble at 37°C and/or bind to plastics or media proteins, factors that 
often are not considered or accounted for in in vitro tests. The 
importance of this cannot be overestimated, as it is crucial for 
data interpretation. Although it is labor intensive, the detection 
of the real free concentration and measurement of the stability 
and availability of the compounds in an in vitro system cannot 
be neglected.
Assay validation
Not all parties were in agreement with the timelines envisioned 
in the EC’s expert panel report (Adler et al., 2011). Some claim 
stellate cells, and cholangiocytes. Multiple cell types in each 
organ system are undoubtedly important in various types 
of toxicity, so a wider variety of cells in the in vitro system 
could provide a better picture of potential toxicity. 
c) Stem cells can represent genetic diversity. This is particularly 
true if induced pluripotent stem cells (iPSC) are used (see 
note on types of stem cells above).
d) Under the appropriate culture and assay conditions, the 
throughput and predictivity of in vitro assays using cell cul-
ture would be increased significantly through the use of stem 
cells.
However, the limitations of the system should not be neglected. 
Stem cell biology is a young science, and so far the culture of 
stem cells is not trivial. Additionally, when stem cells differen-
tiate into different cellular systems, the differentiation rarely 
occurs in 100% of the population, and not all of the cells are in 
the same stage of full differentiation (Ameen et al., 2008). For 
example, hepatocytes, when properly differentiated to produce 
hepatic endoderm cells or hepatocyte-like cells, present char-
acteristics of fetal hepatocytes and do not express fully active 
cytochrome P450 signals (Greenhough et al., 2010). Similarly, 
stem cell-derived cardiomyocytes resemble human heart tissue 
but variably and with gene expression that is not the same as 
in adult heart tissues, indicating that additional differentiation 
protocols are needed (Asp et al., 2010). 
So far, only a limited number of cell types have been differ-
entiated, compared to the variety of potential cell types within 
an organism. Limited phenotypes and functional data are avail-
able for the embryonic stem-derived cells, with few exceptions. 
More research and investigation is needed to determine the state 
of maturation and functionality of the different cellular types. 
When these characteristics can be verified, the possibility of ap-
plying in vitro stem cell-derived models in predictive strategies 
in toxicology will increase dramatically. This is not possible in 
the next couple of years, but, based on the data available so far, 
it may be possible in three to seven years.
4.5.2  Specific considerations for in vitro methods
The following constitute special issues that must be borne in 
mind during the development, validation, and implementation 
of cellular test methods:
Culture methods 
The application of techniques such as 3D culture systems and 
co-culture has great potential for toxicity testing. Several ex-
amples confirm the relevance of 3D culture models to improve 
the structure and the prediction rate, not only for toxicity but 
also in screening for pharmacological assays (Dash et al., 2009; 
Lan and Starly, 2011; Meng, 2010; Nakamura et al., 2011; Toh 
et al., 2009). Similarly, co-culture methods will give a better 
idea of the relevance of interaction and crosstalk between the 
different cell types. Co-culture systems have been proven par-
ticularly relevant in prediction of inflammatory effects and the 
physiological interaction between signaling pathways (Boraso 
and Viviani, 2011; Scharf et al., 1996; Tukov et al., 2006). The 
further development of these methodologies in concert with the 
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4.7  Conclusions and recommendations:  
repeated dose toxicity
It is most likely that a decade or more will be required be-
fore the gaps can be appropriately filled. That said, the authors 
recommend a step that can be taken immediately: the imple-
mentation of more stringent and appropriate ITS for testing. An-
other step that could move forward immediately, and that could 
improve ITS testing schemes, as well as in silico and in vitro 
technologies, is a frank and complete gathering and assessment 
of the repeated dose toxicity data that already exists for a wide 
variety of compounds, and the use of these data for case studies 
investigating the needs and pitfalls for new assays. This would 
require the collaboration of a variety of entities, including com-
mercial, governmental, and non-governmental. The benefits that 
could be reaped by such a concerted effort in data gathering and 
sharing clearly outweigh the difficulties. In order to improve 
the predictivity of current in vitro and in silico tests, and even 
the current tests, the identification of pathways of toxicity must 
continue to move forward. This requires the use of new technol-
ogies in the field of omics and systems biology, combined with 
new cell models and evaluation strategies based on chemical 
inhibitors or gene inactivation. One particular issue that must 
be addressed is the setting of guidelines as to what constitutes 
an appropriate model for each organ system, i.e., what makes a 
heart a heart, a liver a liver, etc. In this context, it will be impor-
tant to consider how immunological and inflammatory reactions 
can be incorporated in such organ systems.
Recommendations: repeated dose toxicity
The following steps are suggested to replace animal test-
ing for repeated dose toxicity in an appropriate and timely 
fashion:
1. Joint task force: A joint effort toward a toxicity data-
base to gather all current data on a wide variety of com-
pounds would greatly improve the quality and speed of 
new test development and validation. Organization of 
this effort should begin immediately. The data should be 
used to support case studies designed to identify test re-
quirements and pitfalls, as well as for test evaluations.
2. Tiered testing systems and decision trees (ITS):  
Although it clearly is not yet possible to replace in vivo 
testing completely, we can refine and reduce the number 
of animals used today. Implementing decision trees, 
tiered approaches and/or applying screening strategies 
is possible immediately, and these can be modified as 
more and more non-animal tests become available. In 
addition to existing animal data, data from in vitro tests 
and data from in silico systems, as well as human data 
(epidemiological and clinical/medical), can be integrat-
ed into these types of approaches. These data should not 
be ignored! The time to act on this is now, for all types 
of compounds.
that the date of 2013 for animal replacement is still possible 
(Balls and Clothier, 2010; Spielmann, 2010; Taylor et al., 2011). 
Taylor and Casalegno, in particular, claim that several alterna-
tive methods are available where the percentage of prediction 
is above 80% (Carfi et al., 2007; Duff et al., 2002; Huang et al., 
2009; Inoue et al., 2007; Langezaal et al., 2002; Pessina et al., 
2001). Although these are all very promising examples, seldom 
more than ten compounds were tested in these assays. They must 
be more appropriately validated with a larger number of com-
pounds, while still achieving a high percentage of prediction to 
be more universally accepted. To that end, it is worth mentioning 
that a good validation, particularly for the complex endpoints 
of repeated dose toxicity, should include a sufficient number of 
compounds, ideally representing a variety of classes. To increase 
the number of classes of compounds that can be used for vali-
dation of common tests, again, collaboration between different 
industries and entities is the ideal.
Each validation must be tailored to the system being tested, 
and certain agreements must be set for all tests for a certain type 
of toxicity (Hartung, 2007b). For example, for organ-specific 
toxicities using in vitro cellular assay tests, it must be decided 
“What constitutes a heart?” and “What constitutes a liver?” 
More broadly, what cell types, gene expression, and physiologi-
cal markers must be set in order for a system to appropriately 
represent the organ in question? Thus, comparison directly to 
current endpoints and markers may be necessary at first, but 
a true assay validation must be tailored to the test or testing 
scheme in question, particularly for repeated dose toxicity.
4.6  In silico prediction 
The value of bioinformatics, in silico technologies, and sys-
tems biology in analyzing the data, identifying new pathways, 
and predicting toxicity is inarguable. Many of the aforemen-
tioned reports and reviews on the replacement of animal tests 
summarize the state of the science for in silico methodologies 
for repeated dose toxicity testing, so we will not provide a 
summary here. However, as we work toward the goal of in 
silico models and methodologies as a key part of toxicity test-
ing, it is of extreme importance to recognize that the quality 
of the data used to create predictive in silico models signifi-
cantly affects the quality of the system itself. If low quality 
data are used, the system is designed to fail. When designing 
in silico methods using in vivo data, it is vital to have data from 
well-designed experiments that indicate the time course of the 
toxicity and that will correlate pathology with molecular and 
mechanistic endpoints. If in silico methods are developed on 
the basis of in vitro data, the quality and predictivity of the ex-
periments become even more important. For example, basing 
an in silico model for pathway analysis on data from tumor cell 
lines would be suspect, since these cell lines often have altered 
signaling pathways. Another example is the use of RNAi data: 
it is essential that the appropriate cell line was used to derive 




eventually can be replaced with simple assays, as in 
the ToxCast program.
b. More sophisticated methods will probably decrease 
the throughput, but, at present, they will most likely 
provide more long-term and stable systems. They 
may, for the foreseeable future, be better at predicting 
more complex organ toxicity (e.g., 3D-systems and 
co-cultures), particularly inflammatory and fibrotic 
processes.
c. Appropriate endpoints must be chosen for each test 
and test system: what do we want to know and what 
toxicity are we trying to predict? Omics approaches 
will get rid of this problem, as many endpoints can be 
evaluated simultaneously (Henn et al., 2009).
d. Real free concentration and stability of the com-
pounds during the exposure in vitro is of major rel-
evance for evaluating the actual toxic dose. Overall, 
the modeling and prediction of compound concentra-
tions will play a key role for QIVIVE.
e. For the complex models of biological processes, a 
significant number of known positive and negative 
compounds are required to evaluate the performance 
of the system. The selection of compounds should 
consider the applicability domain and different 
chemical classes, as well as modes of actions. The 
creation of a reference list of compounds for which 
information on mechanisms of toxicity and potency 
is readily available would speed the validation proc-
ess immensely for all new testing systems.
5. Considerations for the development and validation 
of in silico models: It is extremely important to be sure 
of the quality of data used to build in silico models. Spe-
cific criteria to evaluate the robustness and quality of the 
experimental data used in the development of in silico 
models should be developed and agreed upon in order to 
address this issue and to assist in design and validation 
of high quality in silico models.
3. Understand signaling pathways: Understanding the 
molecules and pathways involved in toxicological events 
is crucial for progress in toxicology. This is probably the 
most important activity for future success in replacing 
animals for RDT testing. We should consider:
a. The signaling pathways involved in toxicity may 
be normal signals that are altered in the duration or 
magnitude of response. Therefore, a quantification of 
the signal is of great relevance. For this reason, two 
different concepts are followed initially. The iden-
tification of PoT is a more long-term goal. An ITS 
based on high-throughput mapping of PoT and their 
disturbance in simple systems may eventually yield a 
good toxicity prediction. In the meantime, while not 
all quantitative relationships of the network of PoT 
are known, and while it is still unclear why chemicals 
affect one cell type more than another, more complex 
systems will be employed to arrive at more apical 
endpoints (Zimmer et al., 2011). The two approaches 
will be complementary and require a parallel devel-
opment for some time.
b. Tools such as RNAi or chemical interference, which 
are often implemented to aid in understanding sign-
aling pathways in various diseases, could help toxi-
cologist understand the signaling pathways involved 
in toxicity.
4. Considerations for development and validation of in 
vitro systems: A large number of potentially useful in 
vitro cellular assays are available, and each of them has 
advantages and disadvantages. It needs to be considered 
that:
a.  All in vitro systems have limitations, and the choice 
of which to use will depend on the question asked. 
This is particularly important in the nearer future, 
with the use of complex test systems. Only these 
experiments, and comparison with high-throughput 
approaches, can show whether the complex systems 
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to inform the general public about the risks that chemicals may 
pose have served us well. We believe it is likely that revamping 
our testing paradigms by basing them on updated and rigorously 
tested science and leaving the precautionary aspect explicitly 
to the risk management process would better serve both those 
involved in carcinogenicity testing and the public.
Our current basic understanding of chemical carcinogene-
sis (Loeb and Harris, 2008; Luch, 2005; Oliveira et al., 2007; 
Williams, 2001; Wogan et al., 2004) is shown in Figures 5.2 
and 5.3. These figures demonstrate a multi-step process in 
which several mechanisms – genotoxic and non-genotoxic – 
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5.1  Introduction: carcinogenicity
In April 2010, the US President’s Cancer Panel published 
the report “Reducing Environmental Cancer Risk” (Reuben, 
2010). Although the report acknowledges that “overall can-
cer incidence and mortality have continued to decline in re-
cent years” (see also Fig. 5.1), it states “the true burden of 
environmentally induced cancer has been grossly underesti-
mated. With nearly 80,000 chemicals on the market … un- or 
understudied and largely unregulated, exposure to potential 
environmental carcinogens is widespread.” This situation 
must be considered in the context that life expectancy has 
tripled (Kirkwood, 2008) during the period in which these 
chemicals were introduced. 
At the same time, the possible health risks posed by chemi-
cals are of considerable concern to the general public (Entine, 
2011), which fuels the demand for safety testing of chemicals. 
Surveys conducted by Eurobarometers in 2005 and 2010 asked 
Europeans the question of how likely they consider the possibil-
ity that environmental chemicals damage their health. In both 
years, around 18% of respondents considered this “very likely” 
and 43% “fairly likely” (Eurobarometer 73.5 from 06/2010 and 
64.1 from 09-10/2005). In strong contrast, the degree of contri-
bution of chemical exposure to the overall cancer rate has been 
estimated at only 4% for occupational exposure, 2% for pollu-
tion, less than 1% for industrial products, and 1% for medicines 
and procedures (Doll and Peto, 1981). These estimates, how-
ever, are outdated and, for example, did not take into account 
the interactions of multiple factors. 
It is not the purpose of this paper to take a position in any of 
these debates but rather to address the issue of how to best test 
chemicals for carcinogenic potential, given the potential of these 
chemicals to exert health effects. At the same time, we have to 
ask ourselves whether traditional precautionary methods used 
5  A Roadmap for the Development  
of Alternative (Non-Animal) Methods  
for Carcinogenicity Testing
Fig. 5.1: Cancer mortality in the US over time
Annual age-adjusted cancer death rates among males and 
females for selected cancers, US 1930-2006. Adopted from 
(Jemal et al., 2010). Rates are adjusted to the 2000 US standard 
population. Due to changes in International Classification of 
Diseases (ICD) coding, numerator information has changed over 
time. Rates for cancers of the lung and bronchus, colon and 
rectum, and liver are affected by these changes.
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It is important to note that carcinogenicity testing was devel-
oped as a result of historical cases of adverse effects, and the 
test models currently in place were developed with the existing 
knowledge at that time. However, the fact that there has been 
much scientific progress relevant to this field since then, com-
bined with the degree of public concern about potential chemi-
cal carcinogenicity, has led us to focus this paper on carcino-
genicity testing.
Standardization of protocols
The cancer bioassay is astonishingly young, given the impor-
tance of the health effect in question: the standardized protocol 
was suggested by the US National Cancer Institute in 1976 and 
adopted by OECD in 1981. The ICH (International Council on 
Harmonisation of Technical Requirements for the Registration 
of Pharmaceuticals for Human Use) only adopted the test for 
use in pharmaceuticals in 1997. 
contribute to cancer initiation and promotion. The potential of 
chemicals to interfere with repair and defense mechanisms, as 
well as detoxification and excretion, further contribute to this 
complexity. 
An ideal carcinogenicity testing system would take all of 
these factors into account. Unfortunately, such a system does 
not exist. In this paper, we assess the available tools for carcino-
genicity testing, introduce emerging tools that could transform 
this testing paradigm, and discuss the potential we see for these 
novel methodologies.
Definition of carcinogenicity1: “Chemicals are defined as car-
cinogenic if they induce tumors, increase tumor incidence and/
or malignancy, or shorten the time to tumor occurrence. Benign 
tumors that are considered to have the potential to progress 
to malignant tumors are generally considered along with ma-
lignant tumors. Chemicals can induce cancer by any route of 
exposure (e.g., when inhaled, ingested, applied to the skin, or 
injected), but carcinogenic potential and potency may depend 
on the conditions of exposure (e.g., route, level, pattern, and 
duration of exposure).”
5.2  Application of the framework to 
carcinogenicity testing
We have applied the assessment framework presented in Chap-
ter 1 to analyze various options as potential alternatives to the 
cancer bioassay (OECD TG 451; OECD, 2009), which is con-
ducted as a 2-year bioassay in rats and mice and is currently the 
only accepted test for carcinogenicity. 
Testing with the cancer bioassay in two species can involve 
600-800 animals, the histopathological examination of more 
than 40 tissues per animal, and costs approximately € 1 mil-
lion per chemical and species (Vanparys et al., 2011). This bio-
assay is obviously time-consuming and expensive, and uses 
large numbers of animals. In addition, the assay’s predictiv-
ity for humans has been challenged (Knight et al., 2006a,b,c; 
Shanks et al., 2009). Thus, while protection against potential 
carcinogenic effects of environmental chemicals is a key de-
sire of the public, this assay is not suitable for broad use, nor 
is it broadly used.
5.2.1  Abolition of useless tests
The concept that genotoxicity is the first and foremost mecha-
nism of chemical carcinogenicity is rarely challenged. How-
ever, there are little or no epidemiological data that support 
the hypothetical existence of widespread chemical carcinogen-
esis. Not only has average age increased continuously over the 
last 150 years (Kirkwood, 2008), during which period about 
100,000 chemicals were introduced into our environment, but 
age-adjusted cancer rates did not increase over this time period 
(Jemal et al., 2009). Furthermore, exposure to mutagens did not 
correlate with oncomutations in people (Thilly, 2003). 
1 http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_r7a_en.pdf  
   (last accessed 08.09.2011)
Fig. 5.2: Chemical carcinogenesis stages and the 
occurrences involved in each one
(modified from Oliveira et al., 2007)
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appears to be a most critical factor. Even when the same strain 
is used, there appear to be problems with standardization that 
hamper the use of historical control groups (Haseman et al., 
1997). In this study, the most commonly used strains showed 
strong weight gain and changes in some tumor incidences that 
resulted in reduced survival over just one decade, which was 
attributed to the intentional or inadvertent selection of breeding 
stocks with faster growth and easier reproduction. Other fac-
tors that have been suggested that could possibly influence the 
bioassay protocol over time include caging protocols, diet, en-
vironmental factors, genetic drift, study duration, and survival 
differences.
An analysis of 1,872 individual species/gender group tests in 
the US National Toxicology Program (NTP) showed that 243 of 
these tests resulted in “equivocal evidence” or were judged as 
“inadequate studies” (Seidle, 2006), suggesting the protocol as 
it stands is not robust. The two-species paradigm also has been 
challenged (Alden et al., 1996) by studies showing that rats are 
more sensitive, and regulatory action is rarely taken on the basis 
of bioassay results in mice (Van Oosterhout et al., 1997; van 
Although it is in many respects a well-standardized protocol, 
it has been criticized as having poorly defined endpoints and 
a high level of uncontrolled variation. Suggestions for aspects 
of the test that could be optimized include proper randomiza-
tion, blinding, better necroscopy work, and adequate statistics 
(Freedman and Zeisel, 1988). However, 20 years after its adop-
tion by OECD, the most recent test guidelines (OECD, 2009) 
still do not make randomization and blinding mandatory, and 
the guideline statistics do not control for multiple testing, de-
spite the fact that about 60 endpoints are assessed in the assay. 
Furthermore, the data analysis is ill-defined: “When applicable, 
numerical results should be evaluated by an appropriate and 
generally acceptable statistical method.” 
Reducing the duration of the assay to 18 months has also been 
suggested (Davies et al., 2000), although others contradicted the 
applicability of this option (Haseman et al., 2001). 
In addition, the assay has not been standardized for animal 
strains, with the only definition being that “young healthy adult 
animals of commonly used laboratory strains should be em-
ployed.” This is contrary to evidence that strain standardization 
Fig. 5.3: Metabolic activation of chemical compounds and genotoxic and non-genotoxic effects of carcinogens
(modified from Oliveira et al., 2007)
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But doses that are hundreds to thousands of times higher than 
normal exposures (such as those often given during animal test-
ing) might be carcinogenic simply because they overwhelm de-
toxification pathways. In these cases, we see tumors along with 
gross histopahologic evidence of tissue damage.” However, 
dose regimens are defended by others (Bucher, 2000), and many 
substances test positive for carcinogenicity only at maximum 
tolerated doses, including some accepted human carcinogens. 
These results also might be interpreted as species differences 
that are hidden by high-dose artifacts at the expense of many 
false-positives.
Predictivity of point of reference (human cancer)
An analysis by Pritchard et al. (2003) suggested 69% predictivi-
ty of human carcinogenicity for the two-species cancer bioassay, 
which ironically dropped to 65% when it was combined with in 
vitro genotoxicity test findings (Pritchard et al., 2003). This con-
trasts with an analysis by Knight et al. (2006a,b), who showed 
that in 58% of cases considered by the EPA, they deemed results 
from a positive cancer bioassay as insufficient for assigning hu-
man carcinogenicity, even though the EPA was far more likely to 
assign this classification than the IARC. A previous comparison 
of known human carcinogens, as classified by the IARC mainly 
based on epidemiology, with corresponding animal data found 
an unconvincing correlation (Freedman and Zeisel, 1988): “The 
research reports of the cancer community (even taken at face 
value) do not sustain the conventional argument for the validity 
of the qualitative extrapolation ... We remain sympathetic to the 
idea that animal data have some predictive value for carcino-
genicity in humans ... But the evidence for such propositions is 
surprisingly weak.” It is also worth noting that the most typical 
sites of tumor formation in humans do not correspond to those 
in rodents (Anisimov et al., 2005), as shown in Table 5.1:
Ravenzwaay, 2010). It is estimated that $ 1-2 million and up to 
1,000 mice over a 3-year period would be saved by eliminating 
the mouse section of each chemical test (Alden et al., 1996).
Reproducibility
Gottmann et al. (2001) compared 121 replicate rodent carcino-
genicity assays from the two sections (National Cancer Insti-
tute/National Toxicology Program and literature) of the Carci-
nogenic Potency Database (CPDB) to estimate the reliability of 
these experiments. They found a concordance of 57% between 
the overall rodent carcinogenicity classifications from both 
sources; this result did not substantially improve when species, 
sex, strain, and target organ information was considered. They 
concluded: “These results indicate that rodent carcinogenicity 
assays are much less reproducible than previously expected, an 
effect that should be considered in the development of structure-
activity relationship models and the risk assessment process.” 
Ironically, cell transformation assays (CTA, discussed in more 
detail below) appear to reproduce the cancer bioassay better 
than it reproduces itself. Thus, it appears likely that the existing 
bioassay would fail any validation investigation that a replace-
ment test would be subjected to.
Potency correlation between species
This is not a classical validation criterion, but it is part of the 
Bradford-Hill criteria to support associations. The apparent cor-
relation between potency of carcinogens in mice and rats has 
been shown to be largely an artifact (Bernstein et al., 1985).
Interspecies and organ site correlation
Concordances of 57% were reported between mouse and rat bio-
assays. Better correlations that were previously reported (71% 
rat to mouse, 76% mouse to rat) were driven by the abundance 
of strong mutagens studied, which are typically positive in all 
sexes, many species, and several organs (Gray et al., 1995). 
An analysis of bioassays in rats, mice, and hamsters, as well as 
comparisons with humans for known carcinogens, has shown 
that the likelihood of a chemical that induces tumors in one spe-
cies in a certain organ also inducing tumors in another species in 
the same organ is less than 50% (Gold et al., 1991, 1998). 
Sex specificity
A critical appraisal of the role of sex hormones (endocrine sta-
tus) on species susceptibilities in chemical carcinogenesis (Toth, 
2002) concluded: “There are compelling indications, particu-
larly in the fields of physiology and metabolism, to conclude the 
limited usefulness of the various animal species in sex hormone 
research. The findings allow only restricted inferences for the 
human species.”
Scientific relevance 
The first critical issue is that of high-dose to low-dose extrapo-
lation. The use of maximum tolerated doses appears to be the 
source of many artifacts. Jay Goodman, Michigan State Uni-
versity, is cited (Schmidt, 2002) as saying: “If we’re dealing 
with a situation in which the likely human exposure is in the 
same ballpark, then these (dosing regimens) may be applicable. 
Tab. 5.1: Most common spontaneous cancers in  
humans and rodents
(adapted from Anisimov et al., 2005)
Cancer Mice Rats Humans
Breast carcinoma + + +
Lung carcinoma – – +
Prostate – + +
Colon – – +
Skin – – +
Stomach – – +
Liver – – +
Endometrial carcinomas – + +
Leukaemia / lymphoma + – +
Thyroid – + +
Bladder – – +
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testing being considered irrelevant compared to the medical 
benefit of the compounds (Davies and Monro, 1995). It is not 
known how many chemicals were rejected over the same period 
(Davies and Monro, 1995). An early analysis of 20 putative hu-
man non-carcinogens found 19 false-positives, suggesting only 
5% specificity (Ennever et al., 1987). The inappropriateness 
of rodent carcinogenicity assays as currently performed has 
been examined by Roe (1987), who notes that: “There can be 
no sense in testing chemicals for carcinogenicity in rats main-
tained under conditions such that 50-100% of them (the control 
animals) develop pituitary and mammary tumors, etc. There is 
no identifiable population of humans for which such rats could 
constitute a model.” The implications of these observations for 
risk assessment have been noted by Bridges (Bridges, 1988). 
However, others see even this as an underestimate (Sobels, 
1987): “... Carcinogenicity is expressed to a different extent 
in different species of rodents, so that bioassay results in only 
two rodent species are likely to underestimate the proportion of 
chemicals with carcinogenic potential.”
Sensitivity
Assessing the sensitivity of the cancer bioassay is made diffi-
cult by the fact that most human carcinogens were designated as 
such, to a large extent, by animal tests (with the discussed prob-
lematic interspecies correlation), and those typically missed are 
not identified by other means. There are strong claims that all 
known human carcinogens are detected with the cancer bio-
assay (Huff, 1999; Rall, 2000), but this could be considered 
a self-fulfilling prophecy, as most of these classifications are 
based on animal experiments. However, not all known human 
carcinogens can be modeled in animals (Silbergeld, 2004). For 
example, there is
– no animal model of cigarette smoke-induced lung cancer, 
– no rodent leukemia induced by benzene, and 
– no genetic point mutations in animals induced by arsenic.
This situation does not necessarily represent a contradiction, as 
these agents are positive for carcinogenicity in other organs or 
by other modes of action. However, achieving the right clas-
sification but for the wrong reason is a questionable outcome. 
Furthermore, the current testing situation leads to an enormous 
number of false-positives; Rall suggests that only one in ten 
compounds is truly carcinogenic (Rall, 2000). 
Despite all of these false-positives, cases of human carcinogens 
that are not detectable in animals remain, e.g., the anticonvulsant 
diphenyl-hydantoin (phenytoin) is classified as carcinogenic to 
humans but showed no carcinogenic effect in experimental mice 
and rats (Anisimov et al., 2005). Ennever and Lave (2003) also 
have discussed the chemical combination of aspirin/phenacetin/
caffeine, which is classified as a human carcinogen but tested neg-
ative in both rodent species (Ennever and Lave, 2003). Johnson 
(2001) presents a list of the known human carcinogens that have 
been tested in the NTP rat bioassay prior to 2000 (Johnson, 2001): 
“The list contains 10 different chemicals, counting the various 
forms of asbestos as one, the three nickel compounds as one, and 
the 10 benzidine-like compounds as one ... (Of) the 13 individual 
chemicals tested in four sex-species groups, two chemicals were 
positive in four groups, one was positive in three groups, six were 
In the absence of human data, it might be considered reasona-
ble to use data from tests in nonhuman primates for comparative 
purposes. Cancer bioassays in nonhuman primates were carried 
out on 37 compounds within 34 years (Takayama et al., 2008); 
the results were “... Inconclusive in many cases,” but carcino-
genicity was shown unequivocally for four of them. 
Taken together, the cancer bioassay is “... Often not relevant 
to human carcinogenesis risk assessment.” (Ward, 2007).
Specificity
About 50% of all chemicals tested in the cancer bioassay test 
positive (see Tab. 5.2), and 53% of 301 chemicals tested by 
the NTP were positive, with 40% of these positives classified 
as non-genotoxic (Ashby and Tennant, 1991). It is sometimes 
claimed that this high positive rate is due to the testing of suspi-
cious substances, especially in early years of identification of 
mutagens. Of substances tested in the NTP simply because of 
exposure considerations, 80% were found not to be carcino-
genic (Fung et al., 1995). In contrast, Johnson identified 60% 
of 128 high production volume chemicals to be rodent carcino-
gens (Johnson, 2003). A similarly high proportion, around 50% 
positives, can be found in various databases for pharmaceuticals 
(MacDonald, 2004). 
Pharmaceuticals are rapidly discontinued when they are 
found to be possibly genotoxic, but also many non-genotoxic 
ones test positive in the cancer bioassay (Silva Lima and Van 
der Laan, 2000). “The database compiled from the ‘Physician’s 
Desk Reference’ (PDR), including registered pharmaceuticals 
only, also provides a good illustration of rodent tumor findings 
being irrelevant to humans” (Davies and Monro, 1995; Silva 
Lima and Van der Laan, 2000). Over two decades, 101 out of 
241 substances entered the market despite positive cancer bio-
assays, presumably primarily as a result of the positive bioassay 
Tab. 5.2: Proportion of chemicals evaluated as carcinogenic 
(modified from Ames and Gold, 2000; Gold et al., 2005)
 Proportion %
Chem. tested in rats and mice 379 / 648 58%
- natural 86 / 165 55%
- synthetic 293 /493 59%
Chem. tested in rats or mice 751 / 1456 52%
- Natural pesticides 41 / 75 52%
- Commercial pesticides 79 /198 55%
- Chemicals in roasted coffee 23 / 32 72%
- Mold toxins 15 / 25 60%
Drugs (PDR) 117 / 241 49%
Drugs (FDA) 125 / 282 44%
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forts (Schmidt, 2002) resulted in a discussion of whether this is 
“bashing the cancer bioassay” (Johnson and Huff, 2002). While 
possibilities for improving the animal test are outside the scope 
of this paper, the discussion shows the difficulties of using the 
cancer bioassay as point of comparison. 
These comments, taken together, indicate that the cancer bio-
assay – although it has never been formally assessed – appears 
to have severe limitations. Furthermore, the assay would not 
stand up to the assessment criteria that any potential replace-
ment test would have to fulfill. However, these limitations are 
not fully understood by many who use the assay for validation 
of alternative methods or regulatory purposes.
It appears timely to address these limitations before em-
barking on the expensive process of developing and validat-
ing replacement strategies that would only then be measured 
against this wrongly-considered “gold standard” test. It might 
be debated whether this represents a case for formal invalidation 
(Balls et al., 2006; Balls and Combes, 2005), but an approach 
based on the principles of evidence-based toxicology (Hartung, 
2010c) seems to be more appropriate in this scenario than for-
mal validation. A formal assessment of the assay would allow 
widespread dissemination – and encourage acceptance – of the 
evidence for the assay’s limitations. 
In line with these suggestions, the REACH guidance by 
ECHA is already quite cautious in its recommendations for use 
of the cancer bioassay (ECHA, 2008): “A carcinogenicity study 
may, on occasion, be justified. If there are clear suspicions that 
the substance may be carcinogenic, and available information 
(from both testing and non-testing data) are not conclusive in 
this, both in terms of hazard and potency, then the need for a 
carcinogenicity study should be explored. In particular, such a 
study may be required for substances with a widespread, dis-
persive use or for substances producing frequent or long-term 
human exposures. However, it should be considered only as a 
last resort.”
5.2.2 Reduction to key events
This approach aims to replace in vivo testing with stand-alone 
alternative methods. Carcinogenicity traditionally is seen as the 
combination of genotoxicity leading to mutation and subsequent 
promotion of the mutation. The development of an in vitro ge-
notoxicity test battery would be aimed at reducing these hazards 
to key events. This rather simplistic view, and the testing ap-
proach that would result, is unconvincing, as many mutagens 
are not carcinogenic and substances do not exist in isolation in 
real life; rather, people are exposed to complex mixtures of sub-
stances, including incomplete carcinogens, such that there are 
situations in which compounds that are either only genotoxic 
or only promoting complement one other. Furthermore, there 
is increasing evidence that many modifying factors influence 
organotropy, growth rate, metastasis, resistance to immune re-
actions and treatment, etc.
The Ames test is the best standalone predictor of the rodent 
bioassay of the traditional genotoxicity test battery, with about 
60% sensitivity (Kirkland et al., 2005). Earlier, Gold et al. 
(1998) reported that out of 465 chemicals, 45% were found to 
positive in two groups, one was positive in one group, and three 
were positive in no (0) groups. Only two human carcinogens (thio-
tepa and benzene) are bona fide trans-species carcinogens. Thus, 
for NTPRB-tested chemicals, it is not evident that human 
carcinogens necessarily demonstrate clear trans-species carcino-
genic effects.” These examples clearly contradict claims of 100% 
identification of known human carcinogens. It is also worth not-
ing that an early assessment of the bioassay suggested only 46% 
sensitivity based on 19 human carcinogens (Salsburg, 1983). 
The fact that rats and mice predict each other only about 57% 
does not fit with an assumption that 100% of human carcino-
gens are detected, as it is fair to assume that humans are not 
better predicted by either species than they predict each other. 
These figures of 57% concordance between species, 10% real 
human carcinogens, and 53% positives in the rat, combine to 
give a sensitivity of 100% with a specificity of 47%. Lave et 
al. previously arrived at an estimate of 70% sensitivity as well 
as specificity, assuming 10% real human carcinogens (Lave et 
al., 1988).
If the same calculation is performed with the assumption that 
20% of all chemicals are carcinogenic in humans, this results in 
75% sensitivity with 53% specificity. Interestingly, when we use 
the suggested 28% positives in rat, if non-suspicious chemicals 
are tested the result is 0% sensitivity and 65% specificity. Thus, 
whatever assumption is used, the assay does not perform well 
by any standard. 
In a telling modeling exercise, Gaylor (2005) showed that in-
creasing the number of animals per group from 50 to 200 would 
result in statistically significant (p<0.01) dose-responses for 
92% of substances tested (Gaylor, 2005). This shows how the 
inherent variability of the test produces false-positives and re-
duces specificity using the current data analysis process.
Applicability domain
An applicability domain, i.e., the part of the chemical universe 
where the cancer bioassay is applicable to make sufficiently cor-
rect predictions, has not been established for the rodent cancer 
bioassay. Occasional reference is made to a better prediction of 
(strong) genotoxic substances, but these substances are exactly 
the ones filtered out by the in vitro genotoxicity testing battery 
and are unlikely to be tested in the bioassay.
Performance standards
Performance standards have been introduced for test meth-
ods as a guide to demonstrating that a given variant of a test 
is equivalent to the originally validated test. No such perform-
ance standards exist for the bioassay, although they would be 
very helpful for evaluation of alternative test methods. Bucher 
reported a discordance rate of 13/38 for the transgenic approach 
(Bucher, 1998), or a level of agreement of 68%, which barely 
differs from the 65% shown by the Salmonella mutation test. 
In response, Johnson showed the fingerprint pattern of organ 
sites affected (Johnson, 1999), concluding “... It seems unlikely 
that transgenic models could ever replicate or faithfully emu-
late the carcinogenic response observed in natural whole ani-
mals.” More extensive evaluations were conducted by an ILSI/
HESI committee (Cohen et al., 2001). An article on these ef-
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included in a ring trial is extremely small, and the complexity 
and duration of the protocol results in transferability and repro-
ducibility issues. A feasibility study conducted to assess some 
aspects of reproducibility showed that the CTA could be used 
for decision making when combined with retrospective assess-
ments of its predictive value, as made possible by a modular 
approach to validation (Hartung et al., 2004). This points out the 
need to transition to novel types of objective assessments (Har-
tung, 2010c). However, such retrospective analysis of existing 
data requires a level of transparency of the process that typically 
is not provided.
The CTA represents a prime opportunity to replicate results of 
the traditional animal-based approach by reducing the tests to a 
key event. A recent evaluation based on 141 studies showed that 
the SHE-7 variant of CTA predictions of rodent carcinogenicity 
gave a sensitivity of 88%, specificity 77%, accuracy 85%, posi-
tive predictivity 89%, and negative predictivity 75% (Benigni 
and Bossa, 2011). More importantly, the detailed review paper 
of OECD 2006 indicated for the CTA a sensitivity of 90% of 
class I (known human carcinogens) and 95% of class II (possi-
ble/probable human carcinogens) (Long, 2007; OECD, 2007).
The CTA can and must undergo further optimization with re-
gard to:
– transition to human cells
– addition of metabolic competence
– automation, especially of foci reading
– possible transition to biomarkers of cell transformation 
measurements
– statistics (Ponti et al., 2007)
The CTA also represents an interesting opportunity for pathway 
of toxicity (PoT) mapping, as discussed below.
A focus on key events, as just described, could also be ap-
plied to non-genotoxic mechanisms of carcinogenicity, such as 
immunosuppression, inflammation, and hormonal activity (Tab. 
5.3). This corresponds to some extent with the type of infor-
mation currently considered in weight of evidence approaches, 
especially in REACH, but it is more likely to form the basis 
be mutagens by the Ames test, 63% were carcinogens, and 72% 
were either, i.e., 79% of mutagens were carcinogens, but 43% 
of carcinogens were not mutagens, and 25% of the non-carcin-
ogens were mutagens. When genotoxicity assays are combined, 
sensitivity inevitably increases but specificity falls: When all 
three tests were performed, 75-95% of non-carcinogens gave 
positive (i.e., false-positive) results in at least one test in the 
battery (Kirkland et al., 2005). For marketed drugs (which typi-
cally exclude substances found to be genotoxic during develop-
ment), no particularly strong concordances were seen between 
the 29% positive for genotoxicity and the 38% with positive or 
equivocal findings in the cancer bioassay (Snyder and Green, 
2001). These results raise strong questions as to whether such 
tests, alone or in combination, can really help to determine the 
carcinogenic potential of substances.
Cell transformation (Berwald and Sachs, 1963, 1965), i.e., 
lack of growth inhibition in the case of confluency, has been 
suggested as a key event reflecting mutagenicity and some ini-
tial effects on cell replication, reduced apoptosis, DNA repair, 
oncogene activation, suppressor gene inactivation, and epige-
netic effects. The value of these assays has been long discussed 
(Combes et al., 1999), leading to parallel test guideline devel-
opment at OECD and prevalidation at ECVAM (Vanparys et 
al., 2011). A key piece of the validation exercise was the de-
tailed review document (DRP) prepared by OECD summariz-
ing existing experience with the assay and some additions to 
this dataset (Mascolo et al., 2010; Mazzotti et al., 2002). The 
data presented in the DRP were considered at an OECD Expert 
Consultation Meeting in 2006. Overall, it was concluded that 
the SHE and BALB/c 3T3 assays had a strong ability to detect 
rodent carcinogens, with a good positive and negative predic-
tive capacity and sensitivities and specificities in the 80% range. 
Unfortunately, detailed information on the validation, its peer-
review by ECVAM’s Scientific Advisory Committee (ESAC) 
(with only the statement now available for public discussion), 
and the subsequent conclusions of OECD are still not available 
(according to personal communications it was decided end of 
2011 to proceed with the OECD guideline for the SHE assay but 
not for the Balb/c 3T3 assay), although a recent review sheds 
some light (Creton et al., 2011). A parallel Japanese validation 
study on an improved assay has been published in the meantime 
(Sakai et al., 2011). 
Perhaps the greatest concern, however, relates to the lack 
of understanding of the mechanisms by which CTAs operate 
(Ashby, 1997; Farmer, 2002). It is puzzling, for example, how 
the 3T3 variant of the assay, which has limited metabolizing 
capacity (Colacci et al., 2011), can so well reflect in vivo car-
cinogenicity in rats, while activation of xenobiotics to form 
reactive substances is considered a key event for genotoxicity. 
The question, therefore, might be turned around: given the high 
false-positive rate of the cancer bioassay (as discussed below), 
does the CTA actually reflect the false-positives of an organism 
overwhelmed with maximum tolerated doses, where metabo-
lism contributes little more?
The CTA validation shows the limitations of traditional 
validation studies. With costs of about € 15,000 per substance 
tested in one laboratory, the number of chemicals that can be 
Tab. 5.3: Mechanisms of non-genotoxic carcinogenicity
  1. Chronic cell injury
  2. Immunosuppression
  3. Increased secretion of trophic hormones
  4. Estrogenic activity 
  5. Receptor activation
  6. Block of gap junctional intercellular communication
  7. Inflammation
  8. Oxidative stress, reactive oxygen and nitrogen species  
(ROS and RNS)




This approach is meant to be precautionary, but is it suffi-
ciently accurate? Certainly, we have to call it prohibitive, as it 
excludes large parts of the chemical universe from many uses. 
A debate intended to improve genotoxicity testing has started 
(Goodman et al., 2007; Lorge, 2009), with the aim of also incor-
porating Tox-21c approaches and new technologies (Elespuru et 
al., 2009). 
Other properties and tests might exclude carcinogenic po-
tential. The concept of “no penetration, no harm” offers some 
opportunities, for example. Large molecular weight typically is 
accepted as an indication of no harm, although fiber toxicity, 
as seen with asbestos and now, increasingly, with nanoparticle 
toxicology, might challenge this (Hartung, 2010e; Hartung and 
Sabbioni, 2011). The major problem in this approach is its reli-
ance on negative data (no uptake). This concept is further re-
fined by the threshold of toxicological concern (TTC) approach, 
where exposure in sufficient quantity, rather than bioavailability 
of integrated testing strategies (ITS) than stand-alone replace-
ments. Notably, REACH guidance by ECHA lists a number of 
in vitro tests that add weight of evidence (Tab. 5.4).
5.2.3  Negative exclusion by lack of key property
The current use of the in vitro genotoxicity battery follows a 
negative exclusion approach, i.e., substances showing no geno-
toxic potential are considered of low carcinogenic potential. The 
limitations of this approach, namely a high false-positive rate of 
the combined use of these assays, are well known (Blakey et al., 
2008; Kirkland et al., 2007) and addressed elsewhere (Benfenati 
et al., 2009; Kirkland et al., 2007; Pfuhler et al., 2009, 2010a). 
It appears that the cancer bioassay produces far too many false-
positive results when compared to human hazards (Ames and 
Gold, 1990), the mutagenicity testing in vivo further adds ge-
notoxic substances that are not carcinogens, and this is further 
aggravated by the over-predictive in vitro battery. 
Tab. 5.4: In vitro tests adding weight of evidence for carcinogenicity assessments according to REACH guidance by ECHA
http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_r7a_en.pdf (last accessed 08.09.2011)
“in vitro cell transformation assay results: such assays assess the ability of chemicals to induce changes in the morphological and 
growth properties of cultured mammalian cells that are presumed to be similar to phenotypic changes that accompany the development 
of neoplastic or pre-neoplastic lesions in vivo (OECD, 2006). The altered cells detected by such assays may possess other targeted 
mechanisms of action, or can subsequently acquire, the ability to grow as tumours when injected into appropriate host animals. As in 
vitro assays, cell transformation assays are restricted to the detection of effects of chemicals at the cellular level and will not be sensitive 
to carcinogenic activity mediated by effects exerted at the level of intact tissues or organisms.
mechanistic studies, e.g. on:
– cell proliferation: sustained cell proliferation can facilitate the growth of neoplastic/pre- neoplastic cells and/or create conditions 
conducive to spontaneous changes that promote neoplastic development.
– altered intercellular gap junction communication: exchange of growth suppressive or other small regulatory molecules between 
normal and neoplastic/pre-neoplastic cells through gap junctions is suspected to suppress phenotypic expression of neoplastic 
potential. Disruption of gap junction function, as assessed by a diverse array of assays for fluorescent dye transfer or the exchange 
of small molecules between cells, may attenuate the suppression of neoplastic potential by normal cells.
– hormone- or other receptor binding: a number of agents may act through binding to hormone receptors or sites for regulatory 
substances that modulate the growth of cells and/or control the expression of genes that facilitate the growth of neoplastic cells. 
Interactions of this nature are diverse and generally very compound specific.
– other targeted mechanisms of action
– immunosuppressive activity: neoplastic cells frequently have antigenic properties that permit their detection and elimination by 
normal immune system function. Suppression of normal immune function can reduce the effectiveness of this immune surveillance 
function and permit the growth of neoplastic cells induced by exogenous factors or spontaneous changes.
– ability to inhibit or induce apoptosis: apoptosis, or programmed cell death, constitutes a sequence of molecular events that 
results in the death of cells, most often by the release of specific enzymes that result in the degradation of DNA in the cell nucleus. 
Apoptosis is integral to the control of cell growth and differentiation in many tissues. Induction of apoptosis can eliminate cells that 
might otherwise suppress the growth of neoplastic cells; inhibition of apoptosis can permit pre-neoplastic/neoplastic cells to escape 
regulatory controls that might otherwise result in their elimination.
– ability to stimulate angiogenesis or the secretion of angiogenesis factors: the growth of pre- neoplastic/neoplastic cells 
in solid tumours will be constrained in the absence of vascularisation to support the nutritional requirements of tumour growth. 
Secretion of angiogenesis factors stimulates the vascularisation of solid tumour tissue and enables continued tumour growth.”
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optimization might be very different: for an ITS, the goal is not 
necessarily the best prediction or highest sensitivity for each test 
component, but value added in complementing the other blocks 
of the strategy. Many earlier developments might need to be 
revised when tests are now considered for ITS instead of stand-
alone applications. 
A number of strategies might be able to improve the predic-
tive value of existing test systems:
– extension of metabolic capacity
– organotypic 3-dimensional (co)-cultures
– more physiologic culture conditions such as homeostasis, 
oxygen supply, cell density
– transition from cell lines to primary cells or stem cell-derived 
systems
– use of human cells, preferably primary cells and possibly a 
battery of different human cell types, ideally derived from 
stem cells
– human cells that have wildtype p53 and are DNA-repair 
competent
– use of genetically stable cells
– refinement and expansion of endpoints measured
– restriction of maximally used concentrations
– standardization and automation
– quality assurance of procedures
– appropriate statistics and prediction models
– definition of applicability domains
– better understanding of the mechanism of action
– knowing the weaknesses and strengths of systems for the de-
velopment of new models
5.2.5  In silico approaches
Due to the enormous costs involved, public interest, and the 
availability of in vivo data (especially from the NTP), carcino-
genicity testing has been subjected to intense in silico modeling. 
For carcinogenicity prediction, however, the use of these models 
is rather limited. Benigni and Bossa summarized (Benigni and 
Bossa, 2006): “Overall, it can be concluded that predictions for 
the individual chemical cannot be taken at face value and can-
not replace the experiments, when necessary. Their main role is 
to complement the information of different nature and from dif-
ferent sources.” Other reviews have come to similar conclusions 
(van Leeuwen and Zonneveld, 2001): “Let us now return to the 
original question: do current models contribute to the aim to re-
late exposure to carcinogenic response? ... We think the answer 
is at best ‘to some extent’. The models used are not overly real-
istic for the purpose of data description, because they ignore es-
sential processes.” And (Benigni, 2004): “Study of the structure 
of the chemicals generates predictions with limited reliability 
for the individual chemicals” but Benigni sees enormous value 
for priority setting for testing. A key prerequisite for improving 
the available models will be to generate larger homogenous da-
tasets for modeling (Patlewicz et al., 2003). 
An impressive discrepancy currently exists between studies 
employing external evaluations, such as the Predictive Toxico-
logy Challenge (PTC), and internal validation results. For the 
PTC a training set of 509 compounds from the NTP was used, 
with results for carcinogenic effects (Helma and Kramer, 2003). 
or no bioavailability, is employed. Exposure issues, as formal-
ized in TTC approaches, are limited by the no-threshold phi-
losophy for cancer hazards, which is under continual discussion 
(Calabrese, 2009; Crebelli, 2000; Kirsch-Volders et al., 2000; 
Lutz, 2000; Morelli, 2000; Neumann, 2009; Rhomberg, 2011). 
However, for some genotoxic mechanisms, such as aneugenic 
activity leading to tumors, thresholds are already accepted. It is 
also important to note that the bioavailability of a compound to 
cells in in vitro culture is often much higher than its bioavail-
ability in tissue.
Ironically, the non-threshold concept and its broad accept-
ance might have been flawed from the beginning (Calabrese, 
2011). It appears that this is actually an example of unsuitable 
statistics, where deterministic calculations are used to handle 
rare events (carcinogenic effects at very low concentrations); a 
switch to probabilistic methods (see Chapter 1) might resolve 
this. For a lay audience, Taleb has explained the concept in his 
bestseller The Black Swan (Nassim, 2010). 
Notably, this testing is applied very differently in different 
sectors, allowing for example, TTC approaches for food con-
taminants (Barlow and Schlatter, 2010; Kroes et al., 2004, 2005; 
Munro et al., 2008; O’Brien et al., 2006; Pratt et al., 2009), or 
margin of exposure (MOE) approaches (Benford et al., 2010), 
in which differences between actual human exposure and the 
point of departure of toxicity in animal experiments are used. 
Some authors have an alternative way of stating this discrep-
ancy: “Analysis also indicates that many ordinary foods would 
not pass the regulatory criteria used for synthetic chemicals” 
(Ames and Gold, 2000; Silva Lima and Van der Laan, 2000). As 
an extreme example, two of the authors have shown that using 
the same regulatory approach for alcohol as for TCDD (dioxin) 
based on carcinogenic potential in rodents would allow a person 
to drink one beer in 345 years (Ames et al., 1990). 
A similarly pragmatic approach allowing TTC would be like-
ly to help in a large number of cases for cosmetics and other 
consumer products, without even the need to introduce new test 
approaches (Kroes et al., 2007). It should be noted that recent 
refinements include genotoxicity data, thus bridging to actual 
test data (Felter et al., 2009). The question that arises is how 
this approach can be validated. Indeed, this might actually be a 
case that is better suited to an evidence-based toxicology (EBT) 
evaluation (Hartung, 2010c) than a prospective ring trial.
Many toxic endpoints, especially in genotoxicity, rely on re-
active chemistry allowing interaction with target structures – the 
absence of structural features allowing direct reactivity or acti-
vation via metabolism represents another example of exclusion 
of a hazard. Rather simple approaches give valuable informa-
tion (Pelkonen et al., 2009), but it seems unlikely that this is 
sufficient for exclusion of a hazard. Still, assays like the peptide 
reactivity assay might be explored as to their predictive value 
for carcinogenicity.
5.2.4  Optimization of tests
Both genotoxicity tests (Speit, 2009) and the CTA (Combes et 
al., 1999) leave room for optimization, as discussed in part ear-
lier. This might improve their value as stand-alone tests as well 
as test blocks in an ITS. It is worth noting that the goals of such 
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5.2.6  Information-rich single tests
The advent of “omics” (genomics, proteomics, etc.), image 
analysis systems, and other high-content measurement systems 
has introduced new opportunities for pattern recognition: instead 
of choosing a more or less meaningful endpoint to represent the 
response of a biological system, a multitude of signals can be re-
corded, hopefully including meaningful ones among many mean-
ingless ones. The art lies in filtering the former, but the avail-
ability of bioinformatics tools for this purpose is increasing. The 
advantage of this approach is that the most informative biomark-
ers can be chosen in an unbiased way, independent of our initial 
understanding of a system. These can be individual endpoints as 
well as patterns, which we call “signatures of toxicity” (SoT). 
When combined with existing biological knowledge, such as our 
understanding of pathways from biochemistry, cell physiology, 
molecular biology or toxicology, these signatures can ultimately 
be translated for assessing perturbations of the living system, i.e., 
using a systems biology approach. At the level of signatures, this 
is a simple correlative approach with many limitations, including 
that epiphenomena cannot be distinguished from causal factors. 
For example, repair responses will correlate with damage, but 
obviously do not cause it. As a result, early response genes are 
typically seen when transcriptomics is used in toxicology. These 
approaches bear the risk of being non-specific and uninformative 
about the mode of action. However, some of these limitations 
might be overcome as our understanding of pathways of toxicity 
increases (see below). As Adler et al. (2011) note: “The mecha-
nisms by which non-genotoxic carcinogens cause tumors are in 
most cases related to tissue- and species-specific disturbances 
in normal physiological control, gene expression patterns impli-
cated in cellular proliferation, survival, and differentiation (Bay-
lin and Ohm, 2006; Esteller, 2007; Widschwendter and Jones, 
2002).” This is almost a definition of systems toxicology.
For carcinogenicity, in vitro transcriptomics approaches are 
emerging (Guyton et al., 2009; Jacobs, 2009; van Kesteren et 
al., 2011; Vinken et al., 2008). These have been applied initially 
to genotoxic carcinogens (Tweats et al., 2007), but the approach 
makes just as much sense for the non-genotoxic mechanisms, 
and there are early indications that genotoxic and non-genoto-
xic effects can be discriminated (Magkoufopoulou et al., 2011; 
Plant, 2008). However, others have found that not even geno-
toxic carcinogens that do not function via DNA adducts can 
be identified (Benigni et al., 2010), although this identification 
seems to be possible in short-term animal tests (Fielden et al., 
2008, 2011; Waters et al., 2010).
5.2.7 Integrated testing strategies (ITS)
Our understanding of chemical carcinogenesis is continuously 
improving (Cohen and Arnold, 2011). This means a compre-
hensive testing strategy, designed to complement an optimized 
genotoxicity testing toolbox, must integrate more and more 
mechanisms and modes of action. There are already sugges-
tions, however, for how to generate ITS for genotoxicity (Pfuh-
ler et al., 2010b; Aldenberg and Jaworska, 2010).
A relatively simple ITS combining the Ames test with the 
CTA for Ames-negative substances resulted in impressive pre-
dictions of the cancer bioassay and reduced in vivo testing needs 
The US FDA used a test set with data from 185 substances. 
Fourteen groups submitted 111 models, but only five were bet-
ter than random at a significance level of p=0.05, with accura-
cies of predictions between 25 and 79% (Toivonen et al., 2003). 
Two previous comparative exercises by the NTP had challenged 
models with 44 and 30 chemicals prospectively, i.e., with chem-
icals which were to be tested only (Benigni and Giuliani, 2003). 
The accuracy of in silico predictions in the first attempt was in 
the range of 50-65%, while the biological approaches attained 
75%. The results in the second attempt (Benigni and Zito, 2004) 
ranged from 25 to 64%. In remarkable contrast, mere internal 
validations can show results of 75-89% predictivity for carcino-
genicity (Matthews et al., 2006; Julien et al., 2004).
It is worth documenting that, although REACH guidance is 
overtly positive about (Q)SAR in respect to other tests, it re-
serves a reluctant tone for discussing the use of (Q)SARs in car-
cinogenicity testing: “The capacity for performing the standard 
rodent cancer bioassay is limited by economic, technical, and 
animal welfare considerations, such that an increased emphasis 
is being placed on the development of alternative, non-animal 
testing methods. However, carcinogenicity predictions through 
use of non-testing data currently represent an extreme challenge 
due to the multitude of possible mechanisms. Prediction of car-
cinogenicity in humans is especially problematic.”
However, it is important not to dismiss in silico options. While 
the REACH assessment is rather skeptical with regard to stand-
alone in silico solutions, they have broad applicability in ITS 
or when combining in vitro and in silico techniques for a stand-
alone test. As a recent consensus report concluded (Benfenati et 
al., 2009): “In silico methods can be used for priority setting, 
mechanistic studies, and to estimate potency. Ultimately, such 
efforts should lead to improvements in application of in silico 
methods for predicting carcinogenicity to assist industry and 
regulators and to enhance protection of public health.”
A worthy summary of the situation was given as early as 
1994 by John Ashby: “The accurate prediction of chemical 
carcinogenicity can only be achieved by a balanced consid-
eration of the following factors: the chemistry and metabolism 
of the test agent, the interaction between toxicity and genetic 
toxicity, the possibility of non-genotoxic events that trigger 
subsequent non-targeted mutagenesis, the difference between 
activities observed in vitro and in vivo, and the possible in-
adequacy and/or partiality of all datasets and observations. 
Extrapolation of activities within a series of congeners is usu-
ally possible, but predictions across different chemical classes/
mechanisms of carcinogenicity are difficult. Artificial intelli-
gence systems can be used to predict one or more of the above 
parameters given adequate learning sets, but the hope for a 
single, coherent and self-contained method of predicting all in-
stances of carcinogenicity is unreal. The future of carcinogen/
mutagen prediction lies with data-rich artificial intelligence 
systems based on known mechanistic principles used selective-
ly within the context of chemical and biological human insight. 
The major current obstacle to progress is the assumption that 
mutagenicity and carcinogenicity are unitary phenomena that 
can be learned and predicted by artificial intelligence systems 
operating in isolation.”
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1. Specificity 
 In contrast to genotoxic compounds, which usually result 
in tumor development in several organs of the same animal 
species and even in several animal species, non-genotoxic 
carcinogens might be more specific with respect to their 
tumorigenic potential, as they frequently induce tumors in 
only mice or rats, one sex, and, in most cases, in one or few 
organs.
2. Existence of a threshold
 Often tumorigenic effects only occur when high doses of a 
compound are used in order to produce prolonged interfer-
ence with normal physiological control and modifications of 
cellular proliferation patterns, i.e., threshold doses exist. In 
addition to the identification of the existence of a threshold, it 
is crucial to assess the mechanism by which high doses exert 
a carcinogenic effect. 
3. Reversibility 
 Tumorigenic/carcinogenic effects of non-genotoxic sub-
stances are observed only when a compound is continu-
ously applied over extended periods and may be at least 
partially reversed after administration of the compound is 
discontinued.
by 90% (Benigni and Bossa, 2011) and the number of CTA by 
almost 50%. Even more tests were avoided (95%) when struc-
tural alerts were combined with the CTA.
Several ITS have been proposed, but their composition has 
been based primarily on the expertise and opinion of their re-
spective proponents, as no principles for ITS composition are 
available (Cohen, 2004; Combes et al., 2007), see Figures 5.4 
and 5.5. There is already an ITS suggested in the ECHA guid-
ance to industry (Fig. 5.6).
Lave and Omenn started to model the combination of the can-
cer bioassay with a screening test as early as 1988 (Lave et al., 
1988). In addition to sensitivity and specificity, the prevalence 
of the hazard among the substances studied is key for such cal-
culations. Taking into account the societal costs of misclassifi-
cation, they suggest that the screening test employed must be 
either the most accurate or the least expensive.
Specific considerations for non-genotoxic carcinogens
Although different mechanisms may be involved in the carci-
nogenic action of non-genotoxic compounds, several common 
characteristics may be defined (Silva Lima and Van der Laan, 
2000):
Fig. 5.4: Proposed guide for evaluating the potential carcinogenicity of chemicals
(modified from Cohen, 2004) 
Each box poses an evaluation to be performed. If the sequence results ultimately in a NO that is in a circle, there is no (or negligible) 
carcinogenic risk in humans. If the sequence results ultimately in a YES that is in a square, it poses a presumptive carcinogenic risk.
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2003) for which ample in vitro testing systems are available. 
The same holds true especially for immunosuppression (Carfi et 
al., 2007; Galbiati et al., 2010; Gennari et al., 2005; Langezaal 
et al., 2001; Lankveld et al., 2010) but also for chronic cell in-
jury, increased secretion of trophic hormones, oxidative stress, 
and reactive oxygen and nitrogen species (ROS and RNS). An 
assay for CYP450 induction in cryopreserved human hepato-
cytes also is currently under prevalidation (Abadie-Viollon et 
al., 2010; Richert et al., 2010). Despite the positive fact that 
existing in vitro tests are already available, and appropriate, for 
testing for a number of non-genotoxic mechanisms, there are 
other non-genotoxic mechanisms that may contribute to carci-
nogenicity and are much more difficult to assess in vitro, such 
as immunesurveillance of cancer cells.
These characteristics suggest that different mechanisms are in-
volved and call for complementing the genotoxic test battery 
with assays that address pertinent non-genotoxic mechanisms 
(Tab. 5.4). 
For example, literature surveys showed that 38 out of 48 en-
docrine-disrupting chemicals (79%) studied were positive in at 
least one cancer bioassay (Choi et al., 2004; Dietrich, 2010). 
A number of endocrine disruptor assays have been developed 
for the respective screening programs, and some of them have 
even been validated and accepted at OECD level. Mode of ac-
tion based tests also are available for many other mechanisms, 
or they can be easily adapted from tests designed for other pur-
poses; for example, inflammation represents another non-geno-
toxic mechanism (Emmendoerffer et al., 2000; Ohshima et al., 
Fig. 5.5: Decision tree testing strategy for carcinogenicity
(redrawn with permission from Combes et al., 2007), C&L = Classification and Labelling, RA = Risk Assessment
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Fig. 5.6: Integrated testing strategy for carcinogenicity
(modified from ECHA, 2008)
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The cancer bioassay is a “one size fits all” assay and is, by 
definition, problematic, as a testing assay can be either specific 
or sensitive – but not both. We believe that an alternative to 
the bioassay, in the form of an integrated testing strategy (ITS) 
using animal-free tests – which is then subjected to probabilis-
tic risk assessment – would provide better information on the 
carcinogenic risks of new and existing chemicals to regulatory 
agencies and the public. In this chapter, we present a roadmap 
for how this might be achieved. 
We start with a summary analysis of the cancer bioassay, but 
we stress that this is by no means a complete and objective as-
sessment of the assay. Indeed, our primary conclusion from this 
paper is a strong recommendation that such an assessment be 
carried out. Only when this is objectively conducted will it be 
possible to move forward effectively in the development of al-
ternative testing strategies. 
We continue with an analysis of the assessment framework 
presented in Chapter 1 with respect to carcinogenicity. We do 
not believe that it will be possible to find a standalone, single 
in vitro assay for carcinogenicity testing, and that reduction of 
carcinogenicity to a key event or negative exclusion by lack of a 
key property is too simplistic for carcinogenicity testing. While 
the cell transformation assay (CTA) provides a surprisingly high 
reproducibility of results compared to the bioassay, these find-
ings should be considered with caution, and we feel the CTA 
needs further evaluation. 
Our vision for an alternative to the cancer bioassay is an ITS 
that uses a combination of in vitro and in silico techniques to 
assess both genotoxic and non-genotoxic carcinogenicity mech-
anisms. Furthermore, we suggest that testing should be sepa-
rated from risk analysis, and that the latter should be done in 
a probabilistic, rather than deterministic, manner. Finally, we 
feel strongly that genotoxicity and carcinogenicity pathways of 
toxicity (PoT) should be investigated as part of the newly estab-
lished Human Toxome project, and this will feed new informa-
tion into the carcinogenicity ITS.
The complexity of potential targets and interactions for sys-
temic hazards prompted the use of whole animal test models 
to mirror as many of these targets and interactions as possible. 
We increasingly understand, however, that these tests inevitably 
bring with them a high number of differences in these targets 
and their interactions. As far as available data can determine, the 
correspondence between different animal species for the cancer 
bioassay is not better than 57% in rats versus mice, and there 
is no reason to assume that any of them predicts humans better 
than they predict each other. Reproducibility issues, small group 
sizes, and poor statistics further limit the reproducibility of these 
assays. With the express purpose of erring on the side of safety, 
animal models have been rendered more sensitive (precautious) 
by high-dose testing, with an overemphasis on any positive (i.e., 
toxicity) findings and the two-species paradigm.
This situation results in two major problems:
– There is no way to model the complexity of the hazard with 
simple systems.
– The results (where available) from animal tests as such do 
not qualify to validate novel approaches against them.
Jaworska and Hoffmann have defined a framework for ITS 
that will inform toxicological decisions in a systematic, trans-
parent, and consistent way (Jaworska and Hoffmann, 2010). 
They reviewed conceptual requirements for ITS and presented 
a roadmap to an operational framework that should be proba-
bilistic, hypothesis-driven, and adaptive, as well as outlining 
properties an ITS should have in order to meet the identified re-
quirements and differentiate them from evidence synthesis. We 
strongly recommend that an ITS framework along these lines 
should be applied to a battery of mode-of-action tests. An ex-
ample of this process in the context of sensitization testing was 
recently published (Jaworska et al., 2011).
5.2.8  Pathways of Toxicity (PoT) and systems toxicology
The concept of PoT, as detailed in Chapter 1, is being pioneered in 
the EPA ToxCast project. Phase 1, focusing mainly on pesticides 
and off-the-shelf available pathway assays in HTS platforms, has 
delivered impressive first results supporting the concept of PoT 
for carcinogenicity and genotoxicity as well (Knight et al., 2009; 
Martin et al., 2009a). The current expansion to more substances 
and substance classes, as well as PoT assays, represents a prime 
opportunity to explore this approach. This approach, however, is 
limited by the use of known PoT and available tests. Unsupervised 
identification of PoT by mapping the human toxome is the logical 
complement to this approach. We strongly recommend that a gen-
otoxicity and carcinogenicity branch of this activity be developed. 
In both cases there are (pre-)validated tests, as discussed above, 
and human-relevant reference substances available. This process 
will lead to new approaches in carcinogenicity testing, especially 
when it is combined with the HTS approaches of ToxCast using 
similar substance sets.
Studies of cancer biology already have identified 12 signaling 
networks that are important in oncogenesis. Almost all cancers 
show perturbations in molecules in one or more of these path-
ways. Although these networks do not represent specific PoT, 
they may be useful starting points from which to look for bio-
markers and identify potentially carcinogenic PoT. However, it 
is important to note that these pathways, as they are understood 
at the moment, are not necessarily predictive of carcinogeni-
city, as perturbations in the pathways often arise only as a later 
outcome of a mutagenic effect. Also, some non-genotoxic car-
cinogenic effects, such as immune surveillance escape, may not 
implicate one of these 12 pathways. 
5.3  Conclusions and recommendations: 
carcinogenicity 
The cancer bioassay is a two-year test conducted in rats or 
mice and is currently the only accepted test for carcinogenic-
ity. Testing a single chemical compound using the cancer 
bioassay requires the use of at least 600 animals and costs ap-
proximately € 1 million – yet the assay is estimated to have a 
concordance of only 57% between rats and mice and to predict 
9 “innocent” chemicals as being carcinogenic for each one it 
correctly identifies.
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negatively filter substances for carcinogenic potential. 
Larger datasets will also benefit modeling attempts. Al-
though some evaluations of the CTA have shown it to 
be a useful alternative to the bioassay, these should be 
treated with caution, as it is difficult to understand how 
a CTA assay can reproduce animal tests better than ani-
mal tests reproduce themselves. To have the CTAs better 
accepted, it would be good to have the applicability do-
main (chemical classes, etc.) retrospectively determined 
on the basis of the information in the detailed review 
document (DRP) prepared by the OECD.
 Furthermore, its predictivity of human carcinogens 
should also be addressed. OECD is currently planning a 
further review of the CTA, and the findings of this pro-
cess should be carefully considered during the develop-
ment of an ITS as an alternative to the bioassay. The 
suggested evaluation of the bioassay will have important 
implications for this review of the CTA assays.
4. Such optimization should include the combination with 
high-content measures, in silico analysis, and automa-
tion for HTS.
5. Carcinogenicity qualifies for ITS development with a 
number of assays representing non-genotoxic mecha-
nisms lending themselves to evaluation. A “CarcinoTect” 
evaluation, in a similar manner to the ReProTect proc-
ess that has been conducted for reproductive toxicology, 
may be a good starting point for the development of a 
carcinogenicity ITS.
6. With (pre-)validated cell systems and ample reference 
compounds, especially from the IARC process, PoT 
identification represents a key priority to accelerate 
Tox-21c. PoT identification requires the complement 
of probabilistic condensation of the information gener-
ated. 
It is not realistic that any in vitro or in silico tool at this stage 
can be fully predictive of a human systemic toxicity. The ques-
tions that must be addressed, however, are how close can we 
come to this and how can we get closer to achieving that goal, 
especially by combining multiple approaches. In vivo alterna-
tives to the bioassay do exist (especially the shorter assays in 
transgenic animals or when replacing the bioassay with a geno-
toxicity testing battery combined with a 28- or 90-day animal 
test), but they are beyond the scope of this paper.
Recommendations: carcinogenicity 
The major recommendations from this report are:
1. It appears that the cancer bioassay has severe limitations. 
Assorted data as to its validity are available, but many of 
the analyses are relatively old. An objective evaluation 
of the test using EBT approaches is warranted. This will 
document the limitations of the assay and allow a more 
critical assessment of when – and indeed whether – it 
should be used. A general feeling in the expert panel was 
that the assay qualifies for invalidation. A better under-
standing of the assay’s limitations also will be informa-
tive for interpretation of assay results in cases where it is 
still used. We also feel that an objective evaluation will 
provide a helpful impetus for the search for alternative 
approaches.
2. It is clear that the cancer bioassay must not be the point 
of reference for validation exercises in future approach-
es. While the assay may continue to be used in some 
cases until alternatives are available, these alternatives 
must not be compared to the bioassay.
3. The CTA and the genotoxicity test battery merit further 
optimization and evaluation in order to positively or 
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per substance. Another driving force is the European ban on 
testing for cosmetics ingredients (Hartung, 2008a). A series of 
activities by ECVAM, including several workshops, have tack-
led this challenge and will be condensed here. The Integrated 
Project ReProTect (Hareng et al., 2005) was one of its offspring, 
pioneering several alternative approaches.
Reproductive toxicity aims to assess possible hazard to the 
reproductive cycle, with certain emphasis on embryotoxicity. 
Only 2-5% of birth defects can be associated with chemical and 
physical stress (Mattison, 2010). This includes mainly the abuse 
of alcohol and other drugs. For the assessment of the prevalence 
of effects on mammalian fertility, the available database is even 
more limited. 
This roadmap paper also has benefitted from the recent discus-
sions, including the recent detailed analysis of the 2013 market-
ing ban for cosmetic ingredient testing in Europe (Adler et al., 
2011; Hartung et al., 2011; Mattison, 2010). In addition, some 
activities under the auspices of ILSI/HESI and the US ToxCast 
project have helped to clarify opportunities and challenges.
This paper will not always distinguish clearly between de-
velopmental and reproductive toxicity, simply considering de-
velopmental effects (teratogenicity) as the key concern within 
reproductive toxicity (which obviously also includes aspects of 
fertility and other impairments of the reproductive cycle). De-
velopmental processes are especially difficult to assess (Knud-
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6.1  Introduction: reproductive toxicity
Developmental and reproductive toxicity was not in the fore-
ground of safety assessments for many years after the shock 
of the thalidomide disaster (Kim and Scialli, 2011) had died 
down. More recently, the European REACH legislation, which 
is extremely demanding in this field (Breithaupt, 2006; Hartung 
and Rovida, 2009a; Rovida and Hartung, 2009; van der Jagt et 
al., 2004; Rovida, 2010), has stirred discussion again, notably 
because tests like the two-generation study are among the most 
costly and require up to 3,200 animals (two-generation study) 
6  A Roadmap for the Development  
of Alternative (Non-Animal) Methods for 
Reproductive Toxicity Testing
Fig. 6.1: Principal manifestations in developmental toxicity
(modified from Pellizzer et al., 2005)
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high-dosage, effect-driven use, while chemicals, if at all, will 
typically affect the human body in a low-dose, long-term man-
ner. Therefore, adapting the risk assessment of pharmaceuticals 
to chemical effects might not be appropriate. Despite that, the 
latter approach was introduced for chemicals several decades 
ago, but it held true only for new chemicals at a certain produc-
tion volume. Very few new chemicals, however, are produced 
in high enough volumes to trigger such testing. Thus, experi-
ence with the predictive value and performance in general for 
ordinary chemicals is more than limited. So are the laboratory 
capacities available to carry out testing. Bremer et al. (2007) 
showed that in both the New Chemicals Database and the US 
EPA HPV database, any given reproductive toxicity test has 
been used for less than 3% of the notified substances (Bremer et 
al., 2007a) (Fig. 6.2).
Fleischer has demonstrated the limited testing facilities and 
a lack of sufficient scientific/technical know-how (Fleischer, 
2007): A survey including 28 major independent and corporate 
laboratories in Europe indicated that only 11 offer two-gener-
ation studies with a capacity of 28 substances per year. This 
total suggests a capacity to carry out about 50 parallel, two-gen-
eration studies in Europe, each lasting about two years. Thus, 
every year 25 new substances can be included. The majority 
of this testing capacity is employed for drugs and pesticides. 
Only about three general chemicals per year have been tested in 
two-generation studies since the introduction of the Dangerous 
Substances Directive in 1981 (Fleischer, 2007). Thus, testing 
of hundreds or even thousands of chemicals in the context of 
REACH will overwhelm available test capacities. This calls for 
adequate prioritizing to make best use of these limited resources 
as well as for the use of any other means to satisfy the informa-
tion requirement by way of an alternative and integrated testing 
strategy.
sen et al., 2011), as the timing of processes creates windows of 
vulnerability, the process is especially sensitive to genetic errors 
and environmental disruptions, simple lesions can lead to com-
plex phenotypes (and vice versa), and maternal effects can have 
an impact at all stages.
6.1.1  Current testing
The treatment of one or more generations of rats or rabbits with 
a test chemical is the most common approach for identifying 
chemically induced adverse effects on reproduction (Fig. 6.1). 
For evaluating developmental toxicity, test guidelines were 
designed to detect malformations in the developing offspring, 
together with parameters such as growth alterations and prena-
tal mortality (Collins, 2006). Developmental toxicity tests are 
considered mainly as screening tests (especially for REACH 
(Rovida et al., 2011)). The shorter and less complex “screening” 
tests, which combine reproductive, developmental, and (option-
ally) repeated dose toxicity endpoints into a single study design, 
are variants. 
As a result of these studies (Tab. 6.1), a No Observed Effect 
Level (NOEL) is determined. These data then are extrapolated 
from animal studies to humans. In this process, safety factors 
are applied. This safety factor is normally 100, i.e., 1% of the 
dose that did not cause any adverse effects is considered safe in 
humans (acceptable daily intake values). The value of 100 is a 
common default as a safety factor (based on the assumption that 
10 is an estimate of interspecies and another 10 of intra-species 
differences), but justifiable deviations are possible in both direc-
tions.
Reproductive toxicity testing has not been developed for, nor 
been largely applied to, chemicals in general – which is often 
overlooked – but has been used predominantly for pharmaceu-
ticals and pesticides. Pharmaceuticals are designed for oral, 
Tab. 6.1: Harmonized guidelines used in screening and testing for developmental and reproductive toxicities  
for EU, US EPA, and OECD
 OECD (Organisation of  OPPTS (Office of  EU Method 
 Economic Co-operation  Prevention, Pesticides, and  
 and Development) Toxic Substances), US EPA 
Prenatal developmental toxicity TG 414 (2001) OPPTS 870.3700 B 31 
  (U.S. EPA, 1998)
Reproduction and fertility effects TG 416 (2001) OPPTS 870.3800 B 35 
  (U.S. EPA, 1998) 
One-generation reproductive toxicity study TG 415 (1983)  B 34
Reproduction/developmental toxicity  TG 421 (1995) OPPTS 870.3550  
screening test  (U.S. EPA, 2000)
Combined repeated dose toxicity study  TG 422 (1996) OPPTS 870.3650  
with the reproduction/ developmental   (U.S. EPA, 2000)  
screening test  
Developmental neurotoxicity TG 426 (2007) OPPTS 870.6300  
  (U.S. EPA, 1998)




tabases are similarly sparse for developmental (or reproduc-
tive) effects including FDA’s Center for Drug Evaluation and 
Research publicly accessible database (16.3%; 58 of 355 listed 
compounds), and FDA’s Center for Food Safety and Nutrition 
database (27.2%; 312 of 1,146 listed compounds; provided 
in Leadscope Databases (Leadscope) (Chihae Yang and Ann 
Richard, personal communication; see also Singh et al., 2010). 
The EPA Integrated Risk Information System (IRIS) contains 
comprehensive reviews for 553 environmental chemicals (as of 
April 2010), and identifies the most sensitive or ‘critical effect’ 
as the basis for setting safe exposure levels to protect the pub-
lic health. The critical effect is the first observed effect deemed 
adverse that is likely to occur in the most sensitive species as 
the dose rate of an agent increases (IRIS, 2010). Less than 
2% of 533 IRIS assessments report the critical effect for the 
derivation of a noncancer reference value (i.e., a safe exposure 
level) as being a developmental (5 of 553) or reproductive (4 of 
553) effect (http://www.epa.gov/IRIS/). This may be due to other 
effects being more sensitive, but more likely due to a lack of de-
The expense and animal use associated with reproductive tox-
icity testing is questionable when considering that reproductive 
toxicity is most probably an event with a low frequency in the 
universe of industrial chemicals. An independent expert panel 
of industrial reproductive toxicologists has concluded that, in all 
likelihood, less than 5% of industrial chemicals possess prop-
erties that could be harmful to the developing child. We have 
found, by reviewing the New Chemical Database of the ECB, 
that 15 two-generation studies have led to only one R60 clas-
sification, whereas 58 one-generation studies have led to three 
classifications (Bremer et al., 2007a). 
Publically available data on reproductive toxicity are very 
rare. Less than 5% of dossiers in the US EPA HPV database 
or the EU New Chemical Database (not public) contain any 
data in this field (Bremer et al., 2007a). Knudsen et al., have 
analyzed available data (Knudsen et al., 2011) in various da-
tabases: “NIEHS’ National Toxicology Program (NTP) online 
database, for example, provides developmental effects data on 
only about 3% of the listed chemicals (70 of 2,330). Other da-
Fig. 6.2: Summary of existing data from the US-EPA HPV database and the ECB database fulfilling the standard  
information requirements of REACH
(modified from Bremer et al., 2007a)
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6.1.2  Framework for replacing systemic toxicity  
by novel approaches
This framework is presented in more detail in Chapter 1. The 
following approaches to overcome animal testing for a given 
area were identified:
1. Abolition of useless tests
2. Reduction to key events
3. Negative exclusion by lack of key property
4. Optimization of existing tests
5. In silico approaches
6. Information-rich single tests
7. Integrated testing strategies (ITS) 
8. Pathways of Toxicity (PoT) and Systems Toxicology
The distinction between (2) and (3) was made to stress that 
identifying positive or negative substances for a given hazard 
represents different approaches with different requirements as 
to prediction models, statistics, etc. Note that this framework 
remains largely on the level of hazard identification. Dose-re-
sponse considerations and quantitative extrapolation to humans 
are not considered.
6.2  Application of the framework to  
reproductive toxicity testing
6.2.1  Abolition of useless tests
Every model has limitations – this holds true for in vivo (Har-
tung, 2008b), in vitro (Hartung, 2007a), and in silico (Hartung 
and Hoffmann, 2009) approaches. It is rare that a model con-
tributes so little that it should be abandoned. In particular, it is 
impossible to predict whether a model cannot be improved to 
make a useful contribution in the future. The proposal by Balls 
and Combes (2005) to formally invalidate useless tests was the 
topic of a joint FRAME/ECVAM workshop (Balls et al., 2006). 
The participants finally agreed that invalidation makes sense 
only for prescribed regulatory tests, since the potential remains 
for further development and possible inclusion into the regula-
tory toolbox. Even though reproductive toxicity testing is not 
likely to be a candidate for abolition, it is worthwhile to apply 
criteria that typically are used for novel tests to illustrate the 
performance of the traditional tests.
The weaknesses of current developmental toxicity safety as-
sessment were recently summarized as follows (Carney et al., 
2011):
– Large numbers of animals required
– High cost per compound (>$ 100,000 per study)
– Long time requirements to evaluate each compound
– Capacity gap: cannot keep pace with increasing demands to 
evaluate existing and new chemicals, as well as mixtures
– Maternal toxicity: can confound data interpretation
– Fundamental knowledge of developmental biology for cur-
rent animal models (e.g., rat, rabbit, monkey) is sparse rela-
tive to mouse or lower organisms
– Uncertainty regarding interpretation of low incidence find-
ings
– Large amount of effort placed on the evaluation of minor 
skeletal variations with little impact on risk assessment
velopmental and/or reproductive effects data, which contributed 
to an increased uncertainty in the database for the choice of the 
critical effect, and resulted in a lower reference value in 85% of 
the cases where an uncertainty factor for an inadequate data-
base was used. Finally, in one of the largest data compilations 
from multiple resources to-date, EPA’s Aggregated Toxicology 
Resource (ACToR) identified available developmental toxicity 
data for less than 30% of the 9,912 chemicals in commerce or 
of environmental interest, out of a chemical domain of 418,513 
generic chemicals (Judson et al., 2009).”
It needs to be stressed that the described effects do not au-
tomatically point to impaired mammalian reproduction, but 
only to observed histopathological effects. The prevalence of 
reproductive toxicity is, most probably, lower than this query 
demonstrates. 
To overcome low sensitivity, regulatory bodies often request 
testing in a second species. It should be stressed that the sensi-
tivity of the test design requesting two species is still unknown. 
But the consequence of requesting two species is dramatic: By 
assuming a maximum prevalence of 5% for developmental tox-
icity in the universe of industrial chemicals, and by requesting 
additional testing in another species in case of a negative first 
study, the number of animals needed for developmental toxic-
ity testing is nearly doubled. Fortunately, in a 2009 amendment 
to REACH, the original consideration of a second species was 
removed, though the respective guidance for developmental 
screening by ECHA has not yet been adapted (Rovida et al., 
2011). In addition, a side-effect of requesting a second species 
that is often overlooked in the current testing practice but that 
will have a high impact on large testing programs, is the in-
crease in the rate of false-positives, and therefore the unwanted 
restrictions of valuable substances (Hartung and Rovida, 2009a; 
Hartung, 2009a). 
Many regulatory agencies have recognized the need for a 
transformative shift and have initiated research programs to 
achieve the vision and goals laid out by the NRC (Leist et al., 
2008b; NRC, 2007). These include the NIEHS NTP Roadmap 
for the 21st Century from 2004 (National Toxicology Pro-
gram, 2004) and the FDA Critical Path Initiative (Woodcock 
and Woosley, 2008; Woosley and Cossman, 2007) of the same 
year. EPA created the National Center for Computational 
Toxicology (NCCT) in 2005 and launched the ToxCast re-
search program in 2006; in 2009, the NRC vision was largely 
adopted as EPA’s toxicity testing paradigm (EPA, 2009). The 
OECD initiated a Molecular Screening for Characterizing In-
dividual Chemicals and Chemical Categories Project in 2007, 
published a monograph on a 2007 Workshop on Integrated 
Approaches for Testing and Assessment, and actively utilizes 
Test Guideline Committees and a QSAR Expert Group to 
ensure global harmonization and validation of any new ap-
proaches. What is most astonishing is the fact that we see 
more US and international activities than European contribu-
tions, though at this moment the highest demand for change is 
created by European legislations; efforts in the EU are mainly 
carried out by research consortia between academia and in-
dustry, with typically only long-term perspectives for transi-
tion into regulatory use.
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suming and labor intensive, and require a significant invest-
ment in examiner training in fetal morphology, coupled with 
extensive proficiency testing.
One issue with skeletal evaluation is the interpretation of 
minor skeletal variations and their impact on risk assessment. 
This issue was the subject of a previous ILSI-HESI expert 
panel project … (Daston and Seed, 2007). Depending on the 
laboratory’s evaluation scheme, a large number of individual 
skeletal variations often are recorded and some occur at a very 
high incidence (sometimes >80%), even in control animals. 
Many laboratories distinguish between several subtly different 
degrees of ossification of individual bones, leading to a large 
volume of statistical analyses and evaluation of correspond-
ing historical control data (reviewed in Carney and Kimmel, 
2007). Although the practice of recording minor skeletal vari-
ations was established many years ago, we have since learned 
that the skeletal system possesses an extensive capacity to 
remodel during postnatal development, and current evidence 
indicates that many of the minor skeletal variations present in 
the term fetus are no longer evident postnatally. ... Thus, mi-
nor skeletal variations, particularly findings such as wavy ribs 
and minor delays in ossification are generally not considered 
adverse in and of themselves (Carney and Kimmel, 2007). ... 
The interpretation of fetal malformations can also be a chal-
lenge, particularly when faced with a low incidence of a par-
ticular malformation occurring in the high-dose group only. As 
highlighted by Palmer many years ago, ‘because low rates of 
malformation are the rule, one faces the recurring nightmare 
of deciding whether one or two malformations are related to 
treatment or accidental’ ... Currently there are few options for 
resolving these issues, which is of particular concern given the 
enormous impact on regulation of the chemical as well as the 
potential labeling of the compound as a teratogen. In some 
cases, the studies have been repeated using extremely large 
sample sizes, but this is obviously problematic in terms of ani-
mal use, costs, and time. Mechanistic studies are another op-
tion, although these may only be possible if higher doses can 
be used to increase the incidence. … statistics often are of lim-
ited help in resolving these uncertainties, as very large num-
bers of offspring are needed to achieve the statistical power 
needed to detect an increase in low incidence malformations. 
To overcome some of these statistical limitations, historical 
control data are considered in judging whether or not a low 
incidence finding seen in a treated group might have been a 
chance occurrence. However, historical control data should be 
used judiciously and within a reasonable time frame, as drift in 
the background incidence can occur over time, as can sudden 
spikes in the incidence of a particular effect.”
The very extensive analysis by Holson et al. is based on expe-
rience with about 1,500 studies (Holson et al., 2006). It also is 
based on a 1984 analysis carried out by the National Center for 
Toxicological Research on behalf of FDA entitled Reliability of 
Experimental Studies for Predicting Hazards to Human Devel-
opment, which was never published in the open literature. They 
show the background of “abnormal” reproductive outcome, 
for example the spontaneous resorption of small litter: 43% of 
rabbits with a single implant resorbed it and 10% terminated 
– Use of high doses that sometimes far exceed human expo-
sure levels
At the same time there is increasing doubt as to the useful-
ness of the 2nd generation for testing of substances. Janer et al. 
(2007) have shown in a retrospective analysis that this made 
no relevant contribution to the regulatory decision-making. 
US EPA obtained similar data (Martin et al., 2009a) supporting 
the development of an extended one-generation study (TG 443, 
OECD; OECD, 2011), originally proposed by the ACSA initia-
tive. Though of lesser relevance here, this shows that (elements 
of) study protocols can indeed be useless and warrant critical 
assessment. 
Another way of asking the question of relevance is whether 
the test is more sensitive (responsive at lower concentrations) 
for reproductive toxicity than the maternal toxicity, i.e., repeat-
ed-dose toxicity. For this comparison, Martin et al. (2009b) ana-
lyzed data in ToxRefDB for 254 chemicals tested in both multi-
generation and 2-year chronic studies, and 207 chemicals tested 
in both multigeneration and 90-day subchronic studies: “For the 
majority of chemicals, potency values between the multigenera-
tion, chronic, and subchronic studies were comparable, with a 
general linear relationship falling within ten-fold of each other. 
However, for four chemicals ... that caused parental or reproduc-
tive effects in the multigeneration study, there was no systemic 
toxicity observed in either the chronic or subchronic studies. 
For another five chemicals ... potencies for the most sensitive 
multigeneration endpoints were more than 10-fold greater than 
for the most sensitive effects in chronic studies. Of these five 
chemicals only thiamethoxam was more potent based solely on 
reproductive endpoints, that is, testicular atrophy.” This means 
with an assessment factor of 10, the hazard of reproductive tox-
icity might be covered for 99.8% of substances.
The assessment here will be based on the most common crite-
ria for validation (Hartung et al., 2004).
Standardization of protocols
The protocol has recently been critically reviewed by Holson 
et al. (2006) and more recently by Carney et al. (2011), who 
conclude: “Developmental toxicity safety assessment is mainly 
a descriptive science designed to detect adverse developmental 
outcomes, namely teratogenicity, intrauterine death, intrauter-
ine growth retardation, and functional deficits. Evaluation of 
teratogenicity requires detailed examinations of fetal morphol-
ogy, including external features, internal organs and tissues, 
and assessment of more than 200 bones of the fetal skeleton. 
These assessments have evolved over time, such that very subtle 
changes (often called variations) can be detected, in addition to 
(real malformations).
The descriptive nature of these fetal examinations brings 
with it some critical challenges … One is that the evaluation 
criteria and nomenclature for fetal morphology has been dif-
ficult to standardize across different laboratories. Although this 
problem would seem to be easily remedied, it has been difficult 
because individual laboratories have built up large volumes of 
historical data based on their own criteria, and they also may 
use different animal strains and evaluate fetuses on different 
days of gestation. Fetal examinations also are very time con-
BASKETTER ET AL.
ALTEX 29, 1/12 61
Reproducibility
These screening protocols have been employed mainly in na-
tional and international programs to gather screening-level 
data for chemicals. However, this study design has limited 
sensitivity and produces a high level of equivocal results that 
often have to be further evaluated in more “definite studies,” 
such as a prenatal developmental toxicity study and/or a two-
generation study. Given that the screening requires 560 ani-
pregnancy prematurely via abortion. 3% and 5% abnormal out-
comes were found for 2 and 3 implants, respectively. The au-
thors also suggest: “The slope of the dose-response curve (is) 
... often steeper in developmental toxicity studies than in other 
toxicity studies,” which means that effects occur only close to 
maximum tolerated doses, which “grossly overpredict risks.” 
Another problem they identify is the high background of spon-
taneous adverse developmental outcomes (Tab. 6.2).
Tab. 6.2: Most commonly occurring developmental variations in control Hra:(NZW)SPF rabbits
(modified from Holson et al., 2006)
Total number examined (1992 – 2003) Fetuses Litters % per litter
External 10 278 1529 –
Twinning 1 1 0.0 – 0.8
Visceral 10 278 1529 –
Accessory spleen(s) 1198 681 4.8 – 33.2
Major blood vessel variation 565 329 0.0 – 17.5
Gall bladder absent or small 150 115 0.0 – 7.8
Retrocaval ureter 142 110 0.0 – 5.4
Hemorrhagic ring around the iris 46 33 0.0 – 3.6
Spleen - small 6 6 0.0 – 1.0
Hemorrhagic iris 4 4 0.0 – 0.8
Liver - pale 2 2 0.0 – 0.6
Eye(s) - opacity 2 1 0.0 – 1.0
Accessory adrenal(s) 1 1 0.0 – 0.7
Renal papilla(e) not developed and/or distended ureter(s) 1 1 0.0 – 1.2
Skeletal 10 278 1529 –
13th full rib(s) 4082 1240 19.4 – 59.1
13th rudimentary rib(s) 1982 1042 8.1 – 32.5
27 presacral vertebrae 1724 766 4.5 – 32.1
Hyoid arch(es) bent 504 357 0.0 – 22.2
Sternebra(e) no. 5 and/or 6 unossified 448 274 0.0 – 11.4
Sternebra(e) with threadlike attachment 146 121 0.0 – 9.1
Sternebra(e) malaligned(slight or moderate) 117 108 0.0 – 5.0
Extra site of ossification anterior to sternebra no.1 106 84 0.0 – 7.4
Accessory skull bone(s) 80 69 0.0 – 5.0
7 th cervical rib(s) 73 59 0.0 – 7.7
25 presacral vertebrae 35 31 0.0 – 7.4
The most commonly occurring manifestations of these findings are:  
(1) right carotid and right subclavian arteries arising independently from the aortic arc (no brachiocephalic trunk),  
(2) left carotid artery arising from the brachiocephalic trunk 
(3) retroesophageal right subclavian artery.
Source: Data collected at WIL Research Laboratories, Inc. 
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(rat, rabbit, or mouse) was capable of detecting more than 61% 
of the teratogens. However, this study should be interpreted with 
caution since Schardein (2000) has provided an extensive study 
in which several hundreds of chemicals have been assessed for 
their interspecies variations. Bailey (2005) examined the data for 
11 groups of known human teratogens across 12 animal species 
and found huge variability in positive predictability, with a mean 
of 61% (Bailey et al., 2005): “Of the 139 individual classifica-
tions across the species tested, a total of 78 (56%) were positive; 
the remaining 44% of results were almost entirely negative. The 
only encouraging aspect to come from these statistics appears to 
be the high positive predictability score for the hamster; however, 
the USFDA published a report detailing the responses of the mice, 
rats, rabbits, hamsters, and monkeys to 38 known human tera-
togens in which the high scoring hamster produced only a 45% 
rate of correct positives (USA FDA Federal Register ‘Caffeine,’ 
1980). Furthermore, the mean percentage of correct positives 
from any one of these species was only 60%... The US FDA re-
port also analyzed the rate of concordance between these species 
and humans for 165 compounds known to be non-teratogenic in 
the latter; the ‘order of merit’ for each species and its negative 
predictive value were completely different from that for the posi-
tive predictive values, ranging from 80% in monkeys to 35% in 
mice and hamsters. The mean negative predictive value for any of 
these species was 54%. Taken together, these predictive values of 
60% and 54% for human teratogens and human non-teratogens, 
respectively, represent a poor return on the investment of animals, 
time, labor and money. The 57% mean value is little better than 
the 50% that would have been obtained by pure chance.”
The “precautionary” response of regulatory toxicology was to 
test in more than one laboratory animal species in order to re-
duce the 40% missed potential developmental toxicants. How-
ever, this inevitably increases the already 40% false-positive 
classifications (Hartung, 2009a). Whether we can afford this 
substantial over-labeling, especially in high-production volume 
chemical evaluation programs, has been discussed elsewhere 
(Hartung and Rovida, 2009a).
Discordance in developmental toxicity testing certainly seems 
to conflict with the widely held dogma stating that the basic 
events in embryo development are highly conserved across spe-
cies, even for species as disparate as fruit flies, frogs, mice, and 
humans. This degree of conservation mainly applies to the most 
fundamental processes in embryogenesis, such as establishment 
of the general body plan, pattern formation, cellular induction, 
and regulation of differentiation via signaling pathways. On the 
other hand, pharmacokinetics and, in particular, maternal meta-
bolism, can vary widely between species and are likely to drive 
interspecies discordance. Placental anatomy and physiology also 
vary greatly between conventional test species and humans. In 
fact, rats, mice, and rabbits utilize two very different types of 
placentae – the inverted visceral yolk sac placenta which is ex-
tremely important in early pregnancy, as well as a chorioallantoic 
placenta which does not become functional until mid-pregnancy. 
In contrast, humans only utilize a chorioallantoic type of placenta 
throughout most of gestation (Georgiades et al., 2002).
Holson et al. (2006) list the following limitations for repro-
ductive toxicity assessments for the most common species:
mals per test, the application of this test in its present form as 
a screening tool should be reconsidered for large toxicological 
programs. The reasons for equivocal results can be several: 
One is that the data are simply inconclusive; another is that 
this is related to either variability or lack of reproducibility. 
Thus it is either reproducibility or robustness of the test that 
has an impact on reproducibility. An improvement of the test 
design to increase accuracy of the test by reducing the number 
of equivocal results is desirable. Notably, the “definitive” mul-
ti-generation studies also have a high rate of equivocal results: 
“The number of equivocal results remained high across these 
six species at just under 25%” (Bailey et al., 2005). 
Hotchkiss et al. (2008) addressed the inherent variability of 
the litter-based endpoints: Power calculations were calculated 
for categorical effects based upon the numbers of malformed 
males versus males without malformations per dose group: “If 
20 animals per dose group are examined for malformations, 
then lesions occurring at an incidence of 25% or greater can be 
detected, whereas an incidence of 10% can be detected if all the 
pups are examined from 20 litters. If only ten males per group 
are examined, as recommended for histopathological analyses 
in some regulatory agency test guidelines, then effects are only 
detected statistically if about 50% or more of the tissues/organs 
are affected; a level of statistical power that many would con-
sider inadequate.”
Scientific Relevance 
The relevance of studies raises a concern: “However, if dosing 
was high enough to cause the above described ‘maternal toxi-
city,’ these doses often also cause some effects in offspring. So 
the crux is that, on one hand the experimenter must apply high 
doses in order to fulfill the guideline requirements, while on 
the other hand results achieved at such doses may lead to the 
classification of a compound.” Holson et al. (2006) observe the 
problem of statistics applied without correction for the multiple 
endpoints assessed: “Because, for example, a standard devel-
opmental toxicity study with ANOVA/Dunnett’s and Kruskal-
Wallis/Mann-Whitney statistical analyses performed on all 
parametric and nonparametric data, respectively, may involve 
as many as 100 to 300 individual hypothesis tests, the possibil-
ity exists for numerous spurious statistical findings.” Another 
biasing effect is the “litter effect,” i.e., the common observation 
that several fetuses of the same litter are affected, thereby “... 
artificially inflating the apparent group response” and leading 
to false-positive results.
Predictivity of point of reference (human reproductive toxicity)
The ability of animal models to predict the human response is 
a fundamental assumption in developmental toxicity and risk as-
sessment, yet varying degrees of discordance among species are 
very common in actual practice. Pronounced interspecies vari-
ances have been described showing not more than 60% correla-
tion between different laboratory mammalian species in the area 
of developmental toxicity. There is no reason to assume that any 
species predicts humans better than, e.g., mice predict rat develop-
mental toxicity of a given chemical. Hurtt et al. (2003) have dem-
onstrated by analyzing 91 veterinary drugs that no single species 
BASKETTER ET AL.
ALTEX 29, 1/12 63
especially at normal exposures and therapeutic dose levels. 
Notable examples include glucocorticoids, benzodiazepines, 
caffeine, carbon dioxide, dopamine, indomethacin, and aspi-
rin (Bailey et al., 2005; Hartung, 2009c). A simple calculation 
shows that a prevalence of 2.5% reproductive toxicants in hu-
mans among industrial chemicals when tested in two species 
(correlating with each other and humans at 60%) will result in 
65% of all substances labeled false-positive, while 2.1% real-
positives (85% of all positives) of the toxicants are identified 
(Hartung and Rovida, 2009a; Hartung, 2009a).
In 1983, Brown and Fabro estimated, that “Of those agents 
thought not to be teratogenic in man, only 28% are negative in 
all species tested” (Brown and Fabro, 1983) (Tab. 6.3).
They also did not find a strong concordance of potency (Tab. 
6.4).
“Rat – susceptible to dopamine agonists (dependence on pro- 
lactin for maintenance of early pregnancy), prone to prema-
ture reproductive senescence following treatment with GABAn-
ergic and other CNS-active agents, increased susceptibility to 
Leydig cell tumors, increased susceptibility to mammary tu-
mors, inverted yolk sac placentation, limited fetal period.
Rabbit – Consume diet inconsistently, prone to abortion and 
toxemia, induced ovulatory, sensitive to local gastrointestinal 
disturbances (e.g., antibiotics), not routinely used in repeat-
ed-doe toxicity studies, prone to resorption when few implan-
tations are present, inverted yolk sac placentation.” 
Specificity
There are many examples of positive results in the routine spe-
cies that have little or no effect in humans (“false-positives”), 
Tab. 6.3: Concordance of human and animal teratogenicity data
(modified from Brown and Fabro, 1983)
Human teratogens ψ  Human non-teratogens-
Test species % with positive response Test species % with no positive response   
 (correct positives)  (correct negatives) 
Mouse 85%ǂ Mouse 35%
Rat 80% Rat 50%
Rabbit 60% Rabbit 70%
Hamster 45% Hamster 35%
Monkey 30% Monkey 80%
Two or more species 80% Two or more species 50%
Any one species 97% All species 28%
From US FDA
ψ 38 compounds: “reports of birth defects in humans associated with intake.”
 -165 compounds: “for which human teratologic effects have not been reported.”
ǂ From the published information, the exact meaning of an 85% response rate is not clear. It could mean, for example,  
   85% of the agents were positive in at least one mouse study, or of all tests of these agents in the mouse, 85% were positive. 
Tab. 6.4: Comparison of teratogenic potency of chemicals in humans and animals
(modified from Brown and Fabro, 1983)
 Lowest effective dose
 (mg/kg/day)
Chemical Humans Animals Species Ratio of Animal dose:human dose
Methyl mercury 0.005 0.2 Cat, rat 50
DESψ 0.02 0.2 Rhesus monkey 10
Methotrexate 0.042 0.2 Rat 4.8
Aminopterin 0.05 0.1 Rat 2.0
PCBs- 0.07 0.125 Rhesus Monkey 1.8
Thalidomide 0.5 2.5 Rabbit 5.0
Phenytoin 2.0 50 Mouse 25
Alcohol 400 1500 Rat 3.8





with fetal malformations, but is not teratogenic in the rat (Bailey 
et al., 2005). However, the identification of known human tera-
togens also was not necessarily in the routine species, and we 
have to keep in mind that this was often retrospective analysis, 
where the effect in humans was known and was looked for in 
the animal studies, creating considerable bias. 
Applicability domain
An applicability domain, i.e., the part of the chemical universe 
where the animal tests give correct predictions, has not been 
established for the different animal studies.
Taken together, no comprehensive critical evaluation of current 
in vivo testing is available, with the exceptions of a book chapter 
by Holson et al. (2006) and two narrative reviews (Bailey et al., 
2005; Carney et al., 2011). There is some concern, which war-
rants a systematic review. Evidence-based toxicology offers a 
toolbox for such evaluations. Hartung and Hoffmann (Hartung, 
2010c; Hoffmann and Hartung, 2006) conclude: “Thus, a crucial 
need remains for an organized and critical analysis of the pri-
mary literature in reproductive toxicology to evaluate the con-
cordance of regulatory reproductive toxicity studies to human 
exposure outcomes.” A critical problem is that reference data 
from humans are difficult to obtain from epidemiology (Fried-
man, 2009). Our knowledge of human teratogens is very much 
limited to drugs. Furthermore, we are lacking a process such 
as IARC for carcinogenicity in the field to achieve consensus 
on the reproductive toxicity of substances. Validation of novel 
tests against the traditional animal models should be done with 
Similarly, Bailey and Knight (2005) summarized their col-
lected data (Bailey et al., 2005): “This means that of 1223 defi-
nite, probable, and possible animal teratogens, fewer than 2.3% 
were linked to human birth defects.”
The consequence of low specificity in order to boost sensitiv-
ity, which can be seen as “precautionary,” creates concerns as to 
the societal costs (Durodie, 2003). A breakdown of embryotoxic 
effects of 74 industrial chemicals, which have been tested ac-
cording to EU Directive 67/548/EEC B31 in the New Chemical 
Database, showed that 34 chemicals have demonstrated effects 
on the offspring, but only two chemicals have been classified 
as developmentally toxic according to the standards applied by 
the national competent authorities (Bremer and Hartung, 2004). 
This demonstrates the lack of confidence in the specificity of 
this “definitive” test.
Sensitivity
The same analysis by Bremer and Hartung (2004) showed that 
55% of these chemical effects to the offspring could not be 
detected within multi-generation studies (Fig. 6.3), which sug-
gests that either the developmental toxicity screening tests are 
over-predictive or that the multi-generation assays lack sensitiv-
ity (Bremer and Hartung, 2004).
This is in contrast to claims that “... Every chemical or drug 
known to be teratogenic in humans, with possibly two excep-
tions, is also teratogenic in one or more laboratory species” 
(Schardein, 2000). One such exception is the prostaglandin E1 
analogue misoprostol: Treatment of humans with this drug for 
peptic ulcer disease or to initiate labor has a strong association 
Fig. 6.3: Correspondence of developmental toxicity screening studies and (multi-)generation reproductive  
toxicity studies in the ECB database
(reprinted with permission from Bremer and Hartung, 2004)
The figure shows that not all embryotoxic effects will be picked up in one/two generation studies. Additional developmental toxicity  
tests are necessary. Further investigation is necessary to understand whether one/two generation studies can be combined with a set of 
in vitro methods for developmental toxicity in a conceptual framework that could perform reliable hazard identification of a chemical. 
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seeks targeted testing that provides sufficient toxicological data 
for hazard identification, but also keeps in vivo testing to a mini-
mum. 
A frequent possible scenario for an alert-driven strategy could 
be unclear histopathological observations in the testes in suba-
cute or chronic toxicity studies. These findings should not auto-
matically trigger additional animal-intensive tests for reproduc-
tive toxicity. These effects should be further explored, however, 
by using in vitro testing batteries analyzing cytotoxic effects on 
specific cell populations of the reproductive organs and/or by 
analyzing relevant hormone production or by monitoring game-
togenesis in vitro. The obtained data will identify if observed 
changes in the tissues of reproductive organs are reprotoxic ef-
fects or if the observed effects are related to general toxicity. 
The establishment of relevant databases (Judson, 2010) such as 
the Fraunhofer society’s database (Bitsch et al., 2006) or Tox-
Cast’s ToxRefDB (Knudsen et al., 2009; Martin et al., 2009a,b) 
will support the development of such a scientific approach. A 
query of the former database (Bremer et al., 2007a) contain-
ing 329 chemicals tested in repeated dose studies (rats) and 203 
chemicals (mice) has demonstrated that major targets of chemi-
cals showing toxicological effects on the testes are target cells 
that can also be cultured in vitro. However, substantial research 
efforts are still necessary to maintain the functionality of target 
cells in vitro and to convert these in vitro models into predic-
tive tests using specific functions as toxicological endpoints. 
Changes of the functionality of certain target cells will point to 
the relevant target mechanisms and will support the interpreta-
tion if the observed effects are relevant to humans.
6.2.3  Negative exclusion by lack of key property
Instead of positively identifying a key property, which would 
lead to classification, it is often more attractive to exclude a key 
property to come to no classification. This is especially the case 
when hazards are relatively rare and positive identification will 
not save many test efforts. Properties that especially come to 
mind are the barrier models suggesting limited bioavailability. 
This can be oral availability on the side of the mother or the 
placental barrier. Models are available for both (Bremer et al., 
2007a; Mose and Knudsen, 2006; Myren et al., 2007; Poulsen 
et al., 2009) and oral uptake (see Chapter 2), but a key problem 
is whether they are sufficiently predictive to completely rule out 
a possible effect, especially as the placental barrier changes its 
properties over time during pregnancy. Bremer et al. note the 
differences of the placenta between rodents and humans (Brem-
er et al., 2007a): “Rodents have an inverted yolk sac placenta, 
which is responsible for the histiotrophic nutrition of the em-
bryo during the first few days of embryonic development. Inter-
ference with the function of this placenta, due to the accumula-
tion of a chemical, can cause embryonic death or embryonic 
toxicity/malformations not occurring in species that lack this 
placental structure. This can result in the false classification of 
a chemical as a developmental toxicant ... This reasoning is, to 
some extent, also valid for the rabbit. Conversely, there may be 
examples where the yolk sac placenta may protect the embryo by 
caution. A formal invalidation (Balls and Combes, 2005) is not 
likely to find major support in the absence of valid alternative 
approaches, given the importance of this subject. Nevertheless, 
it might be worthwhile to examine the in vivo reproductive tox-
icity tests applying the principles of evidence-based toxicology 
(EBT) (Hartung, 2009b). The development of in vitro methods 
might be furthered by evidence that the current test system is not 
providing the safety information we are looking for. 
6.2.2  Reduction to key events
Most reproductive toxicity testing is done to exclude tera-
togenic effects. For this reason, an early focus in alternative 
method development was on tests for embryonic malformations 
(Augustine-Rauch et al., 2010). The most complete reflection 
of embryonic development apparently can be achieved with ze-
brafish embryos (Selderslaghs et al., 2011; Sukardi et al., 2011; 
Weigt et al., 2010, 2011; Yang et al., 2009), for example using 
dynamic cell imaging, or frog eggs (FETAX assay) (Hoke and 
Ankley, 2005), which has been evaluated more critically by IC-
CVAM1. It seems to be timely to evaluate available protocols 
and datasets and define a protocol for formal validation.
By 2002, three well-established tests had already been vali-
dated, i.e., the mouse embryonic stem cell test, the whole rat 
embryo culture, and the limb bud assay (Genschow et al., 
2002, 2004; Piersma et al., 2004; Spielmann et al., 2004). They 
obviously cover only a small part of the reproductive cycle and 
only a small though critical part of embryonic development. 
Among them, the murine embryonic stem cell test (EST) has 
attracted most interest. Originally a counting of beating heart 
cells formed, it is now adapted to other endpoints and to hu-
man cells (Leist et al., 2008a). At present, the EST has its ap-
plication primarily in in-house hazard identification. To reach 
regulatory implementation, further characterization is needed, 
such as definition of biological and chemical applicability do-
main, mechanistic studies to identify developmental pathways, 
comprehensive comparison of the developmental processes 
active in EST, differentiation with in vivo embryogenesis, and 
ultimately predictability of the EST for the developmental 
phase covered.
The entire reproductive cycle with its vulnerabilities most 
probably cannot be broken down to one or few key events. For 
practical purposes, however, we might test for these, especially 
when certain alerts lead to these test needs, typically from find-
ings in repeated-dose testing. Why study the entire reproductive 
cycle when an alert already hints at a certain problem? If these 
data are insufficient for regulatory decisions, but alerts have 
been identified, the existing data can be used as the basis for 
the development of a tailored testing scheme. Depending on the 
nature of the alerts, test batteries of specific validated in vitro 
tests could be triggered in order to confirm or refute observed 
concerns. For example a histopathology in testes observed in 
repeated-dose studies will be followed up by tests on sperma-
totoxicity models, not a two-generation study if the classifica-
tion cannot be done based on the finding alone. This approach, 




bryotoxic potentials of even very closely related structures (de 
Jong et al., 2011). Optimizations of protocols were reported (De 
Smedt et al., 2008; Seiler et al., 2004; Seiler and Spielmann, 
2011). In order to move towards transcriptomics read-outs, PCR 
was employed to monitor specific gene expression (Pellizzer et 
al., 2004). Knudsen and colleagues (Knudsen et al., 2011) dem-
onstrated the mEST’s ability to capture data on disruption of 
developmental signaling pathways as a potential alternative for 
assessing developmental toxicity. “His example focused on the 
expression of genes for the 17 + 2 conserved signaling path-
ways critical to early development (National Research Coun-
cil, 2000), taking the hypothesis that an abnormal activation 
or inhibition of signaling pathways can lead to developmental 
toxicity. The test system uses murine ESCs cultured 3 days as 
hanging drops that form ‘embryoid bodies’ with gene expression 
patterns for ectodermal, mesodermal, and endodermal lineages. 
Analysis of gene expression at 5 days revealed the top expressed 
signaling pathways as Cadherin, Wnt/β-catenin, Hedgehog, In-
tegrin, ND, Nuclear Hormone, and Receptor Ser/Thr kinase.”
The EC report (Adler et al., 2011) (cited literature there) gives 
a comprehensive overview on variants of the embryonic stem 
cell tests with respect “... to their readouts but also in the target 
cell differentiation (Peters et al., 2008; Zur Nieden et al., 2004). 
Depending on the area of application, effects on differentiating 
neural cells (Stummann et al., 2009b; Theunissen et al., 2010), 
cardiomyocytes (Buesen et al., 2009) and skeletal cells (Stum-
mann et al., 2009b; Zur Nieden et al., 2004; Zur Nieden et al., 
2010) have been investigated. Effects on the quantity of differ-
entiated target cells have been assessed by using immunological 
methods such as flow cytometry (Buesen et al., 2009) or mo-
lecular biological methods such as RT-PCRs and omics (Chapin 
et al., 2007; Osman et al., 2010; van Dartel et al., 2009; van 
Dartel et al., 2010; West et al., 2010; Winkler et al., 2009; Zur 
Nieden et al., 2001; Zur Nieden et al., 2004). Several of the 
methodologies could also be automated in order to increase the 
throughput of substances and make the test available for screen-
ing purposes (Peters et al., 2008).” A key development certainly 
is to translate the EST to human stem cells (Pal et al., 2011; 
Pellizzer et al., 2005; West et al., 2010). This promises, finally, 
to overcome species differences for the key health concern of 
reproductive toxicity.
A key limitation of many in vitro tests is the lack of meta-
bolizing capacity (Coecke et al., 2006). Efforts to combine the 
EST with metabolizing systems have been described (Bremer et 
al., 2002; Hettwer et al., 2010) with kinetics modeling. Another 
improvement represented the combination with kinetic mod-
eling (Verwei et al., 2006). Similar optimization work was also 
carried out for the whole embryo culture (Piersma et al., 2008) 
adding metabolizing systems (Luijten et al., 2008). The added 
value and validity of these variants should be assessed system-
atically. Notably, the modular approach (Hartung et al., 2004) 
would allow assessing only the aspects that have been changed, 
and, by establishing performance standards for the murine EST, 
validity could possibly be established with reasonable effort.
Other promising approaches include the use of, or combina-
tion with, computation models of development pathways and 
systems and, finally, high-throughput in vitro approaches as, 
hindering the access of a chemical to it. ... The toxicant concen-
tration reaching the embryo is a critical factor in developmental 
toxicity. Among the mechanisms regulating the disposition of 
toxicants from the maternal circulation to the embryo, drug ef-
flux transporters play a key role, and are possibly responsible 
for interspecies variability.” This argues very much for the use 
of human placentas, which are relatively easily available.
A very promising approach is to use thresholds of toxicologi-
cal concern (Kroes et al., 2005), i.e., TTC, to define exposure 
limits below which an effect is sufficiently improbable, as re-
productive toxicity is considered a threshold effect (Piersma et 
al., 2011). Van Ravenzwaay and coworkers (2011) determined 
such a TTC for reproductive toxicity at 8 μg/kg bw/d. These ap-
proaches can be further refined either by distinguishing classes 
of chemicals or using internal TTC, i.e., basing the threshold on 
plasma concentrations actually achieved. An interesting option 
would be to use experimental barrier model data to modify the 
TTC level.
6.2.4  Optimization of existing tests
Reproductive Toxicity is by its very nature characterized by 
“complexity layered on complexity,” and the devil might be 
found in the details. Reproducibility, robustness, and reliability 
combined with a relevant, sound scientific base will be critical 
for an acceptable test going forward. 
The three embryotoxicity tests validated in 2002 have re-
ceived considerable interest for further optimization. In order to 
review and discuss the next steps of using the tests, an ECVAM 
workshop was held in January 2003 (Spielmann et al., 2006). 
A panel of 12 European and American experts from industry, 
academia, and governmental institutions analyzed the tests for 
chemical and pharmaceutical safety testing in vitro. The out-
come of the workshop can be summarized as follows (Spiel-
mann et al., 2006): 
1. The tests are reliable and transferable to other laboratories. 
2. The prediction models need to be revised in order to receive 
a better discrimination between non- and weak/moderate em-
bryotoxic chemicals. 
3. The tests should also be applied to industrial chemicals to 
demonstrate the reliability and relevance of the system, since 
within the formal validation study primarily pharmaceuticals 
have been tested. 
4. The selected strong developmental toxicants represent a 
limited number of mechanisms of toxicity, mostly affecting 
cell proliferation. Strong embryotoxic chemicals with other 
toxicological mechanisms should be tested in order to en-
hance the reliability for a wider applicability of the tests for 
a broader range of chemicals. 
5. A metabolic system to detect proteratogenic compounds has 
to be integrated in order to extend the applicability. 
6. Other differentiation pathways have to be included in the 
tests. Additional major target tissues such as the nervous 
system and the skeletal system have to be included in order 
to get precise information about the teratogenic potential of 
chemicals.
A lot of work has been done to further optimize the standard 
murine EST, which was shown to distinguish the different em-
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developmental toxicity data is needed. Such a compilation would 
allow investigators to methodically examine a range of consid-
erations when selecting and utilizing toxicological data in train-
ing sets (i.e., various experimental factors, various approaches 
to combining/separating categories of endpoints, and alternative 
scoring systems); 2) Training sets for discrete developmental 
endpoints should be developed. This would allow examination of 
the process used to assemble training sets, as well as the effect of 
alternative processes on the predictive performance of the model. 
The Working Group considers these first two recommended ef-
forts, compiling/analyzing a comprehensive database and devel-
oping/investigating alternative training sets, as complementary 
and iterative exercises; 3) The combined use of multiple types of 
tools and approaches for screening should be investigated.
In conclusion, the Working Group recognizes there is a need 
for valid and efficient methods to screen large numbers of en-
vironmental contaminants for their potential to pose a develop-
mental hazard. Whereas the use of SAR models for exploratory 
studies is encouraged, statistically based SAR models, in their 
current form, are not yet sufficiently developed or validated 
to yield confident predictions with which to identify potential 
developmental toxicants in a screening program. The Working 
Group believes that the efforts recommended in this report will 
contribute to improving the potential of statistically based mod-
els for this application.”
Similarly, Cronin et al. (2002) summarize: “There are a number 
of problems with applying QSARs to reproductive toxicology no-
tably the complexity, subtlety, and sometimes ill-defined nature of 
the endpoints and lack of data available for modeling.” Hewitt et 
al. (2010) conclude similarly: “This study demonstrates the lim-
ited success of current modeling methods when used in isolation. 
However, the study also indicates that when used in combination, 
in a weight-of-evidence approach, better use may be made of the 
limited toxicity data available and predictivity improved.” Rec-
ommendations (condensed here) are provided as to how this area 
could be further developed in the future:
– Availability of suitable toxicity data; almost exclusively data 
collected for pharmaceutical compounds, which may prevent 
the study of predictions made for industrial chemicals.
– Placental transfer can be useful as a modulating factor.
– Existing “global” (Q)SAR models for reproductive and de-
velopmental toxicity must be treated with caution. Given 
the plethora of different mechanisms (many of which are 
unknown) involved within reproductive and developmen-
tal toxicity, a single “catch all” (Q)SAR model is likely to 
show limited performance. If literature data are available, a 
number of structurally/mechanistically restricted “local” (Q)
SARs would be more appropriate.
– At present, category formation approaches are promising but 
they are limited, both by available data from which to select 
category members and by the approaches available to define 
categories.
– Currently, the structural alert approach, as used in DEREK-
fW, requires more alerts to be developed for reproductive 
and developmental toxicity. 
– The importance of time-dependent effects should also be 
considered. 
for example, those being utilized by the EPA ToxCast program 
(Sipes et al., 2011a) (see below). 
6.2.5  In silico approaches
The development of reliable QSARs for reproductive toxicity is 
currently suffering due to a lack of high quality in vivo data and 
the complexity of the reproductive toxicity endpoint, which in-
volves several known and unknown toxicological mechanisms. 
It should be stressed that QSARs can be based on either in vivo 
or on in vitro data. The uncertainty of the origin of data should 
be taken into account when integrating these models into testing 
strategies. 
Some commercially available toxicity prediction soft-
ware packages are claiming to detect reproductive toxicants. 
Maslankiewicz et al. (Bremer et al., 2007a) have reported that 
the software program DEREKfW has been challenged with 
around 100 reproductive toxicants included in Annex I of Direc-
tive 67/548/EEC, and 90% of chemicals classified for “impaired 
fertility” and 81% of chemicals that cause harm to the unborn 
child were not detected. The TSCA chemical category list of 
the new chemical program of US-EPA failed in 77% to detect 
EU-classified chemicals causing adverse effects to mammalian 
fertility and 82% of developmental toxicants have not been cor-
rectly identified. This is in strong contrast to mere internal vali-
dations that show results of >80% correlation for reproductive 
toxicity (Matthews et al., 2007), illustrating the importance of 
objective assessments.
A working group of ILSI/HESI assessed structure/activity re-
lationships (SAR) (Julien et al., 2004) and summarized: “The 
Working Group’s investigation of two statistically based SAR 
systems that have been applied to developmental toxicity eluci-
dated the difficulties in predictive modeling of this toxicity. With 
a statistically based approach, the activity (or inactivity) of 
each training set compound must be captured in a way that can 
be correlated with the presence or absence of chemical structur-
al features. This poses a number of methodological challenges. 
The particular ‘activity’ representing developmental toxicity 
must be defined. Also, an objective, rational, reproducible, and 
transparent process for scoring a training set compound for the 
activity must be developed. Additional methodological chal-
lenges derive from the dynamic nature of development and the 
general sparseness of published developmental toxicity data.
To advance the potential of SAR for predictive modeling of 
developmental toxicity, it will be necessary to develop gener-
al scientific agreement on valid and transparent methodology 
for selecting, categorizing, and scoring developmental toxicity 
data. Such methodology should be developed by an interdisci-
plinary panel of developmental toxicologists and developmental 
biologists, working in consultation with SAR model developers 
and individuals with other relevant expertise (e.g., biostatisti-
cians). The recommendations from this panel should undergo 
peer review.
The Working Group recommended three research efforts that 
will inform the development of improved methodology: 1) A sys-
tematic and holistic analysis of developmental toxicity data of 
adequate quality and quantity should be conducted. Toward this 
aim, a comprehensive, publicly available electronic database of 
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This highlights the need for “virtual models” in which a toolbox 
of dynamic models can be used to interpret HTS data and path-
way-based information. Latest studies from ToxCast have dem-
onstrated the feasibility of predictive modeling of fertility, blood 
vessel development, and prenatal developmental toxicity (Sipes 
et al., 2011a). Angiogenesis can be considered an example, as 
cell-agent based models (ABMs) for angiogenesis have been de-
veloped that recapitulate HTS data at a histological scale (Klein-
streuer et al., 2011). In this regard, (Q)SARs may become more 
informed as we train these read-across methods with information 
from HTS data and cellular ABMs. Another approach emerging 
from the above mentioned data is called: “Towards a virtual em-
bryo.” The final goal is to apply HTS data, in silico tools, and 
models to look globally at developmental processes and toxicities 
in a new way. Predictive and mechanistic models would dynami-
cally integrate data with relevant information about embryonic 
systems. Applying “Virtuomics” and running “what-if” scenarios 
to predict adverse outcomes from different perturbations might 
allow scientifically-based predictions of how development might 
be affected across a range of complex factors. A toolbox of virtual 
tissue models may someday comprise a modular virtual embryo 
for simulating important information as part of an integrated test-
ing strategy2.
6.2.6  Information-rich single tests
Complex phenomena such as elements of the reproductive cycle 
and their perturbations usually can be captured better by multi-
ple endpoints than by a single biomarker. Functional endpoints 
such as formed beating heart cells in the EST already integrate 
many biological pathways, but new technologies allow assess-
ing a multitude of measurements using high-content technolo-
gies. Both omics and image analysis can add new qualities to in-
terpretation of the biological models (Hartung and Leist, 2008). 
However, it is important to keep in mind that whatever fancy 
analysis we add, it can hardly overcome the limitations of the 
underlying model (Hartung, 2010b, 2011). So the same consid-
erations of the limits of both animal and cell models apply.
We also need to keep in mind that the novel technologies pose 
an enormous challenge to the validation process as exemplified 
for toxicogenomics approaches (Corvi et al., 2006). The number 
of parameters to control and document, the sometimes high cost 
per single measurement limiting replicates and numbers of sub-
stances tested, or the complex prediction models for informa-
tion-rich methods, as well as the rapid turnover of technological 
change are only a few examples of challenges faced.
In vitro work so far has combined mainly whole embryo cul-
ture and transcriptomics (Luijten et al., 2010) or the EST with 
metabolomics (Kleinstreuer et al., 2011; West et al., 2010), pro-
teomics (Groebe et al., 2010; Klemm et al., 2008; Klemm and 
Schrattenholz, 2004; Seiler and Spielmann, 2011) or transcrip-
tomics, as summarized recently (van Dartel and Piersma, 2011). 
These approaches use patterns or biomarkers derived from 
a training set of substances to identify substances with simi-
lar mode of action. Their predictive value looks promising but 
awaits formal validation.
– A weight-of-evidence prediction is dependent upon whether 
a valid chemical category can be formed for read-across, (Q)
SAR models, and chemical profilers for specific reproductive 
toxicity effects. 
– A need for collaboration between scientists with experience 
in computational modeling and those with experience in in-
terpretation of developmental toxicity data has been high-
lighted.
– There is value in considering more than one in silico ap-
proach within a weight-of-evidence framework.
There is clearly a need for access to existing animal and human 
data to improve the situation. New technologies and bioinfor-
matic methods can only be utilized if there is increased sharing 
of data. A number of research efforts already allow global ac-
cess to information such as ACTOR, ToxRefDB, the ILSI-HESI 
toxicogenomics project, etc. This concept of data sharing has 
also been incorporated into REACH, which requires that toxi-
cological data be made publicly available, but the summariz-
ing data typically do not qualify for modeling approaches. The 
need to make data available extends to publicly recorded human 
clinical trials and pregnancy registries. 
Complementary to this issue of globally available data is the 
need for consistent and universally accepted terminology for 
characterizing effects. Historically, the developmental toxicol-
ogy community has embraced this concept, with international 
collaborative projects and publications on terminology used in 
the evaluation of fetal specimens (e.g., Makris et al., 2009; Wise 
et al., 1997). This same attention to consistency and precision 
in terminology must also be applied to new technologies for 
developmental toxicity testing. 
Altogether, it is unlikely that in silico approaches as stand-
alone methodologies will make a major contribution to repro-
ductive toxicology in the near future. This is in line with some 
growing skepticism on (Q)SAR as stand-alone methods in regu-
latory safety assessments in general (Doweyko, 2004; Hartung, 
2009b; Hawkins, 2004; Raunio, 2011).
In contrast to the above mentioned drawbacks of (Q)SARs, 
computational toxicology based on High-Throughput Screen-
ing (HTS) data, and cell agent-based models (ABMs) have been 
able to simulate prototype toxicity pathways that affect growth, 
morphogenesis, and development. In vitro profiling manages to 
screen for targets, pathways, and processes to build predictive 
signatures for discrete adverse outcomes from animal data or hu-
man epidemiology where available. Functional assays must ex-
tend these signatures to mechanistic relationships and pathway-
based inferences for an integrated testing strategy. As we increase 
biological knowledge, it will be necessary to build and utilize 
biologically informed models that can simulate downstream con-
sequences of perturbation. In this regard, computational systems 
biology is needed to reconstruct higher-order biological effects 
from the more fundamental in vitro data. These predictive models 
demonstrated the feasibility of predicting ToxRefDB animal tox-
icity solely from the results of HTS data. In the future, it will be 
necessary to perform forward validation of these models without 
dependence on animal data (for compounds lacking such data). 
2  http://www.epa.gov/ncct/v-Embryo/
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The idea of a comprehensive ITS would be to provide for as 
many substances as possible enough information to avoid the 
ultimate animal test. Ideally, all aspects of the human reproduc-
tive cycle would be mapped and translated into test components. 
At the same time, there are some dominant findings, which lead 
to classification as a reproductive toxicant (see Fig. 6.5). 
6.2.7  Integrated testing strategies (ITS)
ITS are a consequence of REACH (van Leeuwen et al., 2007), 
which argues for the use of all available information and views 
use of the definitive animal experiment only as a last resort. 
However, the ITS suggested for reproductive toxicity (Fig. 6.4) 
is relatively simple, not really accommodating any alternative 
methods.
Fig. 6.4: Flow chart for considering whether a substance requires additional testing under REACH for reproductive or 
developmental toxicity
(modified from Scialli, 2008)
Fig. 6.5: Breakdown of embryotoxic effects of 74 industrial chemicals, which have been tested according to EU Directive 
67/548/EEC B31
(reprinted with permission from Bremer and Hartung, 2004)
The figure presents a breakdown of embryotoxic effects of 74 industrial chemicals, which have been tested according to EU 
Directive 67/548/EEC B31. Even if 34 chemicals have demonstrated effects on the offspring only 2 chemicals have been classified 
as developmental toxic according to the standards applied by the national competent authorities. However, by analyzing all the 
developmental toxic effects the data demonstrate mainly that combined embryotoxic effects have been detected, but some chemicals 
also induce specific effects, such as delayed ossification and other skeletal effects. It is important that the experimental design of in vitro 
tests will be set up in a way that these effects can be detected. 
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of exhaustive database and literature searches, data satisfying 
the inclusion criteria for this analysis could not be located in the 
public domain for more than half (53%) of the substances clas-
sified by regulators as being toxic to reproduction. The analysis 
was limited to data on 71 classified reproductive toxicants. Sta-
tistically and biologically significant positive effects have been 
reported as absolute frequency (i.e., the total number of times 
a positive effect was detected in a particular sub-endpoint, ir-
respective of the dose at which the effect was seen). The most 
We have earlier suggested (Bremer and Hartung, 2004) using 
this for a prevalence-based testing strategy, creating tests for an 
ITS specifically addressing these aspects. This reduces mapping 
the human reproductive cycle to those elements which really 
lead to classifications. We called this a “prevalence-driven ap-
proach” (Fig. 6.6).
This concept was further refined by Bremer et al. (2007b), 
who studied in more detail available information on endpoints 
leading to classifications in various databases. Despite a number 
Fig. 6.6: Proposal for a test strategy in order to detect the 
embryotoxic hazard of chemicals
(modified from Bremer and Hartung, 2004)
The flow chart demonstrates a proposal for a testing strategy to 
detect the embryotoxic hazard of chemicals. Three tests based on 
embryonic stem cells and their differentiated counterparts have 
been combined. The reliability of the test strategy has to be tested 
by using selected chemicals with various toxicological pathways. It 
has to be proven that all toxicological mechanisms will be detected 
or if additional systems such as tests for receptor-mediated 
embryotoxicity must be included. It should be pointed out that 
such a test strategy should be part of a general testing scheme 
for toxicological profiling of chemicals. Chemicals with a known 
cytotoxic effect probably will not enter into this testing scheme. 
Chemicals that are known to be metabolized will be tested in 
combination with a biotransformation system. In vitro tests, in grey, 
have been developed, but further test optimization and validation 
is required. 
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A more detailed analysis of the same database was presented 
by Martin et al. (2009b): “19 highly prevalent effects identified 
treatment-related changes to reproductive performance includ-
ing fertility, mating, gestational interval, implantations, litter 
size, and live birth index, demonstrating effects at different stag-
es of the reproductive cycle. ... The fairly restricted set of 19 ef-
fects characterized 151 of the 152 chemicals that demonstrated 
any reproductive toxicity. Additionally, these 19 effects identi-
fied 229 of the 269 chemicals that caused any offspring toxicity. 
The remaining 40 chemicals not identified were predominantly 
affecting pup weight only. This supports the hypothesis that we 
can extract a small finite set of key reproductive effects from 
this dataset for use in developing robust predictive signatures.” 
This strongly supports the idea that a rather limited set of critical 
endpoints might be mapped by either mode of action or PoT-
based tests. It is hoped that with the expansion of the ToxCast 
program further chemical classes will be entered. The ontology 
of effects developed here represents on its own a very valuable 
tool for the field. Similarly, proprietary data could be analyzed, 
even in a blinded manner, to establish more robust frequencies, 
and companies should be encouraged to share these. The analy-
ses of metabolites and biological pathways are likely to identify 
additional nodes that may be important to develop specific tests 
for predictive reproductive toxicity and the PoT approach is 
therefore important for ITS. 
Ideally, not only hazard information is used for an ITS. ITS do 
not necessarily use only new (in vitro) test data but can incorpo-
rate in silico estimations and modeling. A promising integration 
of different information sources is the combination of in vitro 
studies with kinetic modeling (Andersen et al., 2005), which has 
been suggested as Biologically Based Dose-Response Modeling 
for developmental toxicity (Lau et al., 2000). Note also that ex-
isting data can be used, ranging from cell-based tests to animal 
and human data. To the extent that existing information shall be 
integrated into the ITS, it will be necessary to assess its quality. 
A tool was developed (Schneider et al., 2009) to objectively as-
sign the so-called Klimisch scores to either in vivo or in vitro 
studies as a first step. 
Principles for systematic ITS composition (Jaworska and 
Hoffmann, 2010) and validation (Kinsner-Ovaskainen et al., 
2009) are only emerging. A certain consensus exists that the 
reproducibility of each ITS component needs to be assessed. 
However, it is not clear how the predictive value can be as-
sessed without an enormous number of substances tested and 
in the absence of an animal model as point of reference for the 
components. An evaluation stressing more the scientific validity 
of the components appears to be a pragmatic solution. Earlier, 
we termed this a mechanistic validation (Coecke et al., 2007; 
Hartung, 2007b, 2010b), as it confirms that the model reflects 
a scientifically established relevant mechanism, differentiating 
it from an empiric reproduction of a reference test. The careful 
selection of reference compounds (Hoffmann et al., 2008) will 
become even more important. 
6.2.8  Pathways of Toxicity (PoT) and systems toxicology
The area of reproductive toxicity testing appears to be very well 
suited for PoT-based approaches as currently pioneered by the 
frequent ones were 39 cases of body weight changes as a more 
general toxicity parameter, 30 cases of testicular weight/his-
topathology, 28 offspring body weight at birth, and 25 each for 
sperm morphology, sperm count, pregnancy rate, and live off-
spring. Interestingly, uterine weight/histopathology was on the 
lower end with only five cases. Most of the reported effects are 
not isolated, but also appear in combinations. It is, therefore, 
highly relevant for a further analysis, in particular for sub-end-
points occurring with a lower prevalence, to determine if they 
are associated with a more frequently occurring effect. Such 
analysis could allow focusing test development on the most rel-
evant modes of action. These would further diminish the rele-
vance to test for a sub-endpoint with a lower prevalence such as, 
e.g., parturition. Even if parturition is a sub-endpoint with a low 
prevalence of a health effect, which has per se a low prevalence 
in the universe of industrial chemicals, the competent authori-
ties currently request testing for such an endpoint.
For developmental toxicity the search strategy described 
above identified reliable data for 202 of the classified substanc-
es. Given the extensive range of histopathological, functional, 
clinical, and other evaluations undertaken in the context of a 
developmental toxicity study, standardization is important not 
only in relation to the selection of study endpoints but also in 
the terminology used to communicate study results. For the pur-
poses of this analysis, studies were analyzed and catalogued in 
a manner consistent with the recommendations of Chahoud and 
colleagues (Chahoud et al., 1999) using sub-endpoint definitions 
proposed by MacKenzie and Hoar (Derelanko and Hollinger, 
2001). The frequency with which standardized sub-endpoints 
from guideline prenatal developmental toxicity and develop-
mental toxicity studies were reported positive for the 202 sub-
stances in this database ranged from 78 for postimplantation and 
dead, 77 skeletal, 60 body weight, 55 external limbs and digits, 
etc. Offspring sex ratio (4) and parturition (2) were the least 
frequent. These preliminary analyses illustrate how we might be 
guided in developing an ITS of components most relevant for 
regulatory decision making.
 The limited availability of full study records in the public 
domain impedes this approach, but the more recent data made 
available, for example via the ToxRefDB, might help here: 
Knudsen et al. (2009) characterized 283 chemicals (mainly pes-
ticides) tested in both rats and rabbits; 53 chemicals (18.7%) had 
lowest effect levels on development that were either specific (no 
maternal toxicity) or more sensitive than the maternal animal 
in either species: “The primary expressions of developmental 
toxicity in pregnant rats were fetal weight reduction, skeletal 
variations and abnormalities, and fetal urogenital defects. Gen-
eral pregnancy/fetal losses were over-represented in the rabbit, 
as were structural malformations to the visceral body wall and 
CNS. Based upon administered doses, there was a clear hierar-
chy to the sensitivity and specificity of [developmental lowest 
effect levels] dLELs in comparing species, with rat development 
being more sensitive with regards to the number of endpoints 
affected and the number of active chemicals. Many of these 
relationships are consistent with previous database studies of 
developmental toxicology, indicating that they are driven by the 
biology of the test species.” 
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Similar efforts should be extended for the (favorably hu-
man) EST (Kleinstreuer et al., 2011; West et al., 2010). The 
obvious potential of combing stem cell methods with Tox-21c 
approaches was stressed earlier (Chapin and Stedman, 2009). 
This extends from embryotoxicity to other areas such as male 
fertility (Krtolica and Giritharan, 2010) and to link toxicity re-
lated biomarkers uncovered using hES cells with the PoT con-
cept. However, the vision of Tox-21c is not that a tremendous 
number of assays in a centralized facility are used for each and 
every substance. Once critical PoT are identified, they can be 
translated into rather simple assays. For developmental tox-
icity, for example, a total of 17 intracellular pathways have 
been identified as involved in organogenesis (for review see: 
Anon., 2000), cyto-differentiation, growth and tissue renewal, 
of which 5 appear to be the most relevant for early develop-
ment (Fig. 6.7). 
As part of a collaborative project linked to the ReProTect 
project, Michael Schwarz and his group in Tübingen, Germa-
ny, have established a system with ECVAM in which mouse 
embryonic stem cells were stably transfected with luciferase 
reporters specific for the Wnt/beta-Catenin and the TGF-β sig-
naling pathways (the so-called ReproGlo assay, (Uibel et al., 
2010)). The effects of several known human teratogens and 
non-teratogens, including thalidomide, have been investigated 
US-EPA: The ToxCast project has mapped a multitude of path-
way assays to animal reference data: Sipes et al. (2011a) have 
delivered a very impressive proof of principle of the PoT con-
cept across species. This has been started for zebrafish (Sipes et 
al., 2011b), demonstrating the common basis of PoT with mam-
mals. The two most promising alternatives for hazard-based 
identification of developmental activity in the ToxCast battery 
are non-animal embryonic stem cells and zebrafish embryos; 
although the latter should only be seen as an interim approach 
until full replacement tests are available. These models, in tan-
dem with >600 ToxCast assays, provide a unique resource for 
this prioritization. The performance of these test systems needs 
to be looked at closely within the context of ToxRefDB animal 
bioassay data. Early results comparing zebrafish with pregnant 
rat and rabbit have shown similar concordance (e.g., ~56-60%) 
between rat-zebrafish, rabbit-zebrafish, and rat-rabbit. As such, 
the need to develop in vitro extrapolation from concentration 
response to in vivo dosimetry, cross-species differences, and 
life-stage assessments is required. Although most HTS assays 
were based on human cells, they could distinguish PoT that are 
active in either rats or rabbits, explaining species differences. 
This shows how the change in resolution allows annotating PoT 
to different species and measuring them with PoT specific as-
says with high throughput.
Fig. 6.7: Five signaling pathways are important during early development
(Redrawn with permission from Anon, 2000). 
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Dosing: Steady state versus Cmax
It is not clear what would be the best approach to determin-
ing concentrations of compounds to be used in in vitro studies. 
Current expert opinion is that cytotoxicity information is not 
valuable, and that triggering of pathways in reproductive and 
developmental toxicity should be evaluated. Frequently dose-
response analyses for toxicity are performed and subtoxic or 
low doses relative to cytotoxicity are chosen. Given that the in 
vitro models are very different from in vivo, comparisons be-
tween these two systems are useful to assure relevance. A relat-
ed concern is whether steady state concentrations in vivo are the 
reference or whether Cmax values might be more appropriate. 
Many metabolic specialists claim that high doses of compounds 
trigger later cellular events, which are not likely to be seen at 
longer-term steady state levels. These facts should be taken into 
consideration when developing or refining in vitro tests.
Short versus long-term effects
Evidence should be built into in vitro predictive models that al-
low for an understanding of the early identification of events 
that may take longer timeframes to be observed in vivo. If expo-
sure to a compound in vivo takes weeks or months to produce an 
event, do the in vitro tests performed for shorter periods of time 
have the potential to identify these compounds? 
Biological systems 
The main interest lies in developing biological systems that 
model in vivo systems. Obviously, the key issue is that the sys-
tems must be relevant (and most likely based on human rather 
than animal materials). The more complicated systems typically 
move toward systems with cellular interactions and ultimately 
toward 3D cultures. The caution is that the compound doses de-
livered to the cells in these experiments need to be carefully 
considered. The more complex systems typically evolve to po-
larized cells, and it is becoming very clear that cells interact 
very differently with compounds delivered apically versus ba-
solaterally (Benet et al., 2003). Therefore, the addition of com-
pounds to such models needs to be evaluated with relevance to 
the in vivo situation. Both the advantages and disadvantages of 
3D and complex models need to be considered. 
In vivo factors 
Many upstream risk factors are associated with human devel-
opmental defects as an interaction of multiple factors relating 
to genetics, environment, and socioeconomic status. The latter 
includes factors such as prenatal healthcare, maternal nutri-
tion, anxiety, general health, and drug use/abuse. These may 
be difficult to unravel in vivo (adverse outcome pathways) and 
to quantify in vitro (toxicity pathways). As such, alternative 
methods need to address key molecular pathways and cellular 
processes that propagate information across multiple scales of 
biological organization in the developing embryo. Particularly 
important, but as yet under-represented in alternative models, 
is a systematic approach to characterize and analyze multicel-
lular networks within the context of normal biological archi-
tecture. Assays that address 3D configuration and extracellular 
matrix biology are needed.
in this system. The undifferentiated cells are incubated for only 
24 hours; the system is based on a multi-well format and thus 
is well suited for high-throughput analysis. It also allows the 
determination of non-specific toxicity (Alamar Blue assay) 
and the specific response (luciferase-reporter readout) on one 
and the same plate. The test correctly identified human repro-
ductive toxicants such as lithium chloride, retinoic acid, the 
potency of different valproic acid derivatives and (with a me-
tabolizing system) cyclophosphamide. This nicely illustrates 
that PoT-based assays, if representing nodes in the perturbed 
physiological networks, most likely can cover substantial parts 
of the universe of toxicants.
6.2.9  General considerations
Machine learning and ‘omics’
Considering the fact that we do not know everything, and our 
current knowledge base is growing quickly, the identification 
of pathways and nodes of biology that seem to be state-of-the-
art today might be outdated tomorrow. If we develop specific 
assays focused only on what we know, we limit our ability to 
uncover new mechanisms based on new compounds, mixtures, 
or metabolites. An example of this, even within a platform, can 
be seen in metabolomics. When one uses only a targeted ap-
proach, the ability to learn about new biomarkers is limited. In 
contrast, an untargeted approach opens the number of possible 
endpoints to all of the measureable metabolites. Furthermore, 
tests that rely on vast amounts of biomarker data, such as those 
obtained from metabolomic fingerprints, allow a continual “ma-
chine learning” approach of the predictive models. The utility 
of omics-based approaches seems to be an especially efficient 
manner by which to examine many biomarkers simultaneously 
to create knowledge bases that will allow a machine-learning 
approach to insure inclusion of important information.
Compound-related issues
The number of compounds with clearly known human repro-
ductive or developmental adverse effect is relatively small; 
therefore it becomes difficult to compile a relevant set of com-
pounds on which to build predictive model in vitro systems. 
Furthermore, assuming the efforts to predict human reproduc-
tive or developmental effects are successful, compounds that 
cause human reproductive toxicity will not go forward, and 
the set of compounds to be used as reference molecules will 
become self-limited. Predictive training sets need to be stand-
ardized, and to really understand the utility of training sets it is 
recommended that similar structures are used, especially when 
they segregate differently (toxic vs nontoxic). Otherwise, ef-
forts should be made to assure that structures are as diverse as 
possible to facilitate maximizing the “chemical and biological 
space” of the predictive models. Lastly, it would be interesting 
to select some compounds to be predicted from the PoT key 
metabolites and pathway regulators. In conclusion, it is essen-
tial to have a set of compounds compiled and recommended 
for use as a gold standard training set.
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the second species in reproductive toxicity testing by 
FDA. Similarly, the variants of whole embryo culture 
should be followed up almost a decade after validation 
of the original protocol. 
5. The advantage of using human rather than animal de-
rived biological test systems should be taken into ac-
count for every optimization or new development of 
a test system that is designed for human risk assess-
ment.
6. For in silico approaches, the ILSI/HESI Working 
Group recommendations are reiterated: “1) A system-
atic and holistic analysis of developmental toxicity 
data of adequate quality and quantity should be con-
ducted. Toward this aim, a comprehensive, publicly 
available electronic database of developmental tox-
icity data is needed. Such a compilation would allow 
investigators to methodically examine a range of con-
siderations when selecting and utilizing toxicological 
data in training sets (i.e., various experimental factors, 
various approaches to combining/separating catego-
ries of endpoints, and alternative scoring systems); 
2) Training sets for discrete developmental endpoints 
should be developed. This would allow examination 
of the process used to assemble training sets, as well 
as the effect of alternative processes on the predictive 
performance of the model. The Working Group con-
siders these first two recommended efforts, compiling/
analyzing a comprehensive database and developing/
investigating alternative training sets, as complemen-
tary and iterative exercises; 3) The combined use of 
multiple types of tools and approaches for screening 
should be investigated.”
7. Typical alerts leading to reproductive toxicity testing 
from repeated dose studies or developmental toxicity 
testing studies should be identified in order to develop 
mechanistic in vitro tests to clarify the alert.
8. The analysis of findings in reproductive toxicity stud-
ies leading to classifications should be consolidated to 
identify modes of action to translate into test modules 
for an ITS.
9. ITS as Bayesian networks of mode of action tests 
should be formed and optimized by machine learning.
10. PoT from the most promising in vitro tests (stem cells, 
zebrafish, whole embryo culture) should be mapped to 
feed into a Human Toxome database. Similarly, analy-
sis of samples from animal experiments might allow 
PoT identification using omics approaches.
11. Identified PoT should lead to specific test develop-
ment, preferably HTS compatible.
12. A probabilistic risk assessment condensing the infor-
mation from PoT-based tests and other sources needs 
to be developed.
6.3  Conclusions and recommendations: 
reproductive toxicity
It is probably too simplistic just to break developmental and 
reproductive toxicity down into a series of hazards. Issues that 
should be considered or addressed in developmental toxicity 
testing were recently listed by Makris et al. (2011):
– Translational medicine, cross-species extrapolation
– Mode of action data
– Cumulative exposure issues
– Critical windows of exposure and effect
– Latency of response
– Structural vs. functional outcomes
This chapter very much agrees with the emphasis on mode of 
action, or even with finer resolution to PoT. This corresponds 
very well with an emphasis on functional instead of structural 
outcomes. It is hoped that the annotation of PoT to species will 
help the cross-species extrapolation. It is also hoped that the 
early events (points of chemical interaction) will also be predic-
tive for the more latent manifestations. Exposure considerations 
have not been addressed here, with the exception of the TTC 
concept.
There are many considerations involved in non-animal testing 
for stages of the reproductive cycle, and an integrated strategy 
combining in vitro methods with high-throughput screening 
(HTS), predictive computational models, and computer simula-
tion provides the foreseeable path forward.
Recommendations: reproductive toxicity
The following key recommendations are made:
1. The limitations of the pertinent animal test protocols 
for reproductive toxicity testing should be systemati-
cally reviewed in the spirit of evidence-based toxicol-
ogy.
2. The TTC approaches can be further refined by distin-
guishing classes of chemicals or using internal TTC, 
i.e., basing the threshold on plasma concentrations 
actually achieved. An interesting option would be to 
use experimental barrier model data to modify the TTC 
level.
3. The zebrafish embryo teratogenicity assay should be 
evaluated for defining a protocol that will allow formal 
validation, although the test should be seen as an in-
terim approach until a full animal-free replacement is 
available.
4. A human stem cell-based test employing either human 
embryonic stem cells or induced pluripotent stem cells 
should be validated. An evaluation of stem cell variants 
and prediction models should be carried out, especial-
ly since the assay is considered for possibly replacing 
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complement to all novel approaches. New assays in this field 
will be used to enable quantitative in vitro/in vivo extrapolation 
(QIVIVE); here, the main approaches are in silico modeling and 
the integration of input from in vitro barrier and metabolism 
models. With a targeted effort, especially broadening the data-
base for modeling, and the necessary funding, an important con-
tribution could be expected in a few years, in line with the ear-
lier reports’ judgment (Adler et al., 2011; Hartung et al., 2011). 
Skin sensitization has seen the development of about 20 in vitro 
and in silico models, several of which look very promising and 
are currently undergoing validation. We will have to see wheth-
er and how to combine these tests in the most meaningful way. 
Eventually, ITS will be set up that reflect the different modes of 
action and steps in the pathophysiology of skin sensitization.
The main conclusions and recommendations of the report 
can be summarized as follows:
1. Toxicokinetics
– Represents a necessary complement to all in vitro ap-
proaches to allow QIVIVE
– need for “in vitro kinetics” of chemicals in the experi-
mental systems with the goal of producing proper ki-
netic parameters for QIVIVE
– In silico approaches need to be further optimized
– Need for more comprehensive data collections, espe-
cially in vitro data from barrier models
– Problems mainly in the fields of bioavailability and uri-
nary excretion
– Achievable with reasonable investment
2. Sensitization
– Reasonably good animal model (LLNA) capable of gen-
erating potency and dose response information
– Multiple in vitro assays available but unclear which test 
methods provide potency information
– The need to build mechanistic understanding to enable 
data integration for potency determination for hazard 
characterization & risk assessment remains an important 
in vitro challenge
3. Repeated dose testing
– Tox-21c approaches based on PoT represent the key 
perspective; need to focus on defining levels that cause 
adverse effects rather than just hazard identification
– Need for data sharing from industry
– Need for models for PoT identification (e.g., stem cells)
– Need for co-cultures, 3D models, and long-term models
– Human disease knowledge and known toxicants must be 
exploited 
Author conclusions: Thomas Hartung
Discussants: David A. Basketter, Bas Blaauboer,  
Robert Burrier, Harvey Clewell, Mardas Daneshian,  
Chantra Eskes, Alan Goldberg, Nina Hasiwa,  
Sebastian Hoffmann, Joanna Jaworska, Ian Kimber,  
Tom Knudsen, Robert Landsiedel, Marcel Leist, Paul Locke, 
Gavin Maxwell, James McKim, Emily A. McVey,  
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Irmela Ruhdel, Michael Schwarz, Andreas Schepky,  
Greet Schoeters, Nigel Skinner, Kerstin Trentz,  
Marian Turner, Philippe Vanparys, James Yager,  
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Alternative approaches as one-by-one replacements of animal 
tests have advanced over the last two decades, and formal vali-
dation has delivered the proof-of-principle that they do not low-
er safety standards (Westmoreland et al., 2010). Increasingly, 
international acceptance of these methods is being achieved. 
However, currently validated tests address mainly topical and 
acute toxicities. The advances in technologies and the gain of 
toxicological knowledge also appear to make novel approaches 
feasible for systemic toxicities in a not-so-distant future. Based 
on the recent analysis commissioned by the European Commis-
sion (Adler et al., 2011) and its independent review (Hartung et 
al., 2011), this expert group has started to set priorities and to 
identify a roadmap for such a transition. The five whitepapers 
prepared for this purpose differ in approach and style, even after 
discussion, revision, compilation, and editing. 
The framework for a strategy to replace animal tests has only 
been developed during the writing of the whitepapers. It has 
been applied to carcinogenicity (Chapter 5) and reproductive 
toxicity testing (Chapter 6), but not to the other three fields. 
One reason for the differences between the chapters is the 
different status of the areas. Reproductive toxicity testing has 
been pioneered by the ReProTect and the ToxCast projects, and 
the modes of action for genotoxic and non-genotoxic carcino-
genicity appear to be more limited in number and better under-
stood than for chronic organ toxicities. Those two areas form a 
group, together with repeated dose toxicity testing (Chapter 4), 
as all three areas are suitable for ITS and PoT-based approaches, 
which represent not only a departure from one-to-one replace-
ment strategies but also a revolution of testing strategies brought 
about during the last decade. It appears that the large number of 
target tissues and modes of action will make an ITS approach 
difficult, requiring that these be broken down to PoT and Pot-
based assays, which can then be combined in a HTS platform.
The situation for toxicokinetics (Chapter 2) and skin sensiti-
zation (Chapter 3) appears to be very different from the three ar-
eas above: Toxicokinetics has to be seen more as the necessary 
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BASKETTER ET AL.
ALTEX 29, 1/1276
Ames, B. N. and Gold, L. S. (2000). Paracelsus to parascience: 
the environmental cancer distraction. Mutat Res 447, 3-13. 
An, S., Kim, S., Huh, Y., et al. (2009). Expression of surface 
markers on the human monocytic leukaemia cell line, THP-1, 
as indicators for the sensitizing potential of chemicals. Con-
tact Dermatitis 60, 185-192. 
Andersen, M. E. (1991). Physiological modelling of organic 
compounds. Ann Occup Hyg 35, 309-321. 
Andersen, M. E., Thomas, R. S., Gaido, K. W., et al. (2005). 
Dose-response modeling in reproductive toxicology in the 
systems biology era. Reprod Toxicol 19, 327-337. 
Andersen, M. E., Clewell, H. J., Carmichael, P. L., et al. (2011). 
Can case study approaches speed implementation of the NRC 
report: “toxicity testing in the 21st century: a vision and a 
strategy?”. ALTEX 28, 175-182. 
Anisimov, V. N., Ukraintseva, S. V., and Yashin, A. I. (2005). 
Cancer in rodents: does it tell us about cancer in humans? Nat 
Rev Cancer 5, 807-819. 
Anonymous (2000). Scientific Frontiers in Developmental Toxi-
cology and Risk Assessment. Committee on Developmental 
Toxicology, Board on Environmental Studies and Toxicology, 
Commission on Life Sciences, National Research Council. 
Vol. Washington, DC: National Academy Press. http://www.
nap.edu/catalog/9871.html
Anthony, A., Caldwell, J., Hutt, A. J., et al. (1987). Metabolism 
of estragole in rat and mouse and influence of dose size on 
excretion of the proximate carcinogen 1'-hydroxyestragole. 
Food Chem Toxicol 25, 799-806. 
Api, A. M., Basketter, D. A., Cadby, P. A., et al. (2008). Dermal 
sensitization quantitative risk assessment (QRA) for fragrance 
ingredients. Regul Toxicol Pharmacol 52, 3-23. 
Arkusz, J., Stepnik, M., Sobala, W., et al. (2010). Prediction of 
the contact sensitizing potential of chemicals using analysis 
of gene expression changes in human THP-1 monocytes. Tox-
icol Lett 199, 51-59. 
Ashby, J. and Tennant, R. W. (1991). Definitive relationships 
among chemical structure, carcinogenicity and mutagenicity 
for 301 chemicals tested by the U.S. NTP. Mutat Res 257, 
229-306. 
Ashby, J. (1997). Cell transformation assays as predictors of 
carcinogenic potential. Toxicol Pathol 25, 334-335. 
Ashikaga, T., Sakaguchi, H., Sono, S., et al. (2010). A compara-
tive evaluation of in vitro skin sensitisation tests: the human 
cell-line activation test (h-CLAT) versus the local lymph node 
assay (LLNA). Altern Lab Anim 38, 275-284. 
Asp, J., Steel, D., Jonsson, M., et al. (2010). Cardiomyocyte 
clusters derived from human embryonic stem cells share sim-
ilarities with human heart tissue. J Mol Cell Biol 2, 276-283. 
Augustine-Rauch, K., Zhang, C. X., and Panzica-Kelly, J. M. 
(2010). In vitro developmental toxicology assays: A review of 
the state of the science of rodent and zebrafish whole embryo 
culture and embryonic stem cell assays. Birth Defects Res C 
Embryo Today 90, 87-98. 
Bailey, J., Knight, A., and Balcombe, J. (2005). The future of 
teratology research is in vitro. Biogenic Amines 97–145. 
Balls, M. and Combes, R. (2005). Validation at a crossroads. 
Altern Lab Anim 33, 187. 
– Increased focus on modeling of inflammatory/immuno-
logical damage
4. Carcinogenicity
– Possible abolition of current test via an objective assess-
ment with tools of Evidence-based Toxicology (EBT)
– Important ongoing work to optimize genetic toxicity 
battery
– Further evaluation of cell transformation assay required
– ITS including non-genotoxic modes of action should be 
developed
– Tox-21c approaches based on PoT (including metabo-
lomics) represent a key opportunity
5. Reproductive Toxicity
– Analysis of current animal tests by EBT approaches
– Validation of (human) embryonic stem cell test variants
– Validation of zebrafish egg test for teratogenicity
– Extension of ITS approaches, extending the approach of 
ReProTect
– Extension of the ToxCast program currently pioneering 
PoT-based assessments
– Tox-21c approaches based on PoT, especially mapping 
the PoT for reproductive toxicity for a Human Toxome 
database
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